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Abstract 
The protozoan parasite Leishmania of the family Trypanosomatidae is the causative or-
ganism of Leishmaniasis. Leishmania species are spread in tropical regions and in coun-
tries surrounding the Mediterranean Sea. Over 12 million people are infected world wide 
(WHO). Depending on the Leishmania species the disease can range from self-healing 
cutaneous lesions to mucocutaneous lesions destroying mucocutanous membranes in 
nose, mouth and throat. In the visceral Leishmaniasis, the parasites invade the spleen, 
liver and bone marrow and ultimatively cause death. Until today there are no vaccines or 
effective drugs available that protect or specifically heal Leishmaniasis.  
Leishmania are transmitted by the female sand fly of the genus Phlebotomus and Lutzo-
myia. Upon the bite of an infected sand fly, the parasites are inoculated into the mammal-
ian host and enter mononuclear phagocytes like macrophages, dendritic- or Langerhans-
cells. The parasites proliferate within these cells until lyses of the host cells occurs. The 
released parasites invade new host cells. During the next blood meal, a sand fly takes up 
the parasites that undergo a specific life cycle within the fly. Afterwards, the Leishmania 
can be again transmitted into the mammalian host.  
It is known that various glycoconjugates are essential for parasite virulence: they form a 
dense cell surface glycocalyx allowing the survival and proliferation of the parasite in the 
very hostile environments of the sand fly vector and the mammalian host. Among other 
protective functions, they shield the parasite against complement lyses and prevent the 
activation of macrophages. The major components of the glycoconjugates are mannose, 
galactose, glucose and arabinose.  Potential drug targets are therefore enzymes that are 
involved in the synthesis of these glycoconjugates.   
The aim of this study was the identification of enzymes essential for the biosynthesis of 
galactose containing glycoconjugates. A complementation cloning strategy has been 
used and unexpectedly identified the enzyme UDP-glucose pyrophosphorylase (UGP). 
UGP catalyses the formation of UDP-glucose from glucose-1-phosphate and UTP. The 
activation of glucose to the nucleotide sugar is crucial for the entry in biosynthetic path-
ways and UDP-glucose is required for the synthesis of UDP-galactose. Thus, the isolated 
enzyme provides a key function in the biosynthesis pathways involving glucose and ga-
lactose and should be an optimal target for disturbing glycoconjugate synthesis in 
Leishmania.  
The activity of the L. major UGP was proven by an in vivo complementation assay using 
UGP negative E .coli mutant strains and by an in vitro assay system using recombinant 
protein. In addition, the recombinant UGP was kinetically characterised and its oligmeri-
sation status was determined. Despite the high sequence homology to the mammalian 
counterparts, these data showed that differences in the regulation of these enzymes  
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exist. 
Crystallisation trials have been carried out and generated well diffracting crystals that are 
presently used to resolve the 3-dimensional structure. Finally, the role of the UGP in the 
pathomechanism of Leishmania has been investigated by gene deletion. The obtained 
clone demonstrated drastically reduced virulence in a mouse infection model, indicating 
the importance of this gene for pathogen development in the host.  
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Zusammenfassung 
 
Leishmanien sind einzellige Parasiten der Familie der Trypanosomatidae und verursa-
chen die Krankheit Leishmaniose, die besonders in den tropischen Regionen und im 
Mittelmeerraum verbreitet ist. Laut WHO sind weltweit 12 Millionen Menschen infiziert. 
Bei einer Infektion entstehen je nach Art der Leishmanien Hautgeschwüre und Knoten 
(Orientbeule), mucokutane Läsionen, die zum Auflösen der Schleimhäute der Nase, 
Mund und Rachen führen, oder viszerale Leishmaniosen (Kala-Azar), die die Milz, Leber 
und das Knochenmark befallen und  tödlich sind. Bis heute gibt es weder eine spezifi-
sche medikamentöse Behandlungsmöglichkeit noch eine Impfung, die vor Leishmaniose 
schützt.   
Leishmanien werden durch die weiblichen Schmetterlingsmücken der Gattung Phlebo-
tomus sowie Lutzomyia übertragen. Durch den Stich einer infizierten Mücke werden 
Leishmanien auf den Wirt übertragen und von Phagozyten wie z.B. Makrophagen, 
dendritischen Zellen oder Langerhans-Zellen aufgenommen. Die Parasiten vermehren 
sich in der Wirtszelle bis zu dessen Lyse. Die freien Parasiten befallen nun erneut Pha-
gozyten. Bei der Blutmahlzeit einer Schmetterlingsmücke werden Leishmanien aufge-
nommen, die nach ihrem Lebenszyklus in der Fliege wieder auf den Wirt übertragen 
werden.  
Um in der feindlichen Umgebung des Vektors und des Wirtes überleben und proliferieren 
zu können, besitzen Leishmanien eine dichte Glykokalyx. Die verschiedenen Komponen-
ten der Glykokalyx schützen den Parasiten z.B. vor der Lyse durch das Komplementsys-
tem und verhindern die Aktivierung der Makrophagen. Die Hauptkomponenten der Gly-
kokonjugate sind Mannose, Galactose, Glucose und Arabinose. Enzyme, die am Aufbau 
dieser Strukturen beteiligt sind, stellen daher potentielle Angriffsziele bei der Entwicklung 
von Medikamenten zur Behandlung der Leishmaniose dar. 
Ziel dieser Arbeit war es, Enzyme zu identifizieren, die für den Aufbau Galactose-haltiger 
Glykokonjugate essential wichtig sind. Der Einsatz einer Komplementations-
Klonierungsstrategie führte unerwartet zur Identifizierung des Enzyms UDP-Glucose  
Pyrophosphorylase (UGP). UGP katalysiert die Bildung von UDP-Glucose aus Glucose-1 
Phosphat und UTP. Die Aktivierung der Glucose  zu dem Zuckernukleotid ist substantiell 
wichtig für den Eintritt in die biosynthetischen Stoffwechselwege. Außerdem wird UDP-
Glucose für die Synthese von UDP-Galactose benötigt. Somit hat das isolierte Enzym 
eine Schlüsselfunktion für biosynthetische Stoffwechselwege, bei denen Glucose und 
Galactose eine Rolle spielen und sollte ein optimales target für die Störung der Glyko-
konjugat-Synthese in Leishmanien darstellen. 
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Die Aktivität der L. major UGP wurde durch in vivo Komplementations-Assays mit einem 
UGP-negativem E. coli-Stamm als auch durch ein in vitro Assay-System mit rekombinan-
tem Protein bewiesen. Außerdem wurde die rekombinante UGP kinetisch charakterisiert 
und der Oligomerisationsstatus bestimmt. Trotz hoher Sequenzhomologie zu den mam-
malia UGPs zeigten diese Daten, dass Unterschiede in der Regulation der Enzyme be-
stehen. 
Die Kristallisierung der rekombinanten UGP wurde erfolgreich durchgeführt, und gut 
streuende Kristalle werden momentan zur Auflösung der dreidimensionalen Struktur he-
rangezogen.  Zur Evaluation der pathophysiologischen Rolle dieses Enzyms an der 
Leishmaniose wurden L. major Deletionsmutanten hergestellt. Der resultierende Klon 
zeigte im Mausmodell drastisch verminderte Virulenz, was die wichtige Position dieses 
Genes für die Entwicklung des Pathogens im Wirt unterstreicht.  
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1 Introduction 
1.1 Leishmania parasites 
Leishmania are protozoan parasites of the family Trypanosomatidae and are the causa-
tive organism of the disease Leishmaniasis. There are at least 30 different species of 
Leishmania and about 10 infect humans. Depending on the species, this disease con-
sists of a broad range of symptoms. Ulcerative skin lesions occur in cutaneous Leishma-
niasis and are caused by the species L. major, L. mexicana, L. tropica and L. aethiopica. 
Whereas the cutaneous Leishmaniasis is usually self-healing, the mucocutaneous 
Leishmaniasis is more severe and is caused by the species L. braziliensis braziliensis 
(Descoteaux and Turco, 1999). The parasites lead to the destruction of the nose and 
mouth by producing a mucosal granuloma. However, the most severe form of Leishma-
niasis is the visceral Leishmaniasis (Kala-azar) that leads to death if untreated. In this 
form, the species L. donovanii disseminates and infects the liver, spleen and bone 
marrow. At present, there are no specific drugs available to treat Leishmaniasis and 
vaccination strategies show only very limited success. Pentavalent antimonials were 
used to cure visceral Leishmaniasis but many parasites are already resistant to this 
treatment. Second line drugs like pentamidine and amphotericin B are effective to treat 
all forms of Leishmaniasis if administered in high doses, however these drugs are very 
cost intensive (Croft and Coombs, 2003). New treatment strategies are urgently needed 
since over 12 million people are infected worldwide. The disease is spread in over 88 
countries on all continents except Australia (World Health Organisation). 
Leishmania are intracellular pathogens colonizing phagocytes in the human host. In their 
life cycle the parasites depend on an intermediate host, the sand fly. Thus the propaga-
tion of Leishmaniasis is strongly connected to the occurrence of its vector. The life cycle 
and infection mechanism of the parasite are shown in Figure 1. Female sand flies of the 
genus Phlebotomus and Lutzomyia transmit the highly infectious metacyclic promas-
tigote Leishmania into the mammalian host. Before entering macrophages and other 
phagocytes like dendritic- or Langerhans cells by a receptor-mediated process, the 
parasites must resist the non-specific host defence mechanisms like complement lyses. 
After uptake in the cells, the parasites are located in a phagosomal compartment that is 
fused with endocytic organelles to form the parasitophorous vacuole. Inside this vacuole 
Leishmania transform into small, non-motile amastigotes with a short flagellum. They 
proliferate within the macrophages despite the exposure to hydrolytic enzymes and 
acidic pH (Alexander et al., 1992) until the macrophages rupture and release the para-
sites into the environment. Freed parasites infect surrounding macrophages. Upon a 
blood meal of a sand fly, the amastigote containing macrophages or released amas-
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tigotes are ingested. Inside the fly the parasites transform into motile, flagellated promas-
tigotes and attache to the midgut of the vector to avoid excretion. During metacyclogene-
sis, these procyclic forms develop into the non-dividing infective metacyclic promas-
tigotes (Sacks, 1989). The metacyclic promastigotes detach from the midgut wall and 
migrate to the foregut and oesophagus. They are suspended in the sand fly’s salvia that 
supports the establishment of the parasite infection in the host most likely by inhibiting 
oxidative metabolic processes and antigen presentation (Lerner et al., 1991, Theodos et 
al., 1991). During another blood meal Leishmania are transmitted into the mammalian 
host. 
 
 
Figure 1 Life cycle of Leishmania Leishmania undergo two distinct developmental stages. In the mamma- 
lian host they reside within the macrophages as non-motile amastigotes whereas in the sand fly vector the 
amastigotes transform into the flagellated promastigote form (modified from www.dpd.cdc.gov). 
 
In the two distinct developmental stages, this pathogen survives and proliferates in highly 
hostile environments. This is thought to be facilitated by surface components of the 
parasite especially by the glycoconjugates that form a dense cell surface glycocalyx 
(McConville et al., 2002, Turco et al., 2001). For a comprehensive understanding of the 
role of the glycoconjugates in the pathogenesis of Leishmania, the structure, biosynthe-
sis and function of these molecules is intensively investigated. 
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1.2 The glycoconjugates of Leishmania 
1.2.1 Structure and biosynthesis of Leishmania glycoconjugates 
The major glycoconjugates on Leishmania parasites are the lipophosphoglycan (LPG), 
the glycosylphosphatidylinsitol (GPI)-anchored proteins, free glycolipids (GIPLs) and the 
proteophosphoglycans (PPGs). The synthesis of these molecules takes place on both 
sites of the ER as well as in the lumen of the Golgi apparatus (McConville et al., 2002). 
Essential for the biosynthesis of glycoconjugates is the metabolic activation of the re-
spective building blocks, the monosaccharides. This is achieved by the formation of 
nucleotide-sugars, e.g. UDP-galactose, UDP-glucose or GDP-mannose in the cytosol. 
On the cytoplasmic leaflet of the ER, the nucleotide sugars are transferred by specific 
transferases either directly on the target structure (see LPG biosynthesis) or on dolichol-
phosphate (dolichol-P). The dolichol-P-sugar is flipped through the membrane to serve 
as sugar donor for transferases in the lumen of the ER. In addition, nucleotide sugar 
transporters transport the activated nucleotide sugars from the cytosol into the ER or 
Golgi apparatus where they are used by specific transferases. 
As in other eukaryotes, the N-glycan precursors are assembled in the ER on dolichol-P 
and then transferred en bloc to the newly synthesized proteins. However, the parasites 
do not synthesize the common Glc2Man9GlcNAc2 dolichol-PP-linked precursor but a 
Man6-7GlcNAc2 structure (Glc, glucose; Man, mannose; GlcNAc, N-acetylglucosamine). 
Since no Golgi modification occurs, the proteins bear these biantennary high mannose-
type glycans which can be modified with a glucose in α1,3-linkage (Parodi et al., 1993). 
 
LPG is the most abundant glycoconjugate of all promastigote Leishmania with a highly 
conserved backbone structure. It is comprised of a 1-O-alkyl-2-lyso-phosphatidyl-
(myo)inositol (PI)-anchore, a glycan core, a repeating galactose-mannose-phosphate 
(Gal-Man-P) unit with 15 to 30 repeats and a cap structure (Turco et al., 1992, McCon-
ville et al., 1993, Figure 2). LPG as well as the type-2 GIPLs (see below) contain two 
conformers of galactose: the galactopyranose that is common also in higher eukaryotes 
and the unusual galactofuranose that is not present in humans (see 1.3). 
Depending on the species, side chains are attached to the residues of the repeating 
units. In L. major, the C3 hydroxyl group of galactose is glucosylated or galactosylated 
with one to four galactose residues and often terminated with arabinose. The repeating 
units of L. mexicana are modified with glucose whereas in some L. donovanii strains no 
side chain modifications occur. Differences also occur in the nature of the cap structure, 
e.g. in L. major the cap is comprised of the disaccharide Man(α1,2)Man(α1) and in L. 
donovanii of the trisaccharide Gal(ß1,4)[Man(α1,2) Man(α1)]. 
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Figure 2 Structure of Leishmania surface glycoconjugates: a) L. major LPG (R indicates the side chain 
modifications as mentioned in the text), b) Proteophosphoglycan structures of the secreted acid phosphatase 
of L.mexicana c) the GPI-linked glycoprotein gp63 and d) the three classes of GIPLs, Gal, galactopyranose; 
Galf, galactofuranose; Man, mannose; P, phosphate, PI, phosphatidylinositol, R, side chain modification; Glc, 
glucose; GlcN, glucosamine; EtN, ethanolamine; n, number of repeating units: 15-30. 
 
The GPI-anchor precursors of LPG are assembled on both sides of the ER by the se-
quential addition of monosaccharides to a PI-anchor (Ralton et al., 1998). The formation 
of GlcN(glucosamine) -PI and the addition of the second mannose in α1,3-linkage is 
thought to occur on the cytoplasmic leaflet of the ER whereas the first mannose is 
transferred in the lumen of the ER using dolichol-P-mannose as donor substrate (Ilgoutz 
et al., 1999). All further steps including the addition of galactose, glucose, glucose-1 
phosphate, arabinose, mannose and mannose-1 phosphate occur in the Golgi apparatus 
using the corresponding nucleotide-sugars as donor substrates (Hong et al., 2000, 
Figure 3). 
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Figure 3 Glycosylation pathway of LPG, PPGs, GIPLs and N-glycosylated GPI-anchored glycopro-
teins. The N-glycosylated glycoproteins, the type1 and hybrid GIPLs are synthesised in the ER, the PPGs 
are synthesised in the Golgi while the synthesis of LPG and of type2 GIPLs involves both compartments 
(modified from McConville et al., 2002).Man, mannose; Gal, galactopyranose; Galf, galactofuranose; P, 
phosphate, PI, phosphatidylinositol, R, side chain modification; Glc, glucose; GlcN, glucosamine; GlcNAc, N-
acetylglucosamine; EtN, ethanolamine; Ser, serine; n, number of repeating units:15-30. 
 
The most abundant type of protein glycosylation is the phosphoglycosylation of a number 
of cell surface and secreted proteins (Ilg, 2000 (a), Figure 2). This heterogeneous family 
of proteophosphoglycans (PPGs) has phosphoglycan chains similar to those found in the 
repeating units of LPG (Jaffe et al., 1990, Bates et al., 1990). The glycan content can rise 
up to 96% of the mass of the whole molecule (Ilg et al., 1996). As for LPG, the 
phosphoglycosylation takes place in the Golgi apparatus and is initiated by the transfer of 
a Manα1−phosphate to serine and threonine residues in serine- and threonine-rich 
sequences (Moss et al., 1999, Figure 3). It can be elongated with mannose residues or in 
addition with one or two Gal(ß1,4)Manα1−phosphate repeating units as in the case of the 
secreted acid phosphatase of L. mexicana (Ilg et al., 1994). The length and composition 
of the phosphoglycan chains vary considerably in different PPGs. In addition, the expres-
sion of the PPGs is stage specific and the PPG profile differs from species to species (Ilg 
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et al., 1994 and 1996). For example, in L. mexicana three classes of PPGs are described 
(Ilg et al., 1999 and 2000 (a)). In the promastigote stage, two forms of the secreted acid 
phosphatase and a filamentous PPG, which form a gel-like matrix in the midgut of the 
sand fly, exist whereas in amastigotes only the non-filamentous PPG is secreted. In 
contrast, L. major promastigotes do not express a secreted acid phosphatase and 
secrete fewer PPGs than L. mexicana although some strains contain GPI-anchored 
PPGs (Ilg et al., 1999). 
 
Beside the GPI anchored PPGs, there are other GPI-linked proteins in Leishmania, e.g. 
the glycoprotein GP63 (Figure 2). GP63 is a metalloproteinase and the major cell surface 
glycoprotein of promastigotes in all Leishmania strains. GP63 is comprised of a C-
terminal GPI-linker and three N-linked glycans that are transferred in the ER and not 
further modified in the Golgi apparatus (McGwire et al., 1996, Ralton et al., 2002; Figure 
3). The GPI-anchor synthesis includes the addition of GlcNAc to the PI-anchor with a 
subsequent de-N-acetylation to form a GlcNα1,6-PI-anchor and the addition of three 
mannose residues from dolichol-P-mannose and ethanolamine-phosphate in the lumen 
of the ER. In contrast to LPG, the second mannose residue is added in the lumen of the 
ER in a α1,6-linkage rather than in a α1,3-linkage (McConville, 2002). 
 
The GIPLs are low molecular weight glycolipids that are synthesized in all developmental 
stages of the parasite. Three classes of GIPLs can be distinguished that are expressed 
at different levels in different species and depending on the developmental stage 
(McConville et al., 1993, Figure 2). The type-1 GIPLs contain the same glycan structure 
as the protein anchors (Manα1,6Manα1,4GlcNα1,6-PI) whereas the type-2 GIPLs are 
analogous to the LPG-glycan anchor including one galactofuranose (Galf) and up to two 
galactopyranose residues ((Galα1,6Galα1,3)Galfα1,3Manα1,3Manα1,4GlcNα1,6-PI). 
The hybrid GIPLs contain features of both the protein and the LPG anchor 
(Manα1,6(Manα1,3)Manα1,4GlcNα1,6-PI) (Guha-Niyogi et al., 2001). The type-1 and 
hybrid GIPLs are assembled in the ER whereas the galactose residues of the type-2 
GIPLs are added in the Golgi apparatus like for LPG (Figure 3). However, the GIPLs are 
clearly metabolic end products and contain lipid moieties and side chain modifications 
distinct from those added to proteins (McConville et al., 1991 and 1993). 
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1.2.2 Implication of the L. major surface glycoconjugates on the sur-
vival and proliferation in the vector and host 
The cell surface expression of the glycoconjugates in Leishmania is highly dynamic and 
dependent on the developmental stage of the parasite. The promastigotes are coated 
with a 20-40 nm thick glycocalyx that is mainly comprised of LPG, GPI-anchored pro-
teins, PPGs and GIPLs (Pimenta et al., 1991, McConville et al., 2002). These glycocon-
jugates are suggested to play important roles on the survival of the parasite within the 
sand fly and during the initial steps of macrophage infection (Naderer et al., 2004). 
However, the amastigotes down regulate the expression of LPG and GPI-anchored 
proteins and are coated with a layer of GIPLs and host derived glycosphingolipids. The 
almost complete absence of immunogenic proteins and carbohydrates provides an 
effective mechanism to survive in the parasitophorous vacuole of the macrophages. 
Potential roles of LPG, GPI-anchored proteins, GIPLs, and of PPGs on Leishmania 
infectivity are discussed in the following. 
 
1.2.2.1  The role of LPG 
LPG has been described to play an important role in the survival of the parasite in the 
sand fly and in the initial phase of macrophage infection in some Leishmania species 
(e.g. L. major) (Guha-Niyogi et al., 2001). 
LPG facilitates the ability of Leishmania promastigotes to attach and detach from the 
midgut of the sand fly. It also protects the parasite against digestive enzymes (McCon-
ville et al., 1992). In the natural vector of L. major, Phlebotomine papatasi, a ß-galactose 
binding lectin recognizes the terminal ß-galactose of the LPG side chain whereas in L. 
donovanii the terminal galactose and mannose residue of the cap structure are required 
for binding and thus avoid excretion with the digested blood meal (Pimenta et al., 1992, 
Sacks et al., 1995). The species-specific differences in the modification of the side chains 
of the repeating unit and the cap structure may account for the insect host specificity of 
the Leishmania species (Pimenta et al., 1994). During metacyclogenesis of the procyclic 
promastigotes into the infective metacyclic promastigotes, LPG undergoes some struc-
tural changes, which promote the detachment from the midgut. The number of the 
repeating units doubles from 15 to 30 (Sack et al. 1995) and in L. major doubling of the 
repeating units is accompanied by the reduction of galactose containing side chains and 
addition of a terminal arabinose (McConville, 1992, Pimenta, 1992). These alterations 
are believed to mask the sugars that are involved in the midgut attachment in metacyclic 
promastigotes and allow the migration to the mouth part of the sand fly. 
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In addition, the elongation of LPG has been implicated in the prevention of complement 
lyses of the pathogens in the blood stream of the mammalian host. Metacyclic but not 
procyclic promastigotes shed the C5b-C9 complex from the parasite surface without 
insertion into the plasma membrane (Puentes et al., 1990). However, deposition of C3b 
and C3bi on the cell surface of Leishmania by LPG and gp63 allows the entry into the 
macrophages via receptors-mediated endocytosis (Mosser et al., 1993). 
Inside the macrophage, LPG is believed to modulate signal transduction pathways, e.g. 
by inhibiting the protein kinase C and to delay the fusion of the endosomal compartments 
with the phagosome (Turco et al., 1992, Desjardins et al., 1997). By the latter event the 
time window for the differentiation of the promastigote to the amastigote form, which 
resists the exposure to hydrolytic conditions and acidic pH, may be extended (Naderer et 
al., 2004). However, a direct influence of the delayed fusion on parasite survival could 
not be confirmed in experiments carried out with L. mexicana. Moreover, a L. major 
mutant lacking LPG showed conversion to the amastigote stage in in vitro experiments. 
The specific lack of LPG in this mutant was achieved by the deletion of the galactofu-
ranosyltransferase (LPG1) gene. The product of this gene is a glycosyltransferase that 
adds the galactofuranose residue to the LPG precursor (Späth et al., 2000). Interestingly, 
in in vitro studies the L. major LPG1 mutant was still able to attach and invade the 
macrophages but proliferation within the cells was reduced (Späth et al., 2003). In 
addition, the mutant showed a delayed lesion formation in mice infection tests confirming 
an important role of LPG in establishing the infection (Späth et al., 2000). However, these 
data also indicate that invasiveness involves factors beyond the LPG. Potential candi-
dates that may compensate for the LPG functions are other glycoconjugates that remain 
in the mutant parasite.  
In contrast to L. major, no structural rearrangements of LPG occur during meta-
cyclogenesis of L. mexicana promastigotes though the LPG expression is down regu-
lated in the metacyclic promastigotes (Ralton et al., 2003). Consistent with this finding is 
that L. mexicana LPG does not seem to be required for the infection of macrophages (Ilg, 
2000 (b)). This indicates that despite the overall similarity of the glycoconjugates, varia-
tions in the composition of the glycoconjugates in the different Leishmania species may 
result in variant infection mechanisms. 
 
1.2.2.2  The role of PPG 
As mentioned above, filamentous PPGs are secreted by all Leishmania promastigotes 
and form gel-like matrices embedding the parasites (Ilg et al., 1996). It has been sug-
gested that this matrix supports the correct positioning of the parasite in the anterior part 
of the sand fly’s midgut. Evidence that PPGs also protect the parasite from lyses by the 
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complement system and/or proteases that are present in the midgut, is based on a L. 
donovanii mutant lacking the GDP-mannose transporter gene (LPG2, Descoteaux et al., 
1995). Due to this deletion, the synthesis of the mannose containing LPG and PPGs in 
the Golgi apparatus is inhibited. The LPG2 mutant was rapidly killed in the sand fly 
midgut whereas the mutant lacking only LPG (LPG1 mutant, Sacks et al., 2000) survived 
the initial period of the infection. In addition, the deletion of the GDP-mannose transporter 
in L. major showed an almost complete loss of virulence in macrophage- and mice 
infection assays (Späth et al., 2003). Though the L.major LPG1 mutant showed reduced 
infectivity, the more severe phenotype of the LGP2 mutant suggests that PPGs play a 
crucial function in establishing the infection in the mammalian host. 
PPGs are believed to protect the amastigotes from complement lysis and participate in 
the formation of the parasitophorous vacuole (Späth et al., 2003). In addition, PPGs may 
contribute to the attachment and invasion of the parasite into macrophages and may 
modulate signal transduction pathways in the early stages of the infection (Guha-Niyogi 
et al., 2001). 
However, as in the case of the LPG1 mutant, deletion of the GDP-mannose transporter 
in L. mexicana did not result in the loss of virulence, indicating that neither LPG nor 
PPGs are essential for the infection mechanism of this strain (Ilg et al., 2001). These 
findings illustrate that different Leishmania species have developed different mechanisms 
to infect the mammalian host. 
 
1.2.2.3  The role of GP63 
GP63 is synthesized as a GPI-linked protein with about 500 000 copies per cell in pro-
mastigotes. In the amastigote stage, the membrane bound form is down-regulated 
whereas the expression of secreted forms is up-regulated (Medina-Acosta et al., 1989). 
This protease is thought to degrade host macromolecules and to prevent the parasite 
against complement lyses. It may also facilitate the uptake of the parasite into the host 
cells via complement components by macrophage receptors (Alexander and Russel, 
1992). The generation of GP63 deletion mutants is difficult since GP63 is encoded in a 
multi-gene family. Mutants partly depleted in GP63 have been obtained, but raised 
contradicting results. Further investigations are necessary to understand the role of this 
glycoprotein. 
 
1.2.2.4  The role of GIPLs 
In the Leishmania amastigotes the levels of both LPG and GP63 are significantly down-
regulated and thus the GIPLs are the major glycoconjugates in this developmental stage 
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(Naderer et al., 2004). Despite their potential importance in the amastigote stage, little is 
known about the function of these compounds. It has been suggested that the GIPLs 
protect the amastigote outside and inside the macrophage, e.g. by modulating signalling 
events (McNeely et al. 1989, Proudfoot et al. 1995, Tachado et al. 1997). 
An L. major mutant lacking GIPLs and LPG was generated by the targeted gene deletion 
of the alkyldihydroxyacetonephosphate synthase (ADS1, Zufferey et al., 2003). This 
enzyme catalyses the first step in the ether phospholipid synthesis, which is a shared 
structural motif of all GPI-anchored glycoconjugates. Unexpectedly, this deletion did not 
influence the synthesis of GPI-anchored proteins, like GP63. 
Though this mutant showed to be less virulent than the wild type parasites, overall the 
phenotype resembled that of the L. major LPG1 mutant, suggesting that either the GIPLs 
are not important for infectivity in L. major or that other factors compensate for this 
defect. The latter hypothesis is supported by the finding that the mutants express a 
novel, unidentified lipid moiety (Zufferey et al., 2003). 
 
In summary, the glycoconjugates presented here seem to influence the infection mecha-
nism in a complex way, but it is difficulty to assign distinct roles to a particular glycocon-
jugates. Experiments carried out with gene targeted parasites clearly indicate that a 
certain level of redundancy exist in these systems. 
The identification of a more central structure in the Leishmania glycosylation pathways 
and its use as a target to interfere in a broad manner with glycoconjugate biosynthesis is 
therefore an important goal for the design of new efficient drugs to combat Leishmani-
asis. 
 
1.3 The role of galactose containing conjugates in L. major 
The glycoconjugates of Leishmania contain high levels of galactose. In Trypanosomati-
dae, galactose is found as galactopyranose as well as in the unusual conformation 
galactofuranose (Galf). The conversion of UDP-galactopyranose to UDP-galactofuranose 
is catalysed by the UDP-galactopyranose mutase (Figure 4). 
Figure 4 Conversion of UDP-galactopyranose to UDP-galactofuranose is catalysed by the UDP-
galactopyranose mutase. 
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Galactofuranose is widely found in pathogens such as Trypanosoma, Aspergillus or 
Mycobacteria but is absent in the human host. In Mycobacteria, it has been shown that 
Galf is essential for growth and viability, but in Leishmania, its function is still unclear 
(Pan et al., 2001). As described above, the gene deletion of a galactofuranosyltrans-
ferase (LPG1) in L. major resulted in a reduction of virulence in both macrophage and 
mouse infection models. However, this mutant continued to produce Galf containing type-
2 GIPLs, which is the primarily synthesized class of GIPLs in L. major (Zhang et al., 
2004). The GIPLs are the major glycoconjugates of the amastigote cell surface suggest-
ing that these play critical roles in amastigote survival and virulence (Naderer et al., 
2004). Though the ADS1 mutant, which lacks LPG and GIPLs, shows the same pheno-
type than the LPG1 mutant, a potential role of the GIPLs in infectivity cannot be excluded 
due to compensatory effects (see above). In addition, the cloning and gene deletion of 
three LPG1 homologous did not reveal mutants devoid of Galf containing GIPLs (Zhang 
et al., 2004) and indicated the existence of further galactosyltransferases. The LPG1 and 
LPG2 gene deletion mutants of L. major and L. donovanii suggest that LPG and PPG are 
important compounds for the survival of the parasite in the midgut of the sand fly and in 
the initial steps of macrophage infection. However, viable parasites of the L. major LPG2 
gene deletion mutant were isolated from the site of injection in mice months after infec-
tion although the mutant had lost the ability to infect macrophages and form lesions in 
mice infection models. 
Thus, the investigation of unique and singular factors that affect the biosynthesis of LPG, 
PPGs and type-2 GIPLs instead of targeting numerous genes of protein families, like the 
galactosyltransferases, is a promising task. Potential candidates are enzymes involved in 
the biosynthesis of UDP-galactose, e.g. the UDP-glucose pyrophosphorylase or in the 
transport of the activated sugar, the UDP-galactose transporter (see below). 
 
1.4 Enzymes involved in the galactose metabolism 
1.4.1 UDP-glucose pyrophosphorylase 
The UDP-glucose pyrophosphorylase (UGP) catalyses the reversible reaction of glucose-
1 phosphate and UTP to UDP-glucose and pyrophosphate (Figure 5). The enzyme 
represents a key position in carbohydrate synthesis and metabolism. 
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Figure 5 Reaction catalyzed by the UDP-glucose pyrophosphorylase. 
 
In mammals, UDP-glucose is the direct precursor for glycogen and UDP-glucuronic acid 
and is involved in glycosylation reactions. Furthermore, UDP-glucose is required for the 
formation of UDP-galactose and the entry of galactose into glycolysis in organisms that 
utilize the Leloir pathway. In a reaction catalysed by the galactose-1 phosphate uridyl-
transferase, UDP-galactose and glucose-1 phosphate are formed from galactose-1 
phosphate and UDP-glucose (Figure 6 a). Glucose-1 phosphate can be directly metabo-
lised in glycolysis. UDP-galactose can be recycled to UDP-glucose by the UDP-
galactose 4-epimerase or can be used in glycosylation reactions (fig. 6 b). 
In addition, UDP-galactose can be directly formed from UDP-glucose since the UDP-
galactose 4-epimerase catalyses a reversible reaction. 
 
 
Figure 6 Reactions catalyzed by the galactose-1 phosphate uridyltransferase (a) and the UDP-
galactose 4-epimerase (b). 
 
The UGP is ubiquitously expressed in plant and animal tissue as well as in yeast and 
bacteria. In several gram negative bacteria the UGP is required for the synthesis of the 
capsular polysaccharide, which is a major virulence factor in these organisms (Gen-
eveaux et al., 1999). In Klebsiella pneumonia, deletion of the galU gene that encodes the 
UGP results in the loss of virulence, and in Streptococcus pneumonia unencapsulated 
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bacteria are obtained (Chang et al., 1996, Mollerach et al., 1998).  Since, the prokaryotic 
UGPs show no significant sequence homology to their eukaryotic counterpart, the UGP 
might be a suitable target for antibacterial drugs (Konishi et al., 1993, Daran et al., 1995, 
Eimert et al., 1996). In this regard, Kim et al. (2004) reported the crystallization and 
preliminary X-ray study of the UGP from Helicobactor pylori. The identification of the 
active site and catalytic mechanism might help to design specific inhibitors. 
Though the sequence homology of the eukaryotic and prokaryotic UGPs is very low, the 
enzymatic properties seem to be very similar and allow the isolation of UGPs by func-
tional complementation cloning in E.coli galU mutants (Peng et al., 1993). Due to a 
defect in the UGP, the E.coli galU mutant has lost its ability to ferment galactose, which 
can be restored upon the expression of a functional UGP (Sundararajan et al., 1962). 
As observed in the family of prokaryotic UGPs, eukaryotic UGPs were found to share a 
high sequence homology. Enzymes isolated from plants exhibit more than 80 % se-
quence identity. Between mammalian enzymes the identity was found to range between 
92-95 %, whereas the conservation between non-mammalian and mammalian enzymes 
ranges between 33-57 %. Despite the high homology, residues involved in the catalytic 
activity are difficult to predict. Site directed affinity labelling and site-directed mutagenesis 
have revealed the importance of specific lysines in the potato tuber and bovine liver UGP 
(Katsube et al., 1991, Kazuta et al., 1991 a,b, Konishi et al., 1993). Remarkably, not all 
the identified essential lysine residues are conserved. On the other hand, Chang et al. 
(1996) analysed a series of conserved amino acids in the human liver UGP, but none 
could be shown to play a major functional role. Thus, the determination of the three-
dimensional structure seems to be the most definitive way to identify residues important 
for the catalytic activity. Furthermore, the oligomerisation status differs between eu-
karyotic UGPs. The animal UGPs were reported to occur as octamers (Levine et al., 
1969) whereas the plant UGPs were found to be monomers or dimers (Nakano et al., 
1989, Sowokinos et al., 1993). Here, oligomeres have been reported to provide a form to 
sequestrate the active monomer (Martz et al., 2002). 
Plant and mammalian UGPs are very specific for their substrates UDP-glucose or glu-
cose-1 phosphate (Turnquist et al., 1974, Kleczkowski, 1994). However, UGPs isolated 
from human, calf or rabbit liver, from human muscle or yeast were found to exhibit a low 
affinity also for galactose-1 phosphate (Turnquist et al., 1974, Lai et al., 2000). Thus, 
despite the high sequence homology, the eukaryotic enzymes seem to differ with respect 
to their biochemical properties. 
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1.4.2 The UDP-galactose transporter 
The UDP-galactose transporter has been cloned from a number of species (Ishida et al., 
1996, Miura et al., 1996, Oelmann et al., 2001, Bakker et al., 2004) and shown to belong 
to the family of structurally related transmembrane proteins, the so-called nucleotide 
sugar transporter family. In eukaryotes, nucleotide sugar transporters (NSTs) transport 
the nucleotide sugars from the cytosol into the lumen of the ER or Golgi apparatus, 
where the nucleotide sugars are substrates for specific glycosyltransferases. 
NSTs are type III membrane proteins with six to ten transmembrane domains (TMDs) as 
predicted by hydropathy analysis. The study of the transmembrane topology of the 
murine CMP-sialic acid transporter revealed 10 TMDs with the N-and C-terminus facing 
the cytosol (Eckhardt et al., 1999). The cytosolic location of the N- and C-terminus was 
also shown for other nucleotide sugar transporters suggesting an even number of TMDs 
(Ishida et al. 1999, Aoki et al., 1999, Gao et al., 2000).  NSTs function as antiporters in 
an ATP- and ion independent manner (Capasso and Hirschberg, 1984). NSTs exchange 
the nucleotide sugar with the corresponding nucleoside monophosphate, generated in 
the organelle lumen by the sequential action of the glycosyltransferases and nucleoside 
diphosphatases. Over many years, NSTs were regarded as mono-specific transport 
proteins (Bernisone and Hirschberg, 2000), recent findings however, identified the 
existence of multi-substrate transporters in human (Muraoka et al., 2001, Segawa et al., 
2002), C. elegans (Berninsone et al., 2001), Drosophila (Goto et al., 2002, Selva et al., 
2002) and Leishmania (Hong et al., 2000). Still, the substrate specificity with respect to 
the base of the nucleotide sugar is high and so far, no transporter is known which cross-
transports nucleotide sugars containing different bases. 
 
The first genes encoding nucleotide sugar transporters were identified by complementa-
tion cloning in cell lines that had a defect in the corresponding nucleotide sugar trans-
porter. Examples are the yeast UDP-N-acetylglucosamine transporter (Abeijon et al., 
1996), the murine and hamster CMP-sialic acid transporter (Eckhardt et al., 1996 and 
1997), and the human UDP-galactose transporter (Miura et al., 1996, Ishida et al., 1996). 
Later, nucleotide sugar transporters were cloned based on the primary sequence and 
architectural conservation of these proteins (Oelmann et al., 2001). Today, virtually all 
putative NSTs have been identified in the existing databases. Their transport specificity 
cannot be predicted, since primary sequence identities can be high within a species - 
even for functionally different NSTs - and low for transporters recognising identical 
substrates but originating from different species (Bakker et al., 2004). Since the function-
ality of these proteins is highly conserved, the complementation approaches described 
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above provide an ideal basis for the identification and characterisation of NSTs, also in 
heterologeous systems (Berninsone and Hirschberg, 2001; Bakker et al., 2004). 
 
1.5 Glycosylation deficient CHO cells 
Glycosylation deficient cells were generated to study the pathways of glycoprotein and 
glycolipid biosynthesis in mammalian cells and to investigate structure-function-
relationships of carbohydrates expressed on the cell surface. Most glycosylation deficient 
cell lines originate from Chinese Hamster Ovary (CHO) cells. CHO cells are functionally 
haploid, meaning that one allele is inactivated by methylation (Holliday et al.,1990). The 
presence of only one functional allele explains the frequent occurrence of defects in 
these cells. A large number of CHO cell mutants were obtained by selection with plant 
lectins (Stanley and Siminovitch, 1977). Lectins are carbohydrate-binding proteins and 
many exert a cytotoxic effect. Thus, the selection with lectins results in lectin resistant 
mutants (LecR) that express altered carbohydrate structures on their surface (Stanley, 
1984). However, selection with lectins does not guarantee that mutants exhibiting identi-
cal phenotypes also exhibit identical genotypes, since the observed phenotype can be 
due to alterations in a number of enzymes involved in a specific biosynthetic pathway. 
One example is the selection with the sialic acid binding lectin wheat germ agglutinin 
(WGA). In mammals, complex N-glycan structures are terminated with sialic acid (Figure 
7). Defects in the sialylation machinery lead to an asialo-phenotype with surface glyco-
conjugates terminating in penultimate galactose. Asialo-cells are resistant to WGA but 
develop a high sensitivity against lectins recognising galactose. Many CHO cells with 
asialo-phenotype have been selected. Based on the underlying gene defect these cell 
lines could be classified into different complementation groups (Stanley, 1984). For 
example, CHO cells of the complementation group Lec32 exhibit a defect in the CMP-N-
acetylneuraminic acid synthetase (CMP-sialic acid synthetase), a nuclear resident 
enzyme responsible for the activation of sialic acid to CMP-sialic acid (Figure 7). The 
activation of the monosaccharide is essential for the entry in the glycosylation pathway 
because only the activated sugar can be transported by the CMP-sialic acid transporter 
into the Golgi apparatus and used by the Golgi localised sialyltransferases to be incorpo-
rated into glycoconjugates (Figure 7, Münster et al., 1998). 
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Fig.7 Scheme of the galactosylation and sialylation in the Golgi apparatus. 
 
However, CHO cells of the complementation group Lec2 express the asialo-phenotype 
because of a defect in the gene encoding the CMP-sialic acid transporter. 
Another example is the CHO cell line of the complementation group Lec8. Due to the 
lack of a functional UDP-galactose transporter these cells exhibit an agalacto-asialo-
phenotype (Deutscher et al., 1996). The missing UDP-galactose transport from the 
cytosol into the Golgi apparatus confers increased stability towards the cytotoxic and 
galactose binding Ricinus communis agglutinin. 
Up to now, over 40 Lec-variants were identified. The glycosylation mutants provide a 
valuable tool to identify enzymes of the biosynthesis pathway by complementation 
cloning. Using this technique our laboratory could isolate a number of enzymes involved 
in the biosynthesis of glycoconjugates like the murine and hamster CMP-sialic acid 
transporter (Eckhardt et al.,1996 and 1997), the murine CMP-N-acetylneuraminic acid 
synthetase (Münster et al., 1998) and as mentioned above, two UDP-galactose trans-
porter from Arabidopsis thaliana (Bakker et al., 2004).  
 
1.6 Aim of this study 
A common theme in drug developmental strategies is the identification of target struc-
tures that are unique for the pathogen and thus enable highly selective therapeutic 
approaches. The identification of such specific targets provides a particular challenge in 
eukaryotic pathogens that share many biosynthetic pathways with the host. However, for 
many years it is known that a large degree of variation is found in components that form 
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the glycocalyx in host and pathogen and the growing knowledge on the underlying 
biosynthetic pathways has developed new target structures for the therapeutic attack. 
The surface compounds LPG, PPG and GIPLs of L. major are important structures in 
establishing the infectivity in the sand fly vector and the mammalian host. A major com-
ponent of these glycoconjugates is galactose, which in the pathogen is present in two 
conformers, galactopyranose and galactofuranose. In the animal kingdom galactofu-
ranose is unkown, while the sugar is believed to be essential for the integrity and viru-
lence of various pathogens. In Mycobacteria the interference with galactofuranose 
formation has been demonstrated to be lethal. This finding has stimulated studies aimed 
at defining the importance of the sugar also in other pathogens. 
In the light of this situation, the aim of this study was to identify factors involved in the 
biosynthesis of galactose containing glycoconjugates in L. major. Based on our knowl-
edge in the field of complementation cloning, it was my goal to identify UDP-galactose 
transporters from L. major and to resolve the question, whether the activated forms of the 
two galactose conformers (UDP-galactofuranose and UDP-galactopyranose) are trans-
ported by different proteins. Surprisingly, this strategy of complementation cloning led to 
the identification of the UDP-glucose pyrophosphorylase from L. major, an enzyme even 
upstream of the UDP-galactose transporter, that represents a key structure in the galac-
tosylation pathway. The identified protein was further analysed with respect to (i) enzy-
matic characteristics, (ii) structural and kinetic characteristics, and (iii) physiological 
relevance. As will be demonstrated in this study, the UDP-glucose pyrophosphorylase 
provides a highly interesting target for therapeutic approaches, since inactivation of the 
gene in L. major significantly reduced the virulence of the pathogen. 
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2 Material and Methods 
2.1 Materials  
2.1.1  Eukaryotic cell lines 
CHO K1 (C6) :  Chinese hamster ovary cell line, subclone of the fibroblast line       
                                        CHO K1 (ATCC CRL 9618) produced by Dr. M. Eckhardt 
 
CHOP8  :  Chinese hamster ovary cell line Lec 8 defective in the UDP-  
     galactose transporter gene and stable transformed with the   
     polyoma virus large T-antigen (Cummings et al., 1993) 
 
CHO Lec8 : Chinese hamster ovary cell line Lec8 (ATCC CRL 1737) 
 
L. major 5 ASKH : Leishmania major promastigotes cell line, kindly provided by  
    Prof. Joachim Clos (BNI Hamburg) 
 
Additional CHO Lec8 cell lines (Lec 3.2.8 and Lec 4.7.8) were kindly provided by  
Pamela Stanley (Albert Einstein College of Medicine, NY, USA).   
 
2.1.2 Bacterial strains  
 
E.coli XL-1 blue : Genotype: recA1 endA1 gyr96 thi-1 hsdR17 supE44 relA1 lac  
(Stratagene) [F’ proAB lacIqZ∆M15 Tn 10 (Tetr)] 
 
E.coli XL-1 blue : Genotype : ∆(mcrA)183   
MRF’ (Stratagene)      ∆(mcrCB-hsdSMR-mrr) 173 endA1 supE44 thi-1 recA1 gyr96   
                                  relA1 lac  [F’ proAB lacIqZ∆M15 Tn 10 (Tetr)] 
 
 
E.coli BL21(DE3)  : Genotype: F- ompT hsdSB (rB- mB-) gal dcm (DE3) (Novagen) 
 
E.coli DEV6 : Genotype: galU65, relA1, spoT1, thi-1, lacZ(Am), provided by 
Elseviers et al., (1980) through the E.coli Genetic Stock Center, 
New Haven, USA 
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2.1.3 Plasmids  
 
pcDNA3  : Eukaryotic expression vector (Invitrogen) 
 
pcDNA3FL : Eukaryotic expression vector based on pcDNA3 bearing a Flag   
epitope (N-MBYKDDDDK-C) between the restriction sites  
       KpnI/BamHI (synthesised by Anja Münster) 
 
pOTB7-hUGP1 : cDNA clone of human muscle UGP1 obtained from the RZPD 
(Deutsches Ressourcenzentrum für Genomforschung GmbH, 
Berlin) library no.: 958, clone IMAGp958H18235Q2 
 
pCMV-hUGP2 : cDNA clone of human muscle UGP2 obtained from the RZPD 
(Deutsches Ressourcenzentrum für Genomforschung GmbH, 
Berlin) library No. 998, clone IMAGp998K047340Q3   
 
pETBos-GlcAT : Eukaryotic expression plasmid encoding the rat glucuronyltrans-
ferase (supplied by Terayama et a., 1997) 
 
peGFP : Eukaryotic expression plasmid encoding an enhanced green 
fluorescent protein (Clontech) 
 
pUC18  : Cloning vector and prokaryotic expression vector (Stratagene) 
 
pCR4-Topo : Cloning vector allowing the insertion of DNA fragments by TA 
cloning (Invitrogen) 
 
pCMV-Script : Eukaryotic expression vector (Stratagene) 
 
pET 22 b  : Prokaryotic expression vector for the expression of C-terminal  
   6xHis tagged proteins under the control of the T7/lac promoter  
(Novagen).  
 
pET22b-Strep : Prokaryotic expression vector based on pET22b (Novagen) 
including an N-terminal StrepII-sequence (WSHPQFEK) instead 
of the pelB-sequence. The StrepII-adaptor was inserted between 
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the restriction sites NheI und BamH I (synthesised by Dr. Martina 
Mühlenhoff, MH-Hannover). 
 
pYes2/NTA : Yeast expression vector (Invitrogen) 
 
pCR2.1hyg : Cloning vector bearing the hygromycin phosphotransferase 
gene that is inserted between the restrictions sites BspHI and 
NheI (supplied by Dr. Martin Wiese (BNI, Hamburg)). 
 
pCR2.1phleo : Cloning vector bearing the phleomycin binding protein gene that 
is inserted between the restrictions sites NcoI and AvrII (supplied 
by Martin Wiese (BNI, Hamburg)). 
 
pCR2.1neo : Cloning vector bearing the neomycin phosphotransferase gene 
that is inserted between the restrictions sites BspHI and NheI 
(supplied by Martin Wiese (BNI, Hamburg)). 
 
pAth-UGT2 : Eukaryotic expression vector for the expression of the UDP-
galactose transporter 2 from Arabidopsis thaliana (supplied by Dr. 
Hans Bakker, MH-Hannover) 
 
pACM1 : Eukaryotic expression vector based on pCMV-Script for expres-
sion of a C-terminal truncated L. major UGP. The clone was iso-
lated from pool #17 of the L. major cDNA library. 
 
pcDNA3-L. majorUGP :Eukaryotic expression vector based on pcDNA3 for                        
expression of untagged L. major UGP. UGP was amplified from 
pool 19 of the cDNA library using the primer pair ACM4/ACM6 
and inserted between the restriction sites BamHI/NotI of pcDNA3. 
 
pcDNA3FL- 
L. majorUGP : Eukaryotic expression vector based on pcDNA3FL for                                   
expression of N-terminal Flag tagged L. major UGP. UGP was 
amplified from pool 19 of the cDNA library using the primer pair 
ACM5/ACM6 and inserted between the restriction sites        
      BamHI/NotI of pcDNA3FL. 
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pcDNA3-hUGP1 : Eukaryotic expression vector based on pcDNA3 for                        
expression of untagged human UGP. UGP was amplified from 
plasmid pOTB7-hUGP1 using the primer pair ACM12/ACM9 and 
inserted between the restriction sites BamHI/NotI of pcDNA3 
 
pcDNA3-hUGP2 : Eukaryotic expression vector based on pcDNA3 for                        
expression of untagged human UGP. UGP was amplified from 
plasmid pCMV-hUGP2 using the primer pair ACM11/ACM9 and 
inserted between the restriction sites BamHI/NotI of pcDNA3 
 
pcDNAFL-hUGP1 : Eukaryotic expression vector based on pcDNA3FL for                        
expression of N-terminal Flag-tagged human UGP. UGP was 
amplified from plasmid pOTB7-hUGP1 using the primer pair 
ACM10/ACM9 and inserted between the restriction sites 
BamHI/NotI of pcDNA3FL 
 
pcDNA3FL-hUGP2 : Eukaryotic expression vector based on pcDNA3FL for                        
expression of N-terminal Flag-tagged human UGP. UGP was 
amplified from plasmid pCMV-hUGP2 using the primer pair 
ACM8/ACM9 and inserted between the restriction sites 
BamHI/NotI of pcDNA3FL 
 
pET-UGP-His : Prokaryotic expression vector based on pET-22b for expression 
of C-terminally His6- tagged L. major UGP. UGP was amplified 
from plasmid pcDNA3-L.majorUGP using the primer pair  
ACM112/ACM69 and inserted between the restriction sites 
NdeI/NotI of pET22b. 
 
pET22-UGP/ 
thrombin-His : Prokaryotic expression vector based on pET-22b for expression 
of C-terminally His6- tagged L. major UGP. A thrombin cleavage 
site was introduced with the primer ACM113. UGP was amplified 
from plasmid pcDNA3-L.majorUGP using the primer pair  
ACM112/ACM113 and inserted between the restriction sites 
NdeI/NotI of pET22b. 
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pET-UGP-∆38 : Prokaryotic expression vector based on pET-22b-Strep for 
expression of N-terminally by 38 amino acid truncated and 
StrepII- tagged and C-terminally His6- tagged L. major UGP. UGP 
was amplified from plasmid pcDNA3FL-L. major UGP using the 
primer pair ACM92/ACM69 and inserted between the BamHI/NotI 
restriction sites of pET-22b-Strep.  
 
pET-UGP-∆69  : Prokaryotic expression vector based on pET-22b-Strep for 
expression of N-terminally by 69 amino acid truncated and 
StrepII- tagged and C-terminally His6- tagged L. major UGP. UGP 
was amplified from plasmid pcDNA3FL-L. major UGP using the 
primer pair ACM93/ACM69 and inserted between the BamHI/NotI 
restriction sites of pET-22b-Strep.  
 
pET-UGP-∆440-494 : Prokaryotic expression vector based on pET-22b-Strep for 
expression of C-terminally by 54 amino acid truncated and C-
terminally His6- tagged and N-terminally StrepII- tagged L. major 
UGP. UGP was amplified from plasmid pcDNA3FL-L. major UGP 
using the primer pair ACM105/ACM5 and inserted between the 
BamHI/NotI restriction sites of pET-22b-Strep.  
 
pET-UGP-∆390-494 : Prokaryotic expression vector based on pET-22b-Strep for 
expression of C-terminally by 104 amino acid truncated and C-
terminally His6- tagged and N-terminally StrepII- tagged L. major 
UGP. UGP was amplified from plasmid pcDNA3FL-L. major UGP 
using the primer pair ACM106/ACM5 and inserted between the 
BamHI/NotI restriction sites of pET-22b-Strep.  
 
pcDNA3-5’FRs  : Construct used for subcloning of the L. major UGP 5’ flanking 
region (FR) for the further generation of a gene deletion cassette. 
The FR was amplified from genomic DNA using the primer pair 
ACM54/ACM55 and inserted between the restrictions sites 
XbaI/BamHI of pcDNA3. 
 
pcDNA3-3’FRs : Construct used for subcloning of the L. major UGP 3’ flanking 
region (FR) for the further generation of a gene deletion cassette. 
The FR was amplified from genomic DNA using the primer pair 
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ACM56/ACM57 and inserted between the restrictions sites 
KpnI/BamHI of pcDNA3. 
 
pcDNA3-3’5’FRs : Construct bearing the L. major UGP 5’ and 3’ FRs in pcDNA3. 
The 5’FR from plasmid pcDNA3-5’FRs was excised with 
XbaI/BamHI and inserted into the corresponding sites of pcDNA3-
3’FRs. 
 
pUC18-5’3’FRs : Construct to obtain an EcoRI site for subcloning of the L. major 
UGP FRs into pYes2/NTA ∆BspHI/∆NheI. The 5’ and 3’ FRs were 
excised from pcDNA3-3’5’FRs by a XbaI/ KpnI digest and in-
serted between the corresponding restriction sites of pUC18.  
 
pYes2/NTA∆BspHI  : Cloning vector without BspHI site based on the yeast expression 
vector pYes2/NTA . The vector pcDNA3 was digested with NcoI 
and the obtained 900 bp fragment ligated into the BspHI site of 
pYes2/NTA. 
 
pYes2/NTA 
∆BspHI/∆NheI : Cloning vector without BspHI and NheI site based on the yeast 
expression vector pYes2/NTA. pYes2/NTA∆BspHI was digested 
with NheI and AvrII and religated.  
 
p3’5’FRs : Construct bearing the L. major UGP 5’ and 3’ FRs in pY-
es2/NTA∆BspHI/∆NheI. After a XbaI/EcoRI restriction digest of 
pUC18-5’3’FRs the flanking regions were ligated into the corre-
sponding sites of pYes2/NTA ∆NheI/∆BspHI. 
 
p3’5’FRs-hyg : Construct bearing the hygromycin resistance marker flanked by 
the L. major UGP 5’ and 3’ FRs. The hygromycin resistant marker 
was excised with BspHI/NheI from pCR2.1hyg and ligated in the 
corresponding sites of p3’5’FRs. 
 
p3’5’FRs-neo : Construct bearing the neomycin resistance marker flanked by 
the L. major UGP 5’ and 3’ FRs. The neomycin resistant marker 
was excised with BspHI/NheI from pCR2.1neo and ligated in the 
corresponding sites of p3’5’FRs. 
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p3’5’FRs-phleo : Construct bearing the phleomycin resistance marker flanked by 
the L. major UGP 5’ and 3’ FRs. The phleomycin resistant marker 
was excised with NcoI/AvrII from pCR2.1phleo and ligated in the 
BspHI/NheI sites of p3’5’FRs. 
 
p5’UTR : Construct bearing 5’ flanking region 1095 to 16 nucleotides 
upstream of the region used in pcDNA3-5’FRs. The fragments 
was amplified from L. major genomic DNA with the primer pair 
ACM107/ACM108 and inserted into pCR4-Topo. 
 
2.1.4 Oligonucleotides 
All oligonucleotides were purchased from MWG. 
 
Sequencing primers for L. major UGP (5’ ➠ 3’) 
  
ACM1  GGGTGATGCTGAATTAGATG   
  
ACM2  ACCGGCATGGGGCTGTG 
 
Sequencing primers for L. major UGP flanking regions (5’ ➠ 3’) 
 
ACM61  ACTGGCGAATGGTCAGAAAAG 
ACM58  AAGCGTGGTCATCTCGATTAG 
 
Primers for homologous recombination control (5’ ➠ 3’) 
 
ACM94  CACGCTCATGTACGAGTT 
ACM96  CTGGGAAGACGTTGGCGATGC 
ACM99  GACGTCGCGGTGAGTTCAGG  
ACM100  GTCCGAGGGCAAAGGAATAG 
ACM101  GAACGGCACTGGTCAACTTGG 
ACM102  GTGGCCGAGGAGCAGGACTG 
 
Sequencing primers for plasmids (5’ ➠ 3’) 
 
T7  TAATACGACTCACTATA 
Sp6  GCATTTAGGTGACACTATAGAATAG 
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T7term  GCTAGTTATTTGCTCAGCGG 
pRSet-RPnew GGGTTATGCTAGTTATTGC 
 
PCR amplification primers (5’ ➠ 3’) 
 
ACM4 CGCGGGATCCGAAGCAATGGAAAACGAAAACGACATGAA BamHI 
ACM5 CGCGGGATCCGAAAACGACATGAAGTCCCTCAGC NotI 
ACM6 CGTGGCGGCCGCTTAGGCACCATCGGGGATCACAAAC NotI 
ACM8 CGCGGGATCCTCTCAAGATGGTGCTTC  BamHI 
ACM9 ATATGCGGCCGCTCAGTGGTCCAAGATGC  NotI 
ACM10 CGCGGGATCCTCGAGATTTGTACAAGATC  BamHI 
ACM11 ATATGGATCCGCCACCATGTCTCAAGATGGTGC BamHI 
ACM12 ATATGGATCCGCCACCATGTCGAGATTTGTACAAG BamHI 
ACM54 CTGATCTAGAAACGAAGACGAGCTACAGCGCATG XbaI 
ACM55 TAAAGGATCCCCATGGCTTCACCTCCGTGACAGC BamHI/NotI 
ACM56 GAAAGGATCCGCTAGCTAGGGGTCACAAGCTGCTGA BamHI/NheI 
ACM57 ATACGGTACCCCGCCGTCATCTGTCGATTGCACAC KpnI 
ACM69 CTTAGCGGCCGCATCTTGTTGGTCGACTGCTGCG NotI 
ACM92 AGTAGGATCCGTCAGTAAAGGCGAGACAGGGTC BamHI 
ACM93 AGTAGGATCCGCTGTCCTGCAGAGTACCGTTG  BamHI 
ACM105 CTTAGCGGCCGCATTTCCACCAGCGATGGCACGC NotI 
ACM106 CTTAGCGGCCGCATGGAGCGCAGAGCGAGCAGATC NotI 
ACM107 CTGGTGTGCAGAAGGAAGACG   TA cloning 
ACM108 GCATCGCCAACGTCTTCCCAG   TA cloning 
ACM112 CTGACTCCATATGGAAAAGCACATGAAGTCCCTC NdeI  
ACM113 ATATGCGGCCGCAGAACCACGCGGAACCAGCTTGTTGGTCGACTGCTGCG NotI 
 
 
2.1.5 Chromatography columns 
StrepTactin affinity matrix IBA 
HisTrap HP Ni2+ column (5ml) Amersham Biosciences 
HiPrep 26/10 Desalting Amersham Biosciences 
Superdex 200 HR 10/30 Amersham Biosciences 
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2.1.6 Antibodies 
2.1.6.1 Primary antibodies 
mAb anti-penta His :monoclonal antibody (mouse IgG) directed against the His6-
epitope (HHHHHH) (Qiagen) 
mAb 735 :monoclonal antibody (mouse IgG 2a) directed against poly-α2,8-
N-acetylneuraminic acid with a minimum chain length of eight 
residues (Frosch et al., 1985) 
mAb L2-412 : monoclonal antibody directed against glucuronic acid ß1,3-
linked to galactose 
anti-Flag M5 : monoclonal antibody (mouse IgG1) directed against the Flag-
epitope (MDYKDDDDK) (Sigma) 
anti-Flag : chicken polyclonal antibody directed against the Flag-epitope 
(MDYKDDDDK) (Sigma) 
WIC79.3 mAb : monoclonal antibody (mouse IgG1) directed against galactose 
substituted repeating unit of LPG (Gal-Man-PO4) (ascites fluid 
supplied by Martin Wiese) 
LT6 : monoclonal antibody (mouse IgG1) directed against unsubsti-
tuted repeating unit of LPG (Gal-Man-PO4) (Ilg et al, 1993, hybri-
doma culture supernatant supplied by Martin Wiese) 
Anti-calnexin : polyclonal rabbit serum (supplied by Prof. A.Hellinius, ETH 
Zürich, Schweiz) 
Anti-mannosidaseII : polyclonal rabbit serum (supplied by Prof. K.Moreman; Univer-
sity of Georgia, USA) 
 
2.1.6.2 Secondary antibodies, sera and conjugates 
 
Anti-rabbit-IgG Alexa488-conjugate  Molecular Probes 
Anti-mouse-IgG Cy3 conjugate   Sigma 
Anti-mouse-IgG FITC conjugate   Dianova 
Anti-Digoxigenin Fab AP conjugate  Roche 
Anti-mouse-Ig AP conjugate   Dianova 
Anti-mouse-Ig HRP conjugate   Dianova 
Anti-chicken-IgG AP conjugate   Dianova 
Anti-rabbit-Ig HRP conjugate   Dianova 
Streptavidin AP    Dianova 
DAPI     Sigma 
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2.1.7 Molecular weight markers 
 
‘1 kb DNA ladder’     Invitrogen 
‘SDS-PAGE molecular weight standards high range’  BioRad 
‘Prestained Precision Protein Standards’   BioRad 
 
2.1.8 Enzymes 
 
Alkaline calf intestine phosphatase New England Biolabs  
cloned Pfu-DNA-Polymerase  Stratagene 
Glucose-6 phosphate dehydrogenase Roche 
Lysozyme Serva 
Phosphoglucomutase Roche 
Restriction enzymes  New England Biolabs 
T4-DNA-Ligase  New England Biolabs  
Taq-DNA-Polymerase  Sigma 
UDP-galactose-4 epimerase Roche 
UDP-glucose dehydrogenase Roche 
 
Enzymes used for the generation of the L,major cDNA library were part of the  ‘pCMV-
ScriptXR cDNA library construction kit’ from Stratagene. 
 
2.1.9 Culture media and additives 
 
Adenin Sigma 
Alpha MEM GibcoBRL 
Ampicillin, sodium salt Serva 
Anti-Flag M5 sepharose beads Sigma 
Biotinthyramid Molecular probes 
Carbenicillin, disodium salt Fluka 
Complete and incomplete Freund’s adjuvant Becton Dickinson 
European Mistletoe Sigma 
Fetal calf serum Invitrogen 
Hemin Fluka 
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Hygromycin B Sigma 
IPTG (Isopropyl-beta-D-thiogalactopyranoside) Merck 
Kanamycin Sigma 
LB-agar Becton Dickinson 
LB-medium  Becton Dickinson 
M199 powder GibcoBRL 
MacConkey agar (base) Becton Dickinson 
Neomycin Sigma 
Noble agar Becton Dickinson 
OptiMEM Invitrogen 
paraformaldehyde Sigma 
Penicillin/Streptomycin Sigma 
Phleomycin Sigma 
Poly (L)-lysine Sigma 
Ricinus communis agglutinin Sigma 
RotiTMPhenol Roth 
Trypsin/EDTA (0,5%Trypsin, 0,2% EDTA) GibcoBRL 
Wheat germ agglutinin Sigma 
α-D galactose Sigma 
α-D glucose Sigma 
  
2.1.10 Kits and further materials 
 
Cell culture bottles and dishes Sarstedt 
Cellulose acetate filter (0,22µm, 0,8 µm) Sartorius 
Electroporation cuvettes BioRad 
Filterpaper  Whatman 
Hyperfilm MP Amersham Biosciences 
Microtiterplates 96-well polystyrol (U-bottom) Greiner 
Nitrocellulose membrane (0,45 µm) Schleicher & Schuell 
Nylon membrane (Hybond-N+) Amersham Biosciences 
Oligotex mRNA Mini Kit Qiagen 
pCMV-ScriptXR cDNA library construction kit Stratagene 
PCR-tubes (0,2 ml) Biozym 
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Plastic disposable pipettes (5 ml, 10 ml, 25 ml) Sarstedt 
Polypropylentubes (14 ml, 50 ml) Greiner 
Protein Standard kit for gelfiltration Roche 
QIAGEN Plasmid Mini und Midi Kit Qiagen 
QIAquick Gel Extraction Kit Qiagen 
Qiaquick PCR purification kit Qiagen 
Reaction tubes (0.5 ml, 1.5 ml) Sarstedt 
Reaction tubes safelock (1.5 ml, 2 ml) Eppendorf 
RNeasy Midi Kit Qiagen 
Sterile filters Millex GP (0,22 µM) Milipore 
Syringes (2 ml) Braun 
 
2.1.11 Standard buffer and media 
 
20xSSC 3 M NaCl 
0.3 M Sodiumcitrate pH 7.0 
2xLaemmli 200 mM Tris-HCl pH 6.8 
30% (v/v) glycerol 
3% (w/v) SDS 
0.1% (w/v) bromephenol Blue 
5% (v/v) 2-mercaptoethanol 
5xGEBS 20% glycerol 
50 mM EDTA 
0.05% bromephenol Blue  
0.5% sarcosyl 
5xLaemmli 600 mM Tris-HCl pH 6.8 
40% (v/v) glycerol 
10% (w/v) SDS 
0.4% (w/v) bromephenol Blue 
5% (v/v) 2-mercaptoethanol 
AP-buffer 100 mM Tris-HCl pH 9.5  
100 mM NaCl 
5 mM MgCl2 
BCIP 25 mg/ml BCIP in 100% DMF 
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ECL-reagent 125 mM Luminol 
45 mM p-Cumarsäure 
1M Tris/HCl pH 8.5 
15% H2O2 
NBT 50 mg/ml NBT in 70% (v/v) DMF 
PBS 10 mM sodium phosphate pH 7.4 
150 mM NaCl 
PBS/EDTA 10 mM sodium phosphate, pH 7.4 
150 mM NaCl 
2 mM EDTA 
SOB (SOC) 2% bacto tryptone  
0.5% yeast extract  
10 mM NaCl 
2.5 mM KCl 
10 mM MgCl2 
10 mM MgSO4 
(2% glucose) 
 
TAE 40 mM Tris-Acetat 
2 mM EDTA 
pH 8.5 
TBE 100 mM Tris-HCl, pH 8.0 
100 mM Borate 
2.5 mM EDTA 
TE  10 mM Tris-HCl, pH 8.0 
1 mM EDTA 
 
2.1.12 Chemicals 
ABTS  Roche 
Acetic acid (100 %) Merck 
Aceton Baker 
Acrylamide 40% 4 K-Mix (37.5:1) Serva 
AEC Sigma 
Agarose Serva 
Ammonium chloride  Merck 
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Ammonium persulphate (APS) Serva 
Aprotinin   Bayer 
BCA Protein Assay Reagent  Pierce  
BCIP (5-Brom-4-chlor-3-indolyl-phosphat) Fluka 
Bestatin Sigma 
Beta-Mercaptoethanol Sigma 
Biotintyramid Molecular probes 
Borate, sodium salt Merck 
Bromphenol Blue, sodium salt Applichem 
BSA (Fraktion V) Applichem 
BSA protein standard Pierce 
Chloroform Baker 
Citric acid Merck 
CSPD Roche 
Desthiobiotin Sigma 
Dimethylformamide (DMF) Fluka 
Dimethylsulfoxide (DMSO) Merck 
Dipotassium hydrogenphosphate Merck 
Disodium hydrogenphosphate  Merck 
Disodium hydrogenphosphate Merck 
Dithiothreitol (DTT) Sigma 
dNTPs (100 mM each) Pharmacia 
Dry milk Applichem 
EDTA, Disodium salt (Titriplex III) Merck 
Ethanol, abs. Baker 
Ethidium Bromide USB Corporation 
Fast Red Sigma 
Formaldehyde Sigma 
Galactose-1 phosphate Sigma 
Glucose-1 phosphate Sigma 
Glutardialdehyd Roche 
Glycerine (99%) KMF 
Glycine Sigma 
Gucose-1,6 biphosphate Roche 
Hydrochloric acid (38%) Baker 
Hydrogenperoxid Fluka 
Imidazole Fluka 
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IPTG (Isopropyl-beta-D-thiogalactopyranoside)  Merck 
Isopropanol (2-Propanol) Merck 
Korsolex plus Roche 
LipofectAMINE transfection reagent Invitrogen 
Magnesium chloride hexahydrate Merck 
Magnesium sulphate Baker 
Manganese chloride Merck 
Methanol Baker 
Moviol Baker 
NAD+ Roche 
NADP+ Roche 
Naphtol Sigma 
NBT (Nitrotetrazolium bluechloride) Fluka 
Pepstatin Roche 
Phenylmethylsulfonyl fluorid (PMSF) Sigma 
Ponceau S, sodium salt Sigma 
Potassium dihydrogenphosphate Merck 
Pyrophosphate Sigma 
Roti-Blue Coomassie-stain (5x) Roth 
Saponin Sigma 
Sodium acetate Merck 
Sodium azide  Merck 
Sodium chloride Merck 
Sodium dihydrogenphosphate  Merck 
Sodium dodecylsulphate (SDS) Merck 
Sodium hydroxide Merck 
Sodium periodate  Sigma 
TEMED (N,N,N’,N’-Tetramethyl-ethylendiamin) Serva 
TRIS (Tris(hydroxymethyl)-aminomethan) Merck 
UDP-glucose Sigma 
UTP Roche 
 
All chemicals not explicitly listed above were purchased in p.a. quality from either Merck 
or Sigma. 
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2.1.13 Laboratory Equipment 
 
Blotting chamber  Fast-Blot B44 Biometra 
Easy Enhanced Analysis System  
(E.A.S.Y RH-3, Videokamera 429K) 
Herolab 
Elektrophoresis chamber for agarose-gels peqlab 
Elektrophoresis chamber for SDS-PAGE BioMetra 
ELISA-Reader: DigiScan Asys Hitech 
FPLC-system ÄKTA  Amersham Biosciences 
Heatingblock TB1 BioMetra 
HeraSafe Hood Heraeus 
Incubators Heraeus 
Peristaltikpump P-1 Amersham Biosciences 
Scales CP 224S (µg) / CP 3202 (g) Sartorius 
Sonifier 450 Branson 
Spectrophotometer Ultrospec 2100 pro Amersham Biosciences 
Speedvac RVC 2-18 Christ 
Standard Power Pack P25 Biometra 
Thermocycler T1 and T Gradient Biometra 
Thermomixer compact Eppendorf 
Centrifuges :  - Biofuge fresco  
 - Biofuge pico  
 - Multifuge 3 S-R 
 - Centrifuge 5415C 
 - Coulter Avanti J-30I 
Rotors: - JA 25.50 
 - JLA 10.500 
 - JS-24.15 
Heraeus  
Heraeus 
Heraeus 
Eppendorf 
Beckman 
Beckman 
Beckman 
Beckman 
Stratalinker Stratagene 
Electroporator BioRad 
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2.2 Cell biological techniques (CHO cells) 
 
2.2.1  Cultivation of CHO cells 
CHO cells were cultured in a humidified incubator at 37°C and 5% CO2. The cells were 
grown in α-MEM (GibcoBRL) supplemented with 5% fetal calf serum (FCS). Every 3-4 
days, confluent cell layers were detached from the cell culture flask with Trypsin/EDTA 
(GibcoBRL) and transferred to a new devise at a concentration of 5x105cells/75 cm2. 
Cells were counted in a Neubauer chamber. 
 
For long term storage in liquid nitrogen, cells were pelleted by centrifugation (5 min, 
2000xg, RT) and resuspended in culture medium containing 10 % FCS and 10 % DMSO 
at a concentration of 1x107 cells/ml. Aliquots of 1 ml were filled in cryo vials, stored 
overnight at -80°C and then transferred to liquid nitrogen.  
 
To recover frozen cell pellets, the cells were thawed at room temperature (RT) and 
transferred into 10 ml  α-MEM supplemented with 5% FCS. After centrifugation (5 min, 
2000xg, RT) the cell pellet was resuspended in culture medium (5 % FCS) and trans-
ferred to a culture flask. 
 
2.2.2 Transient transfection of CHO cells 
For the transient transfection of CHO cells, the cells were seeded in 6-well plates (9.6 
cm2) at a concentration of 3x105 cells/well and incubated over night.  For each well, a 
transfection mixture was prepared by combining 1 µg DNA in 100 µl OptiMEM with 6 µl 
LipofectAmine in 100 µl OptiMEM. Upon cotransfection with cDNA encoding the rat 
glucuronyltransferase (pEFBos-GlcAT), 0.5 DNA and 0.5 µg pEFBosGlcAT was used. 
After an incubation of 15-30 min at RT, the mixture was filled up to 1 ml with OptiMEM. 
Prior to the addition of the transfection mixture, the cell layer was washed once with 1 ml 
OptiMEM. After 6 hours, 1 ml culture medium was added and the cells analysed after 48 
hours.  
 
2.2.3 Immunocytochemistry  
For immunocytochemistry, transiently transfected CHO cells (2.2.2), were washed once 
with 2 ml TBS and were fixed with 1 ml 1.5% glutarealdehyde for 10 min. The cell layer 
was washed two time with TBS and blocked  in 2% milk powder/TBS. Cells cotransfected 
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with pETBosGlcAT, were stained with rat monoclonal antibody (mAb) L2-412 (1:4000) in 
the same solution, followed by an alkaline phosphatase conjugated α−rat secondary 
antibody (1:4000).  Polysialic acid was detected with the murine mAb 735 (5 µg/ml) and 
an alkaline phosphatase-conjugated α−mouse secondary antibody (1:4000).  The cells 
were washed 3-4 times with 2 ml TBST (0.05% Tween)   after each antibody incubation. 
For colour development, the substrate Fast-Red (Sigma) was dissolved in 0.1 M Tris/HCl 
pH 8.5 and 0.2 mg/ml  Naphtol (Sigma) at a concentration of 1 mg/ml and incubated with 
the cells. The reaction was stopped by the addition of 1 ml water. Plates were analysed 
under a normal light microscope and red cells per plate were scored. The plates could be 
stored in 50% glycerol at 4°C for two years. 
Signal amplification was achieved by using a HRP-coupled secondary antibody followed 
by the incubation with a biotintyramid solution (Molecular Probes) in TBS for 10 min at 
RT, consisting of 0.1 M imidazole pH 7.6; 0.001% H2O2 and 1,7 mM biotintyramid. The 
cells were washed two times in TBST and incubated with Streptavidin AP (1:500).  
 
For colour development using the substrate AEC (3-amino-9ethyl-carbasol, Sigma), the 
cells were incubated with a HRP-coupled secondary antibody and the AEC staining 
solution of 50 mM NaAc, 0.016% H2O2 and 1 mg/ml AEC . Lilac cells were monitored 
under a normal light microscope. 
 
2.2.4 Immunofluorescence 
Transiently transfected CHO cells (2.2.2) were grown on glass cover slides placed in 6 
well plates. The cells were washed two times with PBS and fixed in 4% paraformalde-
hyde (PFA) for 20 min at RT. After three washing steps in PBS, additional binding sites 
were blocked with 0,1% BSA/PBS for 30 min at RT. To permeabilize the cells, 0.2 % 
saponin was added to the blocking solution. After permeabilization, samples were incu-
bated with the primary antibodies diluted in 0.1% BSA in PBS for 1 hour at RT (mouse 
α−Flag M5 mAb 1:1000, rabbit α−mannosidase II antiserum 1:2000, rabbit α−calnexin 
antiserum 1:2000). The cells were washed three times in 0.1% BSA in PBS and bound 
antibodies were detected with the corresponding secondary antibodies diluted in 0.1% 
BSA/PBS: α−mouse IgG Cy3 (1:500) and α−rabbit IgG Alexa488 (1:500). After 1 hour at 
RT, the reactions were stopped by three washing steps in 0.1% BSA/PBS and a final 
wash in PBS. Slides were mounted in moviol and analyzed under a Zeiss fluorescence 
microscope.   
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2.2.5 FACS analysis of CHO cells  
The cells were detached from the cell culture flask with PBS/2 mM EDTA and counted in 
a Neubauer chamber. 1x106 cells per sample were transferred into a 1.5 ml eppendorf 
tube and centrifuged for 1 min at 1500xg. The pellets were resuspended in 1 ml 0.1% 
BSA in PBS and again centrifuged at 1500xg for 1 min. The cells were incubated with 50 
µl of primary antibody (5 µg/ml: mAb 735: 1:1200) for 15 min at 4 °C. After one washing 
step with 350 µl 0,1% BSA/PBS, the cell pellets were resuspended in 50 µl of a secon-
dary antibody dilution (α−rat FITC 1:50 in 0.1% BSA/PBS). After 15 min at 4°C, the 
samples were washed twice with 350 µl 0.1% BSA/PBS and resuspended in 1 ml 
0.1%BSA/PBS. In the FACS analysis, 10 000 cells per sample were counted using a 
Becton Dickinson FACSCalibur. 
 
2.2.6 Selection of galactose negative CHO Lec8 cells 
2.2.6.1  Selection via panning 
Panning describes a technique to separate cells bearing a certain antigen on the cell 
surface from cells devoid of this antigen. The cells are incubated with a corresponding 
immobilized antibody. Positive cells bind to the antibody and can be removed from the 
cell population. To remove, polysialic acid (PSA) positive cells from a CHO Lec8 cell 
population, panning plates with immobilized mAb 735 were prepared. Therefore, 10 cm 
Petri dishes were incubated with 10 ml of a mAb 735 dilution (10 µg/ml) in 50 mM 
Tris/HCl pH 9.5 for 6h at RT. The antibody dilution was removed and used to coat a 
second set of Petri dishes at RT over night. The dishes were washed three times with 
PBS and blocked with 10 ml 1% BSA in PBS at 4°C over night. After two washing steps, 
the plates were stored at -20°C. 
 
Petri dishes coated with mAb 735 were thawed by the addition of 10 ml culture media 
(see 2.2.1). The CHO cell layers were treated with PBS/2 mM EDTA to detach the cells 
from the cell culture flask. 1x107 cells were incubated on the coated Petri dish for 1 hour 
at 4°C. PSA positive cells adhere to the Petri dish whereas PSA negative cells remain in 
the supernatant. To obtain a PSA negative cell line, the cells in the supernatant were 
removed and cultivated. 
 
2.2.6.2  Selection  by lectin treatment 
To obtain galactose and sialic acid negative CHO Lec8 cells, a dilutions series of the 
lectins European Mistletoe, Wheat Germ Agglutinin (WGA) and Ricinus communis 
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agglutinin (RIC) was added to the cell culture medium. As a control, CHO wild type cells, 
that express galactose and sialic acid containing glycoconjugates on the cell surface, 
were treated in the same way. Thus, CHO Lec8 cells and CHO wild type cells were 
seeded on 6 well plates at a concentration of 3x105 cells per well. After 10 hours, the 
lectins European Mistletoe,  WGA and RIC were added to the cell culture media in three 
separate experiments. The lectin Eurpoean Mistletoe was used in the concentrations of 3 
ng/ml, 10 ng/ml, 30 ng/ml, 100 ng/ml 300 ng/ml and 1 µg/ml and WGA in the concentra-
tions of 1 µg/ml, 5 µg/ml, 10 µg/ml, 15 µg/ml and 20 µg/ml. The following RIC concentra-
tions were applied: 300 ng/ml, 1 µg/ml, 3 µg/ml, 10 µg/ml and 30 µg/ml. The galactose 
and sialic acid positive CHO wild type cells, died more rapidly with increasing lectin 
concentrations than the CHO Lec8 cells. The success of the selection was monitored by 
immunocytochemistry using the mAb 735 and the biotintyramid signal amplification step.   
 
2.3 Cell biological techniques (Leishmania major) 
2.3.1 Cultivation of Leishmania major (L. major) 
Promastigote Leishmania major were grown in M199 media supplemented with 10% 
FCS, 40 mM Hepes pH 7.5, 0.1 mM adenine, 0.0005% hemin, 0.0002 % biotin and 50 
U/ml penicillin/streptomycin (M199 culture media). The cultures were maintained in a 
humidified incubator at 26°C by serial passage of 10 ml cultures at dilutions of 1:100 
every 2-3 days. The saturation densities of L. major 5ASKH ranged from 4-5 x107 
cells/ml. If necessary, 5 µg/ml phleomycin, 50 µg/ml neomycin and 50µg/ml hygromycin 
were added to the culture medium. 
 
For long time storage, 1x107 cells were pelleted, resuspended in 500 µl M199 culture 
media supplemented with 10% DMSO and transferred into cryo tubes. Cells were slowly 
frozen in the gas phase of the liquid nitrogen tank over night. The next day the tubes 
were transferred into liquid nitrogen. 
 
To recover frozen L. major, the cryo tube was removed from liquid nitrogen and thawed 
in a water bath at 37°C. The cell suspension was directly added to 10 ml M199 culture 
medium. 
 
2.3.2 Homolgous gene replacment in L. major promastigotes  
Homologlous gene replacement in L. major was achieved by the introduction of the gene 
replacement cassette using electroporation and subsequent selection on selective M199 
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agar.  Protocols were kindly provided by Prof. Jon LeBowitz (Purdue University, West 
Lafayette, USA) and combined with an improved transfection protocol according to 
Robinson et al., (2003).Cells suitable for transfections were harvested in the late loga-
rithmic phase, which ranges from 5x106 cells/ml to 1x107 cells/ml for L. major 5ASKH. 
1x108 cells per sample were pelleted for 10 min at 1300xg and washed once in electro-
poration buffer (21 mM Hepes, pH 7.5, 137 mM NaCl, 5 mM KCl, 0.7 mM NaHPO4, 6 mM 
glucose). After a second centrifugation step, the pellet was resuspended in 500 µl elec-
troporation buffer and mixed with 2 µg linearized DNA bearing a resistant marker cas-
sette in a 4 mm cuvette. The cells were electroporated by two pulses using 25µF and 1.5 
kV and incubated on ice for 10 min. The sample was transferred into 10 ml M199 culture 
medium in a cell culture flask. After 24 hours, the whole culture was centrifuged, resus-
pended in 100 µl culture media and spread on M199 agar (2x M199 culture media 
combined with an equal volume of 2% noble agar) containing the appropriate antibiotics. 
The plates were wrapped with parafilm and placed upright in a 26°C incubator. Colonies 
appeared after 2 weeks and were expanded in liquid culture. The number of colonies is 
dependend on the transformation efficiency which approaches 10-4 at saturating DNA 
concentrations for L. major (Kapler et al, 1990, Coburn et al, 1991), the plating efficiency 
and the DNA construct.  
 
2.3.3 FACS analysis of L. major 
For the FACS analysis, 1x106 log phase parasites per sample were centrifuged at 
1300xg for 10 min. The cells were washed two times in FACS buffer (PBS, 3% FCS, 
0.05% NaN3) and incubated in 100 µl of the primary antibody diluted in FACS buffer for 
30 min at 4°C (WIC 79.3 mAb 1:2000). After one washing step, 100 µl of secondary 
antibody was added to the cells (goat α−mouse FITC, 1:500 in FACs buffer) and incu-
bated for 30 min at 4°C. The cells were washed three times in FACs buffer and finally 
resuspended in 100 µl FACs buffer containing 4% PFA. Per sample, 50 000 cells were 
counted with a Becton Dickinson FACSCalibur system.  
 
2.3.4 Immunofluorescence 
For immunoflourescence labelling, the parasites were immobilized on 10- well glass 
coverslips coated with poly(L)-lysine (0.1 mg/ml in PBS). 2x104 cells per well were 
washed once with PBS and fixed in the well by the addition of 4% PFA. After 15 min at 
RT, the samples were washed twice with PBS and incubated with 50 mM NH4Cl for 
another 15 min at RT. Additional binding sites were blocked with 2% BSA in PBS for 15 
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min at RT. The same buffer was used for the incubation with the primary antibody (WIC 
79.3 mAb 1:2000 (ascites fluid), LT6 1:2 (hybdridoma culture supernatant)). After 1 hour 
at RT, the cells were washed 4 times with PBS and incubated with a mixture of secon-
dary antibody and DAPI in 2% BSA/PBS for 30 min at RT (goat α−mouse Cy3 1:500, 
DAPI 1:100). After five washing steps, the slides were mounted in moviol and analysed 
with a 40 x magnification of a Zeiss fluorescence microscope.  
 
2.3.5 Mice infection assay 
For mice infection assays, 107 cells were centrifuged at 1300xg for 10 min, resuspended 
in 1 ml PBS and again pelleted. The pellet was resuspended in 100 µl PBS and immedi-
ately injected into the left hind footpad of a Balb/c mouse (Charles River). Infection was 
monitored once a week by measuring the infected and the non-infected footpad with a 
Vernier calliper. The median size difference (+/- MAD) of the infected and uninfected 
footpad was plotted against the weeks post infection.  
 
2.4 Biochemical techniques 
2.4.1 Protein estimation 
Protein concentrations were estimated using the ‘BCA Protein Assay Reagent’ (Pierce) 
according to the manufacturers instructions. Briefly, reagents A and B were mixed 50:1 
immediately before use. 200 µl of the mixture were added to 10 µl sample and incubated 
at 55°C for 30 min in 96-well microtiter plates. As reference, a dilution series of 25-200 
µg/ml BSA was included. The absorbance of all samples was measured at 540 nm using 
the ELISA-Reader ‘DigiScan’ (Asys Hitech) and protein concentrations were calculated 
from the BSA standard curve. 
 
2.4.2 Polyacrylamide gelelectrophoresis (SDS-PAGE) 
SDS-PAGE was performed according to Laemmli (Laemmli, 1970). Protein samples 
were seperated on SDS-polyacrylamide gels composed of a 5 % stacking gel (125 mM 
Tris/HCl pH 6.8, 0.1 % SDS, 5 % polyacrylamide) and a 10 % separating gel (375 mM 
Tris/HCl pH 8.8, 0.1 % SDS, 7-14 % polyacrylamide) or 8% ProSieve® 50 (gel solution, 
Cambrex) gradient gel. Gels were prepared by mixing buffer, SDS and the acrylamide 
stock solution (37.5 % acrylamide, 1 % bisacrylamide or ProSieve) and polymerisation 
was initiated by adding 0.1 % TEMED and 1 % ammonium persulphate. Samples were 
mixed with 2x or 5x Laemmli-buffer and heated to 95 °C for 5 min.  Electrophoresis was 
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performed in SDS-electrophoresis buffer (50 mM Tris, 350 mM glycine, 0.1 % SDS) at 15 
mA (stacking gel) and 20 mA (separating gel) per gel.   
 
2.4.3 Coomassie staining of polyacrylamide gels 
For Coomassie staining of protein gels, the colloidal staining solution Roti®-Blue (Roth) 
was used.  Directly after electrophoresis (2.4.2), the gels were incubated in 20 ml 
1xRoti®-Blue in 20 % methanol overnight. The gels were destained in drying buffer (20 % 
ethanol, 10 % glycerol) and dried after 3-4 hours.  
 
2.4.4 Silver staining of polyacrylamide gels 
For silver staining the gels were incubated overnight in fixing solution (30 % ethanol, 
10 % acetic acid, 1.85 % formaldehyde). After two washing steps (20 min, 50 % ethanol) 
the gels were incubated for exactly 1 min in thiosulphate solution (20 mg/100 ml), 
washed three times for 20 sec in deionised water and incubated for 20 min in staining 
solution (0.2 % (w/w) AgNO3, 2.8 % formaldehyde). After two washing steps in deionised 
water for 20 sec, the gels were incubated in freshly prepared developer solution 
(6 % (w/w) NaCO3, 2 % (v/v) thiosulphate solution, 1.85 % formaldehyde) until protein 
bands were lighting up. The reaction was stopped by transferring the gels to stop solution 
(30 % ethanol, 10 % acetic acid) and gels were dried after 1 h incubation in drying-buffer 
(20 % ethanol, 10 % glycerol).  
 
2.4.5 Western Blotting 
Proteins separated by SDS PAGE were transferred to nitrocellulose membranes using a 
semidry blotting chamber (Biometra) at 2 mA/cm2 for 1 h.  Gel and membrane were 
placed between two layers of Whatman filter paper soaked in blotting buffer (48 mM Tris, 
39 mM glycine). To check the transfer efficiency and to label the bands of the unstained 
molecular weight standard, the membrane was reversibly stained in Ponceau S-solution 
(0.2 % (w/v) Ponceau S in 3 % TCA) and destained in deionised water and PBS.  
 
2.4.6 Immunostaining of Western Blots 
The nitrocellulose membranes (2.4.5) were blocked overnight in blocking buffer consist-
ing of 2% milk powder/ PBS or 2% BSA/PBS for AP- or HRP detection, respectively. 
After three washing steps for 5 min in PBS, the membranes were incubated for 1 h with 
the primary antibodies in the corresponding blocking solution (anti-penta His mAb 
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1µg/ml, chicken anti-Flag serum 1:500; WIC 79.3 mAb 1:2000 (ascites fluid)). The blots 
were washed three times for 5 min with PBS and incubated either with a HRP- or AP-
coupled secondary antibody in blocking buffer for 1 hour at RT. 
 
2.4.6.1  Detection of AP coupled secondary antibody 
After secondary antibody incubation ( α−mouse Ig coupled to AP: 1:4000, α−chicken IgG 
coupled to AP 1:4000), the membranes were rinsed three times with PBS and once with 
AP buffer (100 mM Tris-HCl pH 9.5, 100 mM NaCl, 5 mM MgCl2). The visualization of the 
proteins was achieved by incubation with the substrate BCIP/NBT (0.3 mg/ml NBT, 
0.15 mg/ml BCIP in AP-buffer). The reaction was stopped by the addition of water.  
 
2.4.6.2  Detection of HRP coupled secondary antibody 
For the detection of HRP-coupled secondary antibody (α−mouse Ig coupled to HRP: 1:50 
000 in 2% BSA/PBS) the ECL system was used. The membranes were washed 4 times 
for 10 min in TBST (0,1 % Tween). The ECL detection solution was prepared by mixing a 
Luminol  solution (250 mM Luminol, 90 mM p-Cumarsäure, 1 M Tris/HCl, pH 8.5) with a 
hydrogenperoxid  solution (1 M Tris/HCl, pH 8.5, 30% H2O2) in a 1:1 ratio. After 15 min of 
incubation, the ECL solution was soaked off the membrane. The blot was wrapped in a 
plastic sheet and the signals exposed for 1-10 min to a film (Hyperfilm MP). 
 
2.4.7 Solubilisation of CHO cells     
The cells were washed once with PBS. The lysis buffer (50 mM Hepes pH 8.0, 250 mM 
NaCl, 1 mM EDTA, 0.5% IGEPAL, 10% glycerol, 28 µg/ml Aprotinin, 1 mM PMSF) was 
directly added onto the cell layer. The buffer and the cells were incubated for 3 min and 
transferred to an eppendorf tube. After incubation for 30 min at 4°C, the cell debris was 
removed by centrifugation at 13000xg for 30 min at 4°C. An aliquot of the cell lysate was 
mixed with 5x Laemmli buffer and separated by SDS PAGE (2.4.2) and the rest used for 
immunoprecipitation experiments (2.4.8).  
 
2.4.8 Immunoprecipitations 
For immunoprecipitations, at least 5x106 cells per sample were lysed in 1 ml lysis buffer 
as described in 2.4.7. and the cell lysates incubated with 15 µl of a 50% slurry α-Flag M2 
agarose beads (Sigma). After 2 hours at 4°C under permanent rotation, the samples 
were centrifuged at 5000xg for 30 seconds. The supernatant was removed and the 
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beads washed four times with 1 ml lysis buffer (50 mM Hepes pH 8.0, 250 mM NaCl, 1 
mM EDTA, 0.5% IGEPAL, 10% glycerol). The samples were resuspended in 30 µl 2x 
Laemmli buffer, boiled at 95°C for 5 min and separated on a SDS PAGE (2.4.2). 
 
2.4.9 Preparation of L. major lysates 
2.4.9.1  Preparation of lysates for LPG analysis 
For the LPG analysis, 1x108 parasites were centrifuged at 1300 xg for 10 min and 
washed two times with cold PBS. The cell pellets were resuspended in 100 µl lysis buffer 
(50 mM Tris/HCl pH 8,0, 0,1% Triton X-100, 1 mM PMSF, 2 µg/ml Leupeptin, 5 µg/ml 
Pepstatin) and sonified in a beaker resonator 4 times for 30 seconds (Branson, 100% 
Duty cycle, output control 5, 4°C). The success of the lysis was monitored under a 
normal light microscope. Cell debris was removed by centrifugation at 13000xg for 10 
min at 4°C. 2x Laemmli buffer was added to an aliquot of the cell lysates and 12,5 µg 
protein per sample were loaded on a 8% ProSieve gel (2.4.2). 
 
2.4.9.2 Preparation of lysates for in vitro activity assays 
The parasites were pelleted at 1300xg for 10 min and washed to times in cold PBS. The 
pellet was resuspended in in vitro activity assay buffer (50 mM Tris/HCl pH 7.8, 10 mM 
MgCl2, 1 mM PMSF, 2 µg/ml Leupeptin, 5 µg/ml Pepstatin) at a concentration of 1x109 
parasites per ml. The cells were sonified in a beaker resonator 4 times for 30 seconds 
(Branson, 100% Duty cycle, output control 5, 4°C). Cell debris was removed by centrifu-
gation at 13000 xg for 10 min at 4°C. The supernatant was immediately tested in an in 
vitro activity assay (2.4.13.1). 
 
2.4.10  Expression of recombinant protein in E.coli 
For the recombinant expression in E.coli, the pET vector system (Novagen) was used. 
The corresponding expression plasmid was transformed into E.coli BL21 (DE3) and 
grown on an selective LB agar plate (supplemented with ampicillin). A fresh colony was 
transferred directly into 20 -2000 ml LB medium supplemented with 200 µg/ml carbenicil-
lin. The culture was incubated at 15°C under vigorous shaking (160-200 rpm) and ex-
pression induced at an optical density of OD600nm =0.6 with 1 mM IPTG. After 20-24 
hours, the culture was harvested by centrifugation (6000xg, 15 min, 4°C) and washed 
once with PBS. The pellet was stored at -20°C.  
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2.4.10.1 Preparation of soluble and insoluble E.coli fractions 
For analytical preparations, bacterial pellets from 1 ml expression culture were resus-
pended in 100 µl TE per 1 OD. 100 µg/ml lysozyme were added to the suspension and 
incubated for 15 min at 37°C. After sonification in a beaker resonator (Branson, 100 % 
duty cycle, output control 5) for 2 min at 4 °C the soluble (supernatant) and insoluble 
fractions (pellet) were separated by centrifugation (15 min, 13000xg, 4 °C). The soluble 
fraction was mixed 1:1 with 2x Laemmli buffer whereas the insoluble fraction was resu-
pended in 1/5 the original volume TE of 2x Laemmli buffer. The samples were separated 
on a SDS PAGE (2.4.2) and analysed by Coommassie staining ( 2.4.3) and Western Blot 
( 2.4.5). 
 
For large scale protein purifications, a 0,5-2L expression culture was prepared (2.4.10), 
centrifuged at 6000xg for 15 min (4°C) and resuspended in 10 ml buffer A culture per litre 
culture (50 mM Tris/HCl pH 8.0, 300 mM NaCl, 40 µg/ml bestatin, 1 mM PMSF, 4 µg/ml 
pepstatin). The bacteria were lysed by sonification with a microtip (Branson sonifier, 50% 
duty cycle, output control 5) 8 times for 30 sec with a break of 30 seconds between the 
repeats. The suspension was centrifuged at 20000xg for 15 min (4°C). The supernatant 
was filtered through a 0.22 µm Millex-GP filter and applied on the appropriate column. 
 
2.4.11 Purification of UDP-glucose pyrophosphorylase from L. major 
2.4.11.1  Ni2+-chelating chromatography  
Recombinant L. major UGP carrying a C-terminal His6-tag was expressed in E.coli BL21 
(DE3) and lysates of a 2 litre culture prepared as described in 2.4.10.1. A 5 ml His-
TrapHP Ni2+ column (Amersham Biosciences) was equilibrated with 5 column volumes 
(CV) buffer A (50 mM Tris/HCl pH 8.0, 300 mM NaCl) using a peristaltic pump. The 
lysate was passed over the column for 3 times at a flow rate of 1 ml/min and an aliquot of 
the flow through boiled with 2x Laemmli buffer for subsequent SDS PAGE analysis 
((2.4.2). The column was washed with 10 CV buffer A and connected to an FPLC (Äkta 
FPLC, Amersham Biosciences). The following wash and elution steps were performed 
with filtered (0,8 µm cellulose acetate filter) and degassed buffers. After a further wash 
with 1 CV buffer A, unbound protein was eluted with 40 mM imidazole. 1 ml fractions 
were collected throughout the purification. The L. major UGP was eluted with 300 mM 
imidazole using a step gradient. The peak fractions containing the protein were pooled 
and subjected to a desalting step.  
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To clean the column, the gradient was increased to 500 mM imidazole to remove all 
protein. The column was washed with 10 CV buffer A and 10 CV water. For storage at 
4°C, the column was equilibrated with 20% ethanol. 
 
2.4.11.2  StrepII-affinity chromatography  
 A E.coli BL21 (DE3) lysate from 0,5 L culture containing a N-terminal StrepII tagged L. 
major UGP was prepared as described in  2.4.10.1. A 1 ml StrepTactin affinity column 
(IBA) was equilibrated with buffer A (50 mM Tris/HCl pH 8.0, 300 mM NaCl) using a 
peristaltic pump. The lysate was applied 5 times at a flow rate of 1 ml/min. Unbound 
protein was removed by washing with 10 CV buffer A and the column connected to an 
FPLC (Äkta FPLC, Amersham Biosciences). The following wash and elution steps were 
performed with filtered (0.8 µm cellulose acetate filter) and degassed buffers. Bound 
protein was eluted with buffer A containing 2.5 mM desthiobiotin. Protein fractions were 
pooled and analysed on SDS PAGE followed by Coomassie blue staining and Western 
blotting (2.4.5, 2.4.3). The StrepTactin column was regenerated in two subsequent steps 
with buffer R (50 mM Tris/HCl pH 8.0, 300 mM NaCl, 1 mM hydroxyl-azophenyl-benzoic 
acid) and buffer A. The column was washed with 3 CV water and stored in 20% ethanol. 
  
2.4.11.3 Desalting column 
The pooled fraction collected after the Ni2+-chelating chromatography, were subjected to 
a desalting step using a FPLC (Äkta FPLC, Amersham Biosciences). All buffers were 
filtered (0,8 µm cellulose acetate filter) and degassed. A HiPrep 26/10 column (Amer-
sham Biosciences) was equilibrated with 2 CV (1 CV=53 ml) of 50 mM Tris/HCl, pH 7.8, 
10 mM MgCl2 at a flow rate of 3 ml/min but not exceeding a pressure of 0.28 MPa. The 
sample was applied and the peak fraction collected. The protein was aliquoted and flash 
frozen in liquid nitrogen for storage at -80°C.  
The column was regenerated with 2 CV water and 1 CV 20% ethanol.   
 
2.4.12  Size exclusion column 
The oligomerisation status of the purified His-tagged UGP was analysed on a Superdex 
200 HR 10/30 gel filtration column. The column was equilibrated in 2 CV (1 CV=24 ml) 50 
mM Tris/HCl, pH 7.8, 10 mM MgCl2. In gel filtration runs including the substrates for the 
UGP, the buffer was supplemented with 1 mM UTP, 1 mM 2-mercaptoethanol and 1 mM 
glucose-1 phosphate. All buffers were filtered with a 0.22 µm cellulose acetate filter and 
degassed. 100 µl of the purified, filtered (0,22µm cellulose acetate filter) UGP at a con-
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centration of 4 mg/ml was applied to the column and eluted in 1 ml fractions at a flow rate 
of 0.5 ml/min. The fractions were analysed by Coomassie stained SDS PAGE, Western 
Blotting and by an in vitro activity assay (2.4.3, 2.4.5, 2.4.13.1)  
To calibrate the column, two additional runs were performed using the protein standard 
kit from Sigma according to manufacturer’s instructions. These were the same conditions 
(buffers, flow rate, etc) as for the UGP gel filtration. In a first run, bovine serum albumin 
(BSA) at a concentration of 10 mg/ml was applied to the column. In a second separate 
run a mixture of the two proteins bovine carbonic anhydrase and yeast alcohol dehydro-
genase at concentration of 3 mg/ml and  5 mg/ml, respectively was used.  
 
2.4.13  Activity assays of UGP 
2.4.13.1  In vitro activity assay 
The in vitro activity of the UGP was measured by coupled enzymatic assays. In the 
forward reaction, the reaction mixture contained 50 mM Tris/HCl pH 7.8, 10 mM MgCl2, 1 
mM 2-mercaptoethanol, 1 mM UTP, 1 mM glucose-1 phosphate, 1 mM NAD+ and 0.05 
units UDP-glucose dehydrogenase (Roche). In the reverse reaction, the following com-
pounds were mixed: 50 mM Tris/HCl pH 7.8, 10 mM MgCl2, 1 mM 2-mercaptoethanol, 50 
mM UDP-glucose, 50 mM pyrophosphate, 25 mM NADP+, 1 mM Glucose-1.6 biphos-
phate, 2.5 units phosphoglucomutase, 2.5 units glucose-6 phosphate dehydrogenase. 
The reaction was started by the addition of 2 ng purified protein in a total reaction volume 
of 750 µl or by the addition of 1µl to 25 µl parasite or bacterial lysate. The subsequent 
reduction of NAD+ to NADH+H+ was measured at 340 nm in a photospectrometer. The 
initial linear rates of cofactor reduction were used to calculate the enzyme activity by the 
conversion of the increase in OD340 nm to micromoles of NAD(P)H+H+ production based 
on its extinction coefficient (ε= 3,4 cm2/µMol). The protein concentration was determined 
by BCA test (2.4.1). To determine the Km values, one substrate was present at a fixed 
saturating concentration while the other substrate concentration was varied. The initial 
rates were plotted against the substrate concentration and the Microsoft Exel Solver was 
used to approximate the data to the Michael Menten equitation (V=Vmax ([S]/([S]+Km)). In 
addition, Lineweaver Burk plots were used to show the linear dependence and to calcu-
late the Km and Vmax values.  
  
In reactions using galactose-1 phosphate as substrate the following compounds were 
mixed: 50 mM Tris/HCl pH 7.8, 10 mM MgCl2, 1 mM 2-mercaptoethanol, 1 mM UTP, 2 
mM galactose-1 phosphate, 1 mM NAD+, 0.05 units UDP-glucose dehyrogenase, 0.05 
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units UDP-galactose 4-epimerase. The reaction was started and monitored as described 
above. 
 
2.4.13.2  In vivo activity assay 
The in vivo activity of UGPs was tested by the complementation of the E.coli strain DEV6 
galU lacking a functional UGP. A defect in the UGP renders the bacterium unable to 
grow on galactose containing MacConkey agar (base). Complementation restores the 
wild type phenotype and is indicated by a colour change of the colonies from white to red 
by the pH indicator phenol red and the size of colonies. However, this method does not 
allow a quantification of the in vivo activity.  
UGP constructs cloned into a pET vector  were transformed into competent E.coli DEV6 
(2.5.10) and spread on LB/agar plates containing 100 µg/ml ampicillin. The plates were 
incubated overnight at 37°C. MacConkey (base) agar plates supplemented with 100 
µg/ml ampicillin, 1 mM IPTG and either 2% galactose or 2% glucose as carbohydrate 
source were prepared. A few colonies from each LB/agar plates were streaked on one 
glucose- and one galactose-containing MacConkey agar plate. The addition of glucose to 
the MacConkey agar plates served as a control that the transformed plasmid did not 
exhibit a lethal phenotype on this kind of plates. The dishes were incubated at 37°C 
overnight. Big red colonies indicated a complementation of the UGP defect by the trans-
formed construct.    
 
2.4.14  Production of polyclonal L. major UGP antisera 
2.4.14.1 Immunisation of rabbits 
The production of a polyclonal serum was achieved by the immunization of 5 female New 
Zeeland rabbits (Charles River). The immunisation mixture was applied subcutaneously. 
For the priming, 500 µg purified full length L. major UGP recombinantly expressed in 
E.coli (2.4.11.1, 2.4.11.3) was mixed with 500 µl complete Freund’s adjuvant. To obtain 
an emulsion, two syringes connected through a three-way valve were used. Equal 
volumes of the antigen and the adjuvant were filled in separate syringes, connected and 
mixed by first pressing the aqueous antigen solution into the oil of the adjuvant. The 
emulsion was subcutaneously applied at ten different points on the back of the rabbit.  
After 3, 9 and 15 weeks, boosts were given containing 500 µg antigen and 500 µl incom-
plete Freund’s adjuvant. The emulsion was prepared as for the priming and the emulsion 
was subcutaneously applied at 5 different points on the back of the rabbit. 10 ml blood 
was taken before the first immunisation and 10 days after each boost. The blood was 
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incubated at RT for 4 hours followed by an incubation over night at 4°C to allow aggluti-
nation. The serum was obtained by centrifugation of the clocked blood at 3600xg for 15 
min at 10°C. The antibody titer of the serum was tested in an ELISA and the serum 
stored at -20°C.   
 
2.4.14.2  Coating of L. major UGP on ELISA plates 
96-well microtiter plates (U-from, Greiner) were coated with 100 ng per well recombi-
nantly expressed and purified L. major UGP (5µg/ml) at RT for 1 hour. The plates were 
washed twice with PBS and blocked with 150 µl 1% BSA/PBS over night. After two 
washing steps, residual buffer was removed and the plates either used directly or stored 
at -20°C. 
 
2.4.14.3  Determination of antibody titer in rabbit sera 
A serial dilution of the antisera from 1:200 to 1:12800 in 1% BSA/PBS were prepared. 
The coated ELISA plates (2.4.14.2) were incubated with 20 µl/well rabbit antisera dilu-
tion. The preimmunsera were diluted 1:200 and 1:400 and incubated on the same micro-
titer plate. Two wells were treated with 20 µl  anti-penta His mAb (Qiagen, 1:500) and 
another two wells with PBS as positive and negative control, respectively. Additional 
controls included the incubation without antisera as secondary antibody control and the 
treatment of an uncoated well with all used antibodies and buffers. After 1 hour at RT, the 
plates were washed 3 times and incubated with 10 µl/well secondary antibody dilution  
(α−rabbit HRP 1:2000, α−mouse HRP 1:2000) in 1% BSA/PBS for 1 hour at RT. The 
plates were washed three times with PBS and incubated with 40 µl ABTS (2,2’’-Azino-
di[3-ethylbenzthiazolinsulfonate] for 30 min. The ABTS was dissolved in ABTS buffer 
according to manufacturers instruction (Roche). The samples were analysed at 405 nm 
using the ELISA-Reader ‘DigiScan’ (Asys Hitech).  
 
2.5 Molecular biological techniques 
2.5.1  Precipitation of nucleic acids 
DNA was precipitated from aqueous solutions by the addition of 1/3 volume 7.5 M am-
moniumacetate (pH 5) or 0.1 volume of 3 M sodium acetate (pH 5.2) and 2.5 volumes 
ethanol (100%) for 1-2 hours at -80°C or over night at -20°C. After centrifugation 
(13000xg, 30 min, RT), the supernatant was decanted and the pellet washed with 500 µl 
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70% ethanol. The sample was centrifuged for additional 10 min and the supernatant 
completely removed. The pellet was dried and dissolved in water or TE. 
 
2.5.2  Phenol Chloroform extraction 
In order to remove proteins from DNA containing samples, the samples were extracted 
with phenol/chloroform and precipitated (2.5.1). 
Thus, an equal volume of RotiTMPhenol was added to the DNA sample, mixed and 
centrifuged at 13000xg, RT for 5 min. The upper aqueous solution was removed and 
combined with an equal volume of chloroform. The sample was again centrifuged 
(13000xg, 5 min, RT) and the DNA of the aqueous solution precipitated (2.5.1).  
  
2.5.3  Hot phenol extraction 
To improve the quality of L. major mRNA, a hot phenol extraction was applied.  
Equal volumes of RotiTMPhenol and extraction buffer (100 mM LiCl, 100 mM Tris/HCl pH 
8.0, 10 mM EDTA, 1% SDS, 3% PVV) were heated to 80°C until one phase was ob-
tained. 1/10 volume of mRNA solution was added and mixed. The solution was combined 
with ¼ volume chloroform and centrifuged for 5 min at 13000xg. The upper phase was 
precipitated by the addition of 1/10 volume sodium acetate (pH 5.2) and 2 volumes 
ethanol (100%). After 30 min at -20°C, the sample was centrifuged (13000xg, 10 min, 
4°C) and the dried pellet dissolved in 2 times the original volume water. The mRNA was 
further purified by the addition of 3 M LiCl and precipitated over night at 4°C. After cen-
trifugation the pellet was washed with 5 volumes 80% ethanol. The dried pellet was 
resuspended in water. The quality of the mRNA was analysed by a RNA agarose gel 
electrophoresis (2.5.16).     
 
2.5.4  Determination of DNA and RNA concentrations 
DNA and RNA concentrations were determined photometrically and calculated from the 
absorbance measured at 260 nm: c(DNA) = absorbance(260 nm) x 50 µg/ml and c(RNA) 
= absorbance(260nm)x40 µg/ml.  
Very low DNA concentrations were estimated on ethidium bromide plates by comparing 
the signal intensity with serial dilutions of a DNA sample with known concentration.  100 
ml of 0.8% agaorse in TAE buffer was molten and cooled down to 50°C. The solution 
was supplemented with 1 µg/ml ethidium bromide and poured in 5 Petri dishes. After the 
plates hardened, they were kept at 4°C. The standard was prepared by seven serial 
dilutions in 100 mM EDTA in a range of 10 ng/µl to 200 ng/µl and stored at -20°C.  
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1µl of standard and sample dilutions was carefully spotted on the agar and incubated for 
15 min at RT. The DNA was detected at 302 nm using the ‘Easy Enhanced Analysis 
System’ (Herolab). 
 
2.5.5  Agarose gel electrophoresis of DNA 
DNA samples were diluted in 5xGEBS and separated on horizontal agarose gels (0.6 to 
1.5 % agarose in TBE buffer). To extract DNA fragments from agarose gels, ethidium 
bromide containing agarose gels in TAE buffer were used. Electrophoresis was per-
formed at 5 V/cm in TBE buffer. The DNA was detected after staining in ethidium bro-
mide (50 µg/ml) at 302 nm. For documentation the ‘Easy Enhanced Analysis System’ 
(Herolab) was used.  
 
2.5.6  General cloning techniques 
2.5.6.1 Restriction enzyme digest and dephosphorylation of DNA 
Restriction enzymes and reaction buffers were used according to the manufacturers 
instructions (New England Biolabs). For preparative digests, 2 µg of DNA were incubated 
with 5 U of enzyme in a total volume of 50 µl with the added volume of enzyme less than 
10%. The reaction was incubated over night at 37°C.   For analytical digests, 1 µg of 
plasmid DNA was incubated for 2 hours at 37°C with  5 U of enzyme.  
 
The 5´-phosphate groups of vector DNA that was linearized with one restriction enzyme, 
were removed to avoid self-ligation of the vector fragments. Per µg of vector DNA 1 U of 
calf intestine alcaline phosphatase (NEB) was directly added to the restriction enzyme 
mix.   
 
2.5.6.2 Isolation of DNA fragments from agarose gels 
To isolate DNA fragments after restriction enzyme digest, DNA was separated on an 
agarose gel and the desired fragments were excised from the gel. For further DNA 
purification the  ‘Qiaquick PCR Purification Kit’ (Qiagen) was used according to the 
manufacturers instructions. The gel slice was completely dissolved in 300 µl buffer QG 
per 100 mg gel at 50°C and applied to a Qiaquick column. The column was centrifuged 
(1 min, 13000xg) and the flow through discarded. After one washing step with 500 µl 
buffer PE, bound DNA was eluted in 50 µl EBC (10 mM Tris-Cl pH 8.5).   
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2.5.6.3 Ligation of DNA 
30 ng of digested (and if necessary dephosphorylated) vector DNA and a 3 molar excess 
of the respective insert were incubated with 1 Weiss-U of T4-DNA-Ligase (NEB) in 20 µl 
ligation buffer (50 mM Tris-HCl pH 7.8, 10 mM MgCl2, 1 mM ATP, 10 mM DTT, 25 µg/ml 
BSA). The ligation mix was incubated overnight at 16°C and transformed into competent 
E.coli cells.  
 
The sequencing of constructs generated by PCR amplification steps was done by the 
companies MWG and GATC. 
 
2.5.7  Analytical plasmid preparation 
For analytical plasmid preparations, the ‘Qiaprep spin Miniprep Kit’ was used according 
to the manufacturers instructions. 3 ml LB medium containing the appropriate antibiotic 
were inoculated with a single bacterial colony from a selective agar plate and incubated 
for 12-16 h at 37°C and 250 rpm. 2 ml of the culture were pelleted by centrifugation (1 
min, 13000xg, RT) and resuspended in 250 µl buffer P1 (50 mM Tris/HCl pH 8.0, 10 mM 
EDTA, 100 µg/ml RnaseA). 250 µl of buffer P2 (1 % SDS, 0.2 M NaOH) and 350 µl of 
chilled buffer P3 (3.0 M potassium acetate, pH 5.5) were added, each buffer addition 
followed by a cautions mixing step. The samples were centrifuged (10 min, 13000xg, RT) 
and the supernatant applied on a Qiaprep spin column. The column was washed with 
750 µl buffer PE and the DNA eluted with 50 µl TE buffer.   
 
2.5.8  Preparative plasmid preparation 
For plasmid isolation in preparative scale the ‘Qiagen plasmid Kit Midi’ was used accord-
ing to the manufacturers instructions. 
A 100 ml LB medium containing the appropriate antibiotic was inoculated with a single 
bacterial colony from a selective agar plate for 12-16 h at 37°C and 200 rpm. The culture 
was centrifuged (15 min, 6000xg, 4°C) and the bacterial pellet resuspended in 4 ml buffer 
P1 (50 mM Tris/HCl pH 8.0, 10 mM EDTA, 100 µg/ml RnaseA). After the addition of 4 ml 
buffer P2 (1 % SDS, 0.2 M NaOH) and cautious mixing the bacterial lysis was allowed to 
proceed for 5 min at room temperature. Then 4 ml of chilled buffer P3 (3.0 M potassium 
acetate, pH 5.5) were added, the sample was again cautiously mixed, incubated on ice 
for 15 min and centrifuged (30 min, 20000xg, 4°C). The supernatant was poured over a 
filter and applied to a QIAGEN-Tip 100 column equilibrated in buffer QBT (750 mM NaCl, 
50 mM MOPS pH 7.0, 15% isopropanol, 0.15% (v/v) TritonX-100). After two washing 
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steps with 10 ml buffer QC (1 M NaCl, 50 mM MOPS pH 7.0, 15% isopropanol) the 
bound plasmid DNA was eluted in 5 ml buffer QF (1.25 M NaCl, 50 mM Tris-HCl pH 8.5, 
15% isopropanol) and 3.5 ml isopropanol were added to the eluent. After centrifugation 
(30 min, 20000xg, 4°C), the pelleted DNA was washed in 2 ml ethanol (70 %) and 
recentrifuged (15 min, 20000xg, 4°C). The dried DNA pellet was dissolved in 100 µl TE 
buffer and stored at -20°C. The DNA concentration was determined as described in 2.5.4 
 
2.5.9  Transformation of competent E.coli  
2.5.9.1 Transformation of chemically competent E.coli 
100 µl of competent E.coli were thawed on ice and 10 ng of plasmid DNA or 20 µl of 
ligation mix (2.5.6.3) were added. The mix was left on ice for 30 min, subjected to a 
45 sec heat shock at 42°C and incubated on ice for 2 min. 1 ml of LB-medium was 
added, the cell suspension was incubated at 37°C for 1 hour and plated on selective LB-
agar plates containing the appropriate antibiotics. 
 
2.5.9.2 Transfomration of electrocompetent E.coli 
Electrocompetent XL1-Blue MRF’ were purchased from Strategene and electroporated 
according to the manufacturers instructions. 40 µl competent E.coli were thawed on ice 
and mixed with 5 µl of a ligation reaction. The mixture was transferred into a 0.1 cm 
cuvette and placed into a Bio-Rad electroporator. The sample was pulsed once with 
1.7kV, 200 ohms and 25 µF. Immediately, 960 µl of sterile SOC medium was added and 
the cell suspension transferred to a 15 ml culture tube. After 1 hour incubation at 37°C 
(200 rpm), the transformation was spread on selective LB-agar plates containing the 
appropriate antibiotic.   
 
2.5.10  Preparation of chemically competent E.coli 
Chemically competent cells were prepared according to a protocol published by Molthoff 
et al., (1990). E.coli were grown on LB agar plates containing the appropriate antibiotic. 
One colony was inoculated in 2 ml SOB and incubated over night at 37°C. 200 ml SOB 
medium were inoculated with 1 ml of the starter culture and incubated for 1-2 days (200 
rpm) at 18°C until an OD600nm of 0.6 was reached. The culture was centrifuged at 2000xg 
for 10 min at 4°C. The supernatant was removed and the pellet resuspended in 1/3 of the 
original volume cooled TB (250 mM KCl, 10 mM Hepes, free acid, 15 mM CaCl2, 55 mM 
MgCl2). The solution was centrifuged as before and the pellet resuspended in 1/12 of the 
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original volume TB. DMSO was added to a final concentration of 7% and the cells divided 
into 100 µl batches. The batches were immediately flash frozen in liquid nitrogen and 
stored at -80°C. 
 
2.5.11  Preparation of E.coli DMSO stocks 
For long time storage, 930 µl of an E.coli over night culture was mixed with 70 µl DMSO 
(final 7%) and frozen at -80°C.  
2.5.12  Polymerase chain reaction (PCR) 
2.5.12.1 Amplification of fragments for cloning 
To amplify DNA-fragments by PCR reaction, 10 ng of plasmid DNA or genomic DNA, 
sense and antisense primer (25 pmol each), 2,5 U Pfu-polymerase (Stratagene), dNTP´s 
(20 µM each) and 5% DMSO were mixed in a total volume of 50 µl 1xPCR buffer 
(Stratagene). The PCR-mix was initially denatured at 95°C for 2 min in a thermocycler 
followed by 8 consecutive cycles of: 45 sec denaturing at 95°C, 45 sec annealing of the 
oligonucleotide primers (5°C below their calculated melting point) and elongation at 72°C 
for 120 sec per kb of synthesis product. Another 17 cycles followed with increasing the 
elongation time in each round for 10 sec. PCR reaction were either performed using the 
‘GeneAmp System 2400’ (Perkin Elmer) or the ‘T1-Thermocycler’ (Biometra). The sam-
ples were subjected to a PCR clean up reaction using the ‘Qiaquick PCR purification kit’. 
The PCR reaction was mixed with 5 volumes of buffer PB and applied on a Qiaquick 
column. After centrifugation for 1 min at 13000xg, the column was washed with 750 µl 
buffer PE and bound DNA fragments eluted in 50 µl TE. The DNA concentration of the 
eluent was determined on ethidium bromide agarose plates (2.5.4) and directly used for 
restriction digests (2.5.6.1). 
 
2.5.12.2 Analysis of L. major ugp gene deletion mutants by polymerase chain 
reaction  
To analyse the correct insertion of the resistant marker cassettes into the Leishmania 
genome, the obtained clones were subjected to a 5’ and 3’ PCR reaction. In the 5’ PCR 
reaction, a sense oligonucleotide primer (ACM96) was designed that bound 5’ to the 5’ 
flanking region used for homologous recombination. The antisense primer (ACM99: Hyg, 
ACM101: Phleo) was directed against the 5’ end of the resistance marker to yield an 
PCR product of about 1.5 kb. In the 3’ PCR reaction, the antisense primer (ACM 94) 
annealed to a sequence 3’ of the 3’ flanking region used for homologous recombination, 
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whereas the sense primer was directed against the 3’ end of the resistant marker (ACM 
100: Hyg, ACM102: Phleo). As for the 5’ end the PCR product encompassed 1500 
nucleotides. In a 20 µl reaction, 10 ng genomic DNA, 4 pmol of sense and antisense 
primer, dNTP´s (20 µM each), 0.5 U Taq polymerase and 5% DMSO were mixed in 1x 
PCR buffer (Sigma). After 7 min of a initial denaturation step at 95°C, the PCR-mix was 
incubated in a Thermocycler for 30 of the following cycles: 45 sec denaturation at 95°C, 
45 sec annealing at 60°C, 1 min elongation at 72°C. In a final step, a 10 min elongation 
at 72°C was applied. The samples were loaded on a 1% agarose gel and the DNA 
visualized with ethidium bromide (2.5.5). Clones positive for both reactions were sub-
jected to Southern Blot analysis (2.5.14). 
2.5.12.3 Preparation of digoxigenin (DIG) labelled DNA probes 
For the synthesis of DIG-labelled DNA probes, a dNTP mix containing 2 mM 
dATP/dGTP/dCTP, 1.3 mM dTTP and 0.7 mM DIG-11-dUTP was prepared. To amplify 
the probes, 10 ng of plasmid DNA (pCR2.1hyg, pCR2.1phleo, p5’UTR, pcDNA3-L. 
majorUGP), 4 pmol of sense and anitsense primer (Hyg probe: ACM85/ACM86; Phleo 
probe: ACM87/ACM88; UGP probe: ACM52/ACM53, 5’UTR probe ACM 54/ACM62), 5 µl 
of dNTP mix and 1.25 U Taq polymerase in a total volume of 50 µl in 1x Taq PCR buffer 
were mixed. After 3 min of an initial denaturation step at 95°C, the PCR-mix was incu-
bated in a Thermocycler for 30 of the following cycles: 10 sec denaturation at 95°C, 30 
sec annealing at 58°C, 1 min elongation at 72°C. In a final step, a 7 min elongation at 
72°C was applied. Except for the UGP probe that was gel purified (2.5.6.2) after synthe-
sis, the PCR products were directly used in Southern Blot analysis. 
 
2.5.13  Isolation of genomic DNA from Leishmania 
To isolate genomic DNA from Leishmania, 1x108 cells were centrifuged (1300xg, 10 min 
4°C) and resuspended in 400 µl TELT (50 mM Tris/HCl, pH 8.0, 62.5 mM EDTA, 2.5 M 
LiCl, 4% Triton X-100). After an incubation for 5 min at RT, 400 µl RotiTMPhenol was 
added and mixed for 5 min at 4°C. To separate the phases, the solution was centrifuged 
for 10 min at 14000xg and 4°C. The upper phase was combined with 400 µl chloro-
form/isoamylalcohol (24:1), incubated for 5 min at 4°C and centrifuged as before. The 
DNA of the aqueous phase was mixed with 1 ml ethanol (100%), incubated on ice for 5 
min and centrifuged. The supernatant was removed and the pellet washed with 1 ml 70% 
ethanol. After centrifugation, the dried pellet was resuspended in 100 µl TE and the DNA 
stored at 4°C. 
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2.5.14  Southern Blot analysis  
2.5.14.1 Preparation of the blots 
For the preparation of the blots, 2.5 µg DNA was digested with 5 U enzyme in a total 
volume of 25 µl at 37°C over night. The complete digest and 1 ng of PCR product of the 
corresponding DNA probe were separated on a 0.7% agarose gel containing 5 µg/ml 
ethidium bromide. The gel was incubated for 15 min in 250 mM HCl to depurinate the 
DNA and two times for 10 min in denaturing solution (0.5 M NaOH, 1.5 M NaCl).  
The DNA fragments were transferred to a nylon membrane by capillary forces in denatur-
ing solution over night. The set up is described in the following: 
 
1 glass plate 
1 thick whatmann filter paper soaked in denaturing solution 
1 thin whatmann filter paper soaked in denaturing solution 
agarose gel up side down 
nylon membrane, soaked in denaturing solution 
3 thin whatmann filter paper, soaked in denaturing solution 
6 layer dry cellulose filters 
glass plate  
 
The next day, the membrane was washed for 10 min in 50 mM sodium phosphate buffer 
pH 7.2 at RT and dried. The DNA was fixed to the membrane by UV crosslinking (Strata-
linker, Stratagene). The membrane was hybridised and developed as described in 
2.5.14.2 and 2.5.14.3. 
 
2.5.14.2 Hybridisation of Southern Blots  
The crosslinked membrane was prehybridised in high SDS (7% SDS, 50% formamid, 5x 
SSC, 50 mM NaPO4, pH 7.0, 0.1% N-lauroylsarcosine, 2% blocking solution (Roche)) for 
1 hour  at 42°C. The DIG-labelled probe was combined with an equal volume of TE, 
denatured for 5 min at 95°C and immediately placed on ice. The probe solution was 
incubated with the membrane in 10 ml high SDS over night at 42°C. After the hybridisa-
tion, the membrane was rinsed once in 1 x SSC (0.1% SDS) and washed two times in 
2xSSC (0.1% SDS) for 15 min at RT. After two washing steps with 0.1x SSC (0.1% SDS) 
for 30 min at 65°C, the bound probe was detected with CSPD (2.5.14.3). 
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2.5.14.3 Chemiluminescence detection 
The membrane was rinsed once in buffer 1 (0.1 M maleic acid, 0.15M NaCl, pH 7.5) and 
blocked for 30 min with buffer 2 (10x blocking solution (Roche) diluted 1:10 in buffer 1). 
The bound probe was detected with AP-coupled α−DIG Fab fragment (1:10000 in buffer 
2) for 10 min at RT. The membrane was washed three times with buffer 1 containing 
0.3% Tween. After equilibration in buffer 3 (100 mM Tris/HCl pH 9.5, 100 mM NaCl), the 
membrane was incubated with 10-12 drops of CSPD (Disodium 3-(4-methoxyspiro {1.2-
dioxetan-3.2’-85’-chloro} –tricyclo [3.1.1.13.7] decan}-4-yl)phenylphosphate, Roche) for 
15 min at 37°C. The CSPD was removed and the membrane sealed into plastic foil. Due 
to the dephosphorylation of the CSPD by the AP activity, light of 477 nm was emitted. 
The signals were visualized on Hyperfilms MP. 
 
2.5.15  Isolation of total RNA and mRNA 
For the purification of total RNA, the ‘RNeasy Midi Kit’ was used according to manufac-
turers instructions. 100 mg cells were pelleted and resuspended in 2 ml RLT buffer 
containing 20 µl 2-mercaptoethanol (14.5 M stock solution) and passed over two Qi-
ashredder columns (Qiagen) to lyse the cells. The lysate was carefully mixed with 1 
volume of 70% ethanol. The sample was applied to the RNeasy midi spin column and 
centrifuged for 5 min at 4000xg. The flow through was discarded and the column washed 
once with 3.8 ml buffer RW1 and twice with 2.5 ml buffer RPE by centrifugation. Total 
RNA was eluted in two steps with 150 µl RNase-free water each time. 
mRNA was isolated from the purified RNA using the ‘Oligotex mRNA Mini Kit’ according 
to manufacturers instructions. The volume of the total RNA was adjusted to 250 µl with 
RNase free water, mixed with 250 µl buffer OBB (20 mM Tris/HCl pH 7.5, 1M NaCl, 2 
mM EDTA, 0.2% SDS, ) and 15 µl Oligotex suspension ( 1 mg polysteren latex particles 
coupled to dC10T30 oligonucleotides in 10 ml of 10 mM Tris/HCl pH 7.5, 500 mM NaCl, 1 
mM EDTA, 0.1 % SDS, 0.1% NaN3). The buffer QBB and the Oligotex suspension were 
prewarmed to 37°C. To disrupt secondary structures of the RNA, the sample is heated to 
70°C for 3 min. The hybridisation of the poly(A)-RNA to the Oligotex beads was mediated 
for 10 min at RT. The Oligotex-mRNA complex was centrifuged for 2 min at 13000xg and 
the supernatant was removed. The beads were resuspended in 400 µl buffer OW2 (10 
mM Tris/HCl pH 7.5, 150 mM NaCl, 1 mM EDTA) and applied on a spin column. The 
column was centrifuged for 1 min 13000xg and the flow through discarded.  After one 
washing step with 400 µl buffer OW2, mRNA was eluted by the addition of 40 µl buffer 
OEB (5 mM Tris/HCl pH 7.5) prewarmed to 70°C. To achieve a maximum yield, the 
elution step was repeated and the eluats combined. 
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2.5.16  Agarose gel electrophoresis of RNA 
RNA was separated on a 1.2 % agarose gel according to a protocol from Kevil et al., 
(1997) that avoids the use of formamide. The agarose was dissolved in 1x TBE buffer 
including 1 µg/ml ethidium bromide. The samples were mixed with 6x loading buffer 
(0.25% w/v bromphenol blue, 0.25% w/v xylene cyanol, 30% w/v glycerol, 1.2% SDS, 60 
mM Sodium phosphate (pH 6.8)), denatured for 5 min at 75°C and immediately loaded 
on the agarose gel. The gel was electrophoresed at 7-10 V/cm for 90 min and analysed 
using the ‘Easy Enhanced Analysis System’ (Herolab).  
 
2.5.17  Generation of a cDNA library 
The L. major cDNA library was constructed using the ‘pCMV-ScriptXR cDNA library 
construction kit’ from Stratagene. In contrast to the manufacturers instructions, the size 
fractionation was achieved by agarose gel electrophoresis. This change allowed the 
generation of the cDNA library without the use of radiolabeled nucleotides.  
In the reverse transcription of the mRNA, a 50 base oligo(dT) linker primer containing a 
XhoI restriction site and methylated dCTP was used. After second strand synthesis, an 
EcoRI adapter was annealed to the 5’ end of the DNA and the cDNA digested with XhoI. 
Since XhoI only cuts in the linker primer but not in the hemimethylated cDNA, the cDNA 
can be cloned unidirectional into the eukaryotic expression vector pCMV-Script pre-
digested with EcoRI and XhoI.   
For the first strand cDNA synthesis, 5 µg of mRNA were mixed with 5 µl first strand 
buffer, 3 µl of first strand methyl nucleotide mixture, 2 µl of linker primer (1.4 µg/µl),1 µl of 
RNase Block Ribonuclease Inhibitor (40 U/µl) and 1.5 µl StrataScript reverse transcrip-
tase (50 U/µl) in a total volume of 50 µl. After incubation for 1 hour at 42°C, 20 µl of 10x 
second strand buffer, 6 µl of second strand dNTP mixture, 2 µl of RNaseH (1.5 U/µl) and 
11 µl of DNA polymerase I (9 U/µl) and 116 µl of RNase free water were added and 
incubated for 2.5 hours at 16°C to allow the second strand synthesis. The cDNA was 
blunted by the addition of 23 µl blunting dNTP mix and 2 µl of cloned Pfu DNA poly-
merase. After 30 min at 72°C, the reaction was extracted with phenol/chloroform and 
precipitated over night by the addition of sodium acetate and ethanol (2.5.1). The dried 
pellet was resuspended in 9 µl of EcoRI adapter, 1 µl 10x ligase buffer, 1 µl of 10 mM 
ATP and 1 µl of T4 DNA ligase (4U/µl). The reaction was incubated for 2 days at 4°C 
followed by a heat inactivation for 30 min at 70°C. The phosphorylation of the EcoRI 
ends was achieved by adding 1 µl 10x ligase buffer, 2 µl of 10 mM ATP, 6 µl water and 1 
µl of T4 polynucleotide kinase (10 U/µl) and incubation for 30 min at 37°C. As for the 
ligase, the kinase was heat inactivated for 30 min at 70°C. The cDNA was digested with 
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XhoI for 1.5 hours at 37°C by the addition of 28 µl XhoI buffer supplement and 3 µl of 
XhoI (40 U/µl).  
The reaction was precipitated over night at -20°C by adding 5 µl 10xSTE buffer (1 M 
NaCl, 200 mM Tris/HCl pH 7.5, 100 mM EDTA) and 125 µl of 100% ethanol. The dried 
pellet was resuspended in 20 µl 5 mM Tris/HCl pH 8.0/ 2 mM EDTA and separated on a 
0.9% TAE agarose gel containing 5 µg/ml ethidium bromide. DNA fragments of 500-5000 
bp were isolated using the ‘Qiaquick Gel Extraction kit’ (2.5.6.2).  
150 ng purified cDNA was ligated into 300 ng pre-digested pCMV-Script vector for two 
days at 4°C. The ligation reaction was precipitated by the addition of ammonium acetate 
and 100% ethanol (2.5.1). The dried pellet was resuspended in 10 µl water and electro-
porated into 80 µl XL-1 blue MRF’ electrocompetent E.coli cells (2.5.9.2). The transfor-
mation was spread over 80 LB agar plates supplemented with 50 µg/ml kanamycin. 
About 20 000 colonies per plate were obtained. The plates were soaked in 10 ml LB 
medium. 1 ml DMSO stocks (7% DMSO final) of each plate were prepared and stored at 
-80°C (2.5.11). 2 ml of each culture were used to prepare plasmid DNA (2.5.7). The rest 
of the culture was kept as 2 ml pellets at -20°C. One plate referred to one cDNA library 
pool. 
  
2.5.18  Complementation cloning 
Complementation cloning is used to isolate a specific gene from a cDNA library. A cell 
line defective in the desired gene, is transfected with pools of the cDNA library. Pools 
containing the appropriate plasmid DNA restore the wild type phenotype, which can be 
detected by specific antibodies in immunocytochemistry. To enrich the plasmid DNA of 
the L. major UDP-galactose transporter the following steps were applied:   
The pools of the cDNA library and a plasmid encoding the rat glucuronyltransferase 
(pEFBos-GlcAT) were transfected in CHO Lec8 cells lacking a functional UDP-galactose 
transporter (2.2.2). After 48 hours, the reexpression of galactose on the cell surface was 
detected in immunocytochemistry using the mAb L2-412 (2.2.3). Positive pools were 
subdivided (sibling selection). Therefore, a small aliquot of the corresponding DMSO 
stock (2.5.11) was inoculated into 3 ml LB medium and depending on the desired size of 
the subpools x µl spread on LB agar plates containing 50 µg/ml kanamycin. After over 
night incubation at 37°C, the colonies were soaked off the plates. The culture was used 
to prepare plasmid DNA and new DMSO stocks. The plasmid DNA was again trans-
fected and the procedure repeated until the pools size allowed the analysis of single 
colonies.  
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3 Results 
3.1 Identification of the target gene 
3.1.1 Cloning strategy 
In order to identify the UDP-galactose transporter of L. major, complementation cloning in 
CHO Lec8 cells, which lack the UDP-galactose transporter (Deutscher et al., 1986) was 
performed. In CHO WT cells, the UDP-galactose transporter transports the activated 
sugar, UDP-galactose, from the cytosol into the lumen of the Golgi apparatus. In the 
Golgi, UDP-galactose functions as a substrate of galactosyltransferases. The galactosy-
lated glycans can be further modified by sialyltransferases (see Figure 8). In the case of 
the neuronal cell adhesion molecule (NCAM), the homopolymer of α2,8-linked sialic 
acids, the polysialic acid, can be added by polysialyltransferases. CHO Lec8 cells that 
lack a functional UDP-galactose transporter are unable to generate the acceptor struc-
tures for the subsequent sialylation and polysialylation reactions (see Figure 8).   
 
 
Figure 8. Comparison of CHO WT and CHO Lec8 cells. Due to the missing UDP-galactose transporter in 
CHO Lec8 cells, no galactosylation and sialylation takes place. 
 
Reconstitution of the UDP-galactose transport activity in Lec8 cells restores the wild type 
situation resulting in the reexpression of galactosylated and (poly-) sialylated glycans. A 
L. major cDNA library was constructed and transfected into CHO Lec8 cells for the 
isolation of the L. major UDP-galactose transporter by complementation cloning. In 
immunocytochemistry, complementation could be detected either with the monoclonal 
antibody (mAb) 735, specifically recognising polysialic acid (polySia) or with the mAb L2-
412, which recognises glucuronic acid ß1,3-linked to galactose. This epitope is normally 
not present in CHO cells but can be generated by transfection of a plasmid encoding a 
rat glucuronyltransferase (pEFBos-GlcAT, Terayama et al, 1997) into these cells. Moni-
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toring of the complementation process via mAb L2-412 therefore requires co-transfection 
of the pEFBos-GlcAT plasmid DNA (see Figure 9). 
 
Figure 9 Principle of complementation cloning in CHO Lec8 cells. By coexpression of a functional UDP-
galactose transporter and a glucuronyltransferase, the epitop recognized by the mAb L2-412 (glucuronic acid 
ß1,3-linked to galactose) is formed and can be detected.  
 
A problem in association with this cloning strategy resided in the fact that these highly 
sensitive monitoring systems demonstrated a basal (even so very low) galactosylation 
capacity of the CHO Lec8 cells. Further optimisation steps were therefore required to 
improve the signal-noise ratio in the experimental system.   
 
3.1.1.1 Optimisation of cell culture and antibody staining conditions 
CHO Lec8 cells have been selected after chemical mutagensis using the cytotoxity of 
plant lectins (Stanley et al., 1981). Due to the missing terminal glycosylation they show 
resistance to the sialic acid binding lectin WGA (wheat germ agglutinin) and the galac-
tose binding lectins European mistletoe and Ricinus communis agglutinin. Assuming that 
the lacking selection pressure during culturing of Lec8 cells may have let to the appear-
ance of revertants, the cells were resubmitted to the lectin selection procedure (2.2.6.2). 
However, this treatment did not reduce the background galactosylation.  
In a second approach, a panning step was carried out with the help of the mAb 735 
immobilised on Petri dishes (2.2.6.2). Using this technique, polySia positive cells that 
bind to the coated Petri dish can be separated from polySia negative cells that remain in 
the supernatant. However, overlaying of CHO Lec8 cells resulted in 100% binding to the 
Petri dishes. 
Finally, also the subcloning of CHO Lec8 cells did not reveal a cell line with blocked 
galactosylation. Together these experiments clearly demonstrated that Lec8 cells exhib-
ited a basal galactosylation capacity, which was not sufficient to limit growth of cells in 
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the presence of cytotoxic lectins but detectable, if highly sensitive surface staining 
methods were applied. 
In order to solve the problem the staining protocol was adjusted to generate an optimal 
signal to noise ratio, which allowed the clear differentiation between complementation 
and background galactosylation in immunocytochemistry. As a first step, different stain-
ing procedures with the mAb 735 were tested. Because, the signal intensity with an 
alkaline phosphatase (AP)-coupled secondary antibody was not high enough, a signal 
amplification step using a biotinylation reaction with biotintyramid was applied (2.2.3). 
Biotin was detected with AP-conjugated streptavidin and the substrate Fast Red. How-
ever, the amplification step also augmented the background staining (data not shown). 
This was also the case, if the mAb L2-412 was used to monitor complementation (see 
Figure 10 a). However, the direct detection of the mAb L2-412 with an AP-coupled 
secondary antibody and development with the substrate Fast Red revealed a good signal 
to noise ratio (see Figure 10 b and compare Figure 13 b, c lanes 2 and 3). This protocol 
was used to identify the L. major UDP-galactose transporter by complementation cloning.   
 
 
Figure 10 Optimisation of the CHO Lec8 cell staining protocol. The cells were transfected with pEFBos-
GlcAT encoding a rat glucuronyltransferase and analysed by immunocytochemistry. In a) the cells were 
stained with mAb L2-412 and HRP-coupled secondary antibody. The peroxidase activity of the HRP-coupled 
secondary antibody generates biotin radicals upon incubation with biotintyramid that biotinylate near by 
structures. Biotin was detected with AP-conjugated streptavidin and the substrate Fast Red. In b) the epitope 
was detected without the additional amplification step using the mAb L2-412 and AP-conjugate secondary 
antibody. 
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3.1.2 Generation of a L. major cDNA library  
Procyclic promastigote Leishmania major upregulate galactose containing side chain 
modifications of the virulence factor LPG. In order to generate a cDNA library containing 
enzymes involved in the galactosylation of phosphoglycans, mRNA from procyclic 
promastigote L. major was isolated (2.5.15). The mRNA was further purified by a hot 
phenol extraction followed by a LiCl precipitation to improve the reversed transcription 
into unidirectional cDNA (2.5.3). The cDNA was size fractionated and fragments between 
500 bp and 5000 bp were ligated into the pCMV-Script vector, pre-digested with EcoRI 
and XhoI. The ligation reaction was transformed into electrocompetent XL-1 blue MRF’ 
E.coli cells (2.5.17). 86 pools of 20 000 independent colonies were generated yielding a 
total number of 1.7 million independent clones. A DMSO stock and a plasmid mini-
preparation of each pool was prepared (2.5.7, 2.5.11). The pCMV-Script vector is a 
mammalian expression vector driven by the human cytomegalovirus (CMV) immediate 
early promoter and promotes constitutive expression of cloned inserts in the mammalian 
cell. Since the vector does not contain an ATG initation codon, only cDNA inserts con-
taining start codons are expressed.  
 
3.1.3 Complementation cloning in CHO Lec8 cells 
To isolate a cDNA that complements the CHO Lec8 cell defect, plasmid DNA of 22 pools 
was transfected, with each pool consisting of 20 000 independent colonies. Plasmids 
encoding the Arabidopsis thaliana (A.th.) UDP-galactose transporter 2 (pAth-UGT2, 
Bakker et al 2004, Figure 12 f) and the empty vector pCMV-Script (Figure 12 h) were 
transfected as positive and negative controls, respectively. Cotransfection of the plasmid 
pEFBos-GlcAT enabled  immunocytochemistry with the mAb L2-412 (see 3.1.1 and 
2.2.3). Positive cells stained red after incubation with alkaline AP-coupled secondary 
antibody and the AP substrate Fast Red.  
Compared to the empty vector control, eight positive pools were identified (Figure 12 a). 
The positive pool # 17 was selected for further sibling selection (Figure 11 and 2.5.18). 
Therefore, an aliquot of the corresponding E.coli stock was subdivided into 27 pools and 
amplified on LB/agar plates. 15 pools of 1200-1500 (# 17.1 - 17.15) and 12 pools of 
about a 100-120 independent colonies (# 17.16 – 17.27) were obtained. The colonies 
were combined and plasmid DNA and E. coli stocks were prepared from each culture. 
The DNA of the smaller pools (# 17.16 - 17.27) was combined to one pool of 1200 
colonies. 
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Figure 11 Principle of sibling selection. The pools of a L. major cDNA library were transfected in CHO 
Lec8 cells and analysed by immunocytochemistry. A positive pool was identified (indicated by red stained 
cells) and the corresponding E. coli stock further subdivided. The cDNA of subpools was again transfected 
into CHO Lec8 cells. The procedure was repeated until a single clone was obtained. 
 
The pools were transfected in CHO Lec8 cells and analysed by immunocytochemistry as 
described before. One positive pool was detected. Since this pool was the combined pool 
# 17.16 – 17.27 (Figure 12b), the DNA of the 12 individual pools was transfected in the 
consecutive round. Again, one pool was positive (# 17.22, Figure 12 c) and the corre-
sponding E. coli stock was further subdivided into 19 pools of 50-60 independent colo-
nies. To conserve the individual colonies, a replica plate of each pool was prepared. After 
transfection of the plasmid DNA and immunocytochemistry, four pools showed a clear 
enrichment of a complementing cDNA (17.22.14; 17.22.16, 17.22.23; 17.22.27; Figure 
12d). The individual colonies of one pool (17.22.14) were picked and grouped into 9 
pools of 7 colonies. Again, a replica LB/agar plate of the single colonies was prepared. 
The analysis of the pools identified 1 positive pool (17.22.14 E,  Figure 12e). The plasmid 
DNA of the 7 individual clones was transfected and two positive clones were detected by 
immunocytochemistry (17.22.14 E1; 17.22.14E2, Figure 12f). To confirm the comple-
menting activity, single colonies from each clone were prepared and the DNA again 
transfected into CHO Lec8 cells. All colonies derived from these two clones were positive 
and named pACM1. Table 1 gives a summary of the number of screened clones and 
positive pools in each round.   
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round number of pools number of colonies/pool number of positive pools 
1                         22                               ~20000                                         8 
2                         16                          1200-1500                                         1 
3                         12                              100-150                                         1 
4                         19                                  50-60                                         4 
5                           9                                        7                                         1 
6                           7                                        1                                         2 
Table 1 Summary of the sibling selection procedure. The table indicates the numbers of screened pools, 
of clones per pool, and of identified positive pools per complementation cloning round. 
 
 
Figure 12 Identification of a L. major cDNA clone complementing CHO Lec8 cells. CHO Lec8 cells were 
transfected with pEFBos-GlcAT encoding a rat glucuronyltransferase and a pool of the L. major cDNA library 
containing a) 20 000, b) 1200-1500 (17.16-27) c) 100-150 (17.22), d) 50-60 (17.22.14) and e) 7 (17.22.14E) 
independent clones. In immunocytochemistry the cells were analysed with the mAb L2-412 and an AP-
coupled secondary antibody. Due to the use of the substrate Fast Red, complemented cells stain red. In f) 
the complementation by the single clone 17.22.14E2 (pACM1) and in g) the positive control A. th. UDP-
galactose transporter is shown. The negative control with the empty vector is shown in h). 
 
3.1.4 Confirmation of CHO Lec8 cell complementation by the isolated 
L. major clone 
In the immunocytochemistry staining protocol used above, bound mAb L2-412 was 
detected with an AP-coupled secondary antibody. To exclude any cross reactivity with 
the alkaline phosphatase resulting in a false positive signal, positive cells were detected 
with a secondary antibody coupled to horseradish peroxidase (HRP) using AEC (3-
amino-9 ethyl-carbasol) as a substrate. This protocol confirmed CHO Lec8 cell comple-
mentation by the isolated clone (Figure 13a). 
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In addition, incubation without secondary antibody resulted in a completely negative 
background excluding an alkaline phosphatase activity of the L. major clone itself (data 
not shown).  
An alternative protocol to identify Lec8 complementation is the detection of polySia with 
the mAb 735. This protocol did not require the cotransfection of other transferases but 
the signal intensity by direct detection was comparably low and a signal amplification 
step had to be applied (see 3.1.1.1). The result of this experiment confirmed the com-
plementation of Lec8 cells by pACM1 (Figure 13b).  
 
     
Figure 13  Confirmation of CHO Lec8 cell complementation by the isolated L. major clone pACM1. 
The cells were transfected with clone pACM1 (lane 1), pcDNA3-A.th.UGT2 (lane 2), or empty vector control 
(lane 3). Rat glucuronyltransferase cDNA was cotransfected in a) and c). After 48 hours, cells were stained in 
a) with the mAb L2-412, α−rat HRP-coupled secondary antibody, and the substrate AEC. In b) the cells were 
analysed with the mAb735 and α−mouse HRP-secondary antibody. Here, staining was amplified by biotinyla-
tion as described in the text. In c) cells were stained using the mAb L2-412 in combination with α−rat AP-
coupled secondary antibody and the substrate Fast Red. 
 
To directly compare the results of the different staining methods, cells were transfected 
with pACM1 and pEFBos-GlcAT and stained with the same protocol as described above 
for the complementation cloning (Figure 13c). Each time the A.th. UDP-galactose trans-
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porter 2 and an empty vector were expressed as positive and negative controls, respec-
tively (Figure 13, lanes 2 and 3). 
All experiments clearly confirmed the complementing activity of the isolated clone 
pACM1. As mentioned in 3.1.1.1, the mAb 735 staining procedure resulted in a higher 
background level (compare Figure 13, lane 3). 
 
3.1.5 Analysis of the isolated cDNA clone 
3.1.5.1 Analysis of the nucleotide sequence 
The clone pACM1 was sequenced with vector primers. For the complete sequencing of 
the insert, additional primers were designed from the obtained sequence information. 
The analysis of the 1582 bp nucleotide sequence revealed an open reading frame of 
1462 bp, or 490 amino acids using the first in frame start codon at position 124. Though 
a poly-(A) tail was present in the cDNA there was no in frame stop codon, indicating that 
the isolated clone was not complete. A BLAST search in the database of the L. major 
genome project (The Wellcome Trust Sanger Institute, program Omni Blast) identified a 
sequence of 733 bp that aligned to the nucleotides 1460-1587 of the isolated cDNA clone 
(Figure 14). Since L. major have no introns, the missing sequence of 46 nucleotides 
including the first in frame stop codon could be identified.  
 
 
1437 CTGGTGGAATGCAAACGCGTGACGGTGAAGGGGCTGGTTCAGTTCGGTGCTGGCAACGTGCTCACAGGCACGGTCACGAT 
   1 CTGGTGGAATGCAAACGCGTGACGGTGAAGGGGCTGGTTCAGTTCGGTGCTGGCAACGTGCTCACAGGCACGGTCACGAT 
 
1517 CGAGAACACGGACAGCGCCTCGGCGTTTGTGATCCCCGATGGTGCCAAAAAAAAAAAAAAAAAAAA 
  81 CGAGAACACGGACAGCGCCTCGGCGTTTGTGATCCCCGATGGTGCCAAGCTGAACGACACAACGGCGTCACCGCAGCAGT 
 
 
 161 CGACCAACAAGTAGGGGTCACAAGCTGCTGAGCAAAATGACGATGCACAGATGTAGCGTCGCACTGAGCATGGCCGACAA 
 
 241 AACCGGTCGAGCGGGGCGGGGAAGGGTGCAGCACCGCTGATGCCCGGCGGCAAGTGCACTCATGTCTCTCTCTATATATA 
 321 TATATGTCTGTGTATAGGTATATGCTTGTATGTGCAGGTGTCCACTGTTGGCTGCCCCCCCCTCTGAAGAGCCACTAACA 
 401 TCACAGCAGCTCCTTCGTCGTGAGGTGAGGCGGCGGCAGCAGTCGGTGCCTGCCTGCACTCCCTCCCCACCTACGATACT 
 481 CTACCCCACCCCCTCCACCAACGTCTTTAACGTGTTGCTACGCAGAAACACGCGTGCGTGCGTGTGTGCTATTCCCTGCC 
 561 TTATCCCCTTCCCTTCTTCGTCTTCTACCGGCATGTGCTCAACAATCTCGCGCCCCTCCGCGGATGAAGCTAGTACCAAA 
 621 GAGGGGCGTCAGCATCGCTGTGGTGTTGGCGATCGCCCCCCCCACGCTGCCCTCTCCCCCATTGCCCCACTTGCACGCAT 
 701 CCACGCACACCAC 
Figure 14 Sequence alignment of the nucleotides 1437-1565 of the isolated cDNA pACM1(upper lanes) 
and a sequence stretch (LM23_BIN_Contig1792) of the L. major genome project database (lower lanes) 
obtained by chromosome shot gun sequencing (The Wellcome Trust Sanger Institute). The poly-(A) tail is 
underlined. The first in frame stop codon is underlined .  
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Using the primers ACM04 and ACM07 the complete open reading frame was amplified 
by PCR from the L. major cDNA library pool #19, a positive pool identified in the first 
round of complementation cloning. After BamHI/NotI digest, the PCR fragment was 
cloned into the mammalian expression vector pcDNA3 resulting in the construct 
pcDNA3-L. major UGP.  
The open reading frame of the resulting sequence consisted of 1485 bp which encodes 
for a protein of 495 amino acids (Figure 15) with a predicted molecular mass of 54.5 kDa. 
This sequence complemented the CHO Lec8 cells as well as the initially isolated trun-
cated form. If not stated otherwise, the complete sequence cloned into the vector 
pcDNA3 (pcDNA3-L. majorUGP) was used in all subsequent experiments. 
Since conserved DNA motifs that usually characterise promoters in other eukaryotes are 
absent in Leishmania (Kapler et al., 1990), the sequence upstream of the isolated cDNA 
was analysed for a second in frame start codon. As for the 3’ region, a sequence of 600 
bp was obtained in the database of the L. major genome project (The Wellcome Trust 
Sanger Institute). No second in frame start codon could be detected up to position -460. 
At this site polydinucleotide repeats were present that mark the intertranscript region of 
Leishmania genes. This data indicated that the isolated clone is complete at the 5’end.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results                                                                                                                                            71 
  
  -123                                                         CACGAGGCTTTATTGTCATTGATCTACTTAGCAT               
   -90  CATCTGCAAAACCCACTCGCACCTCCTGACCGGCACTCTACCCCTAATCCCGCTATCCTCCTCGCTCGTGCTGTCACGGAGGTGAAGCA 
 
     1   M  E  N  D  M  K  S  L  S  A  A  A  Q  A  C  V  K  K  M  R  D  A  K  V  N  E  A  C  I  R  
     1  ATGGAAAACGACATGAAGTCCCTCAGCGCCGCCGCTCAGGCGTGCGTAAAGAAGATGCGCGACGCCAAGGTGAACGAGGCATGCATTCGC 
 
    31   T  F  I  A  Q  H  V  M  V  S  K  G  E  T  G  S  I  P  D  S  A  I  M  P  V  D  S  L  D  A  
    91  ACCTTCATCGCACAGCACGTCATGGTCAGTAAAGGCGAGACAGGGTCCATTCCCGACTCCGCCATCATGCCGGTCGACTCCCTCGATGCC 
 
    61   L  D  S  L  T  I  E  C  D  N  A  V  L  Q  S  T  V  V  L  K  L  N  G  G  L  G  T  G  M  G  
   181  CTGGACAGCCTCACCATTGAGTGCGACAACGCTGTCCTGCAGAGTACCGTTGTGCTGAAGCTGAACGGCGGCCTCGGCACCGGCATGGGG 
 
    91   L  C  D  A  K  T  L  L  E  V  K  D  G  K  T  F  L  D  F  T  A  L  Q  V  Q  Y  L  R  Q  H  
   271  CTGTGCGACGCCAAGACGCTGCTCGAGGTCAAGGATGGCAAGACGTTTCTTGACTTTACAGCGCTTCAGGTACAGTACCTTCGCCAGCAC 
 
   121   C  S  E  H  L  R  F  M  L  M  D  S  F  N  T  S  A  S  T  K  S  F  L  K  A  R  Y  P  W  L  
   361  TGCAGCGAGCACCTGCGCTTTATGTTGATGGACAGCTTCAACACCTCCGCTAGCACCAAGAGCTTTCTGAAGGCGCGCTACCCGTGGCTG 
 
   151   Y  Q  V  F  D  S  E  V  E  L  M  Q  N  Q  V  P  K  I  L  Q  D  T  L  E  P  A  A  W  A  E  
   451  TACCAGGTCTTTGACTCAGAGGTGGAGCTGATGCAGAATCAGGTGCCCAAAATACTGCAGGACACGCTCGAGCCGGCGGCCTGGGCCGAG 
 
   181   N  P  A  Y  E  W  A  P  P  G  H  G  D  I  Y  T  A  L  Y  G  S  G  K  L  Q  E  L  V  E  Q  
   541  AACCCGGCGTACGAGTGGGCGCCGCCGGGGCACGGTGACATCTACACCGCTCTGTATGGCTCCGGCAAGCTACAGGAACTCGTCGAGCAG 
 
   211   G  Y  R  Y  M  F  V  S  N  G  D  N  L  G  A  T  I  D  K  R  V  L  A  Y  M  E  K  E  K  I  
   631  GGCTACCGCTACATGTTCGTCAGCAACGGGGACAACCTCGGCGCCACCATCGACAAGCGCGTGCTGGCGTACATGGAGAAAGAGAAGATC 
 
   241   D  F  L  M  E  V  C  R  R  T  E  S  D  K  K  G  G  H  L  A  R  Q  T  V  Y  V  K  G  K  D  
   721  GACTTTCTGATGGAGGTGTGCCGCCGAACGGAGAGCGACAAGAAAGGCGGTCACCTGGCTCGGCAGACGGTGTATGTGAAGGGCAAGGAC 
 
   271   G  Q  P  D  A  E  K  R  V  L  L  L  R  E  S  A  Q  C  P  K  A  D  M  E  S  F  Q  D  I  N  
   811  GGTCAACCAGACGCCGAGAAGAGGGTGCTGCTGCTGCGGGAGTCCGCCCAGTGCCCCAAGGCGGACATGGAAAGCTTCCAGGACATCAAC 
 
   301   K  Y  S  F  F  N  T  N  N  L  W  I  R  L  P  V  L  L  E  T  M  Q  E  H  G  G  T  L  P  L  
   901  AAGTACTCCTTCTTCAACACGAACAACCTATGGATCAGGCTCCCGGTGCTCCTGGAGACGATGCAGGAGCACGGCGGCACGCTGCCGCTG 
 
   331   P  V  I  R  N  E  K  T  V  D  S  S  N  S  A  S  P  K  V  Y  Q  L  E  T  A  M  G  A  A  I  
   991  CCGGTCATCCGAAACGAGAAGACGGTCGATTCATCTAATTCAGCATCACCCAAGGTGTATCAACTGGAAACTGCCATGGGTGCCGCGATC 
 
   361   A  M  F  E  S  A  S  A  I  V  V  P  R  S  R  F  A  P  V  K  T  C  A  D  L  L  A  L  R  S  
  1081  GCCATGTTCGAAAGCGCATCGGCCATTGTCGTGCCGCGCAGCCGCTTCGCGCCAGTGAAGACGTGCGCCGATCTGCTCGCTCTGCGCTCC 
 
   391   D  A  Y  V  V  T  D  D  F  R  L  V  L  D  D  R  C  H  G  H  P  P  V  V  D  L  D  S  A  H  
  1171  GACGCCTACGTCGTGACGGACGACTTCCGGCTCGTCCTGGACGATCGCTGCCACGGCCACCCGCCTGTCGTTGACCTCGACAGCGCGCAC 
 
   421   Y  K  M  M  N  G  F  E  K  L  V  Q  H  G  V  P  S  L  V  E  C  K  R  V  T  V  K  G  L  V  
  1261  TACAAGATGATGAATGGCTTTGAGAAGCTCGTGCAACACGGCGTGCCATCGCTGGTGGAATGCAAACGCGTGACGGTGAAGGGGCTGGTT 
 
   451   Q  F  G  A  G  N  V  L  T  G  T  V  T  I  E  N  T  D  S  A  S  A  F  V  I  P  D  G  A  K  
  1351  CAGTTCGGTGCTGGCAACGTGCTCACAGGCACGGTCACGATCGAGAACACGGACAGCGCCTCGGCGTTTGTGATCCCCGATGGTGCCAAG 
 
   481   L  N  D  T  T  A  S  P  Q  Q  S  T  N  K  -  
1441 CTGAACGACACAACGGCGTCACCGCAGCAGTCGACCAACAAGTAG 
 
 
Figure 15 Open reading frame, amino acid sequence and 5’ untranslated region of the isolated cDNA, underlined 
letters represent the start and stop codon 
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3.1.5.2 Analysis of the amino acid sequence 
The cloned sequence was aligned to sequences of UDP-galactose transporters from 
different species but no homology was found. A blast search using the program 
BLASTX2.2.3 and the databases GenBank, PDB, Swissprot, PIR and PRF of the Na-
tional Center for Biotechnology (NCBI) revealed that the cloned sequence showed a very 
high homology to eukaryotic UDP-glucose pyrophosphorylases (UGPs).  
As mentioned in 1.4.1, UGPs catalyse the formation of UDP-glucose and pyrophosphate 
from UTP and glucose-1 phosphate in a reversible reaction. 
A sequence alignment with a human UGP (muscle form 2) (EMBL BC002954), the 
S.cerevisiae UGP (EMBL X69584), and two plant UGPs (potato (EMBL D00667) and 
barley (EMBL X91347) showed a sequence identity of 40%, 38%, 37% and 39% and a 
sequence homology of 53%, 57%,55% and 56%, respectively (Figure 16). Several motifs 
consisting of 15-20 amino acids are strongly conserved in various eukaryotic UGPs but 
the function of these motifs is not clear yet. Characteristic for all eukaryotic UGPs is a 
segment of conserved residues encompassing alignment positions 80-95 
(KLNGGLGTXMGX4K). A very similar motif (XLXGGXGTXXGX4K) is also conserved in 
UDP-N-actetylglucosamine/galactosamine pyrophosphorylases (UAPs) and is named the 
pyrophosphorylase consensus motif (see Figure 16, Peneff et al., 2001). According to the 
solved crystal structure of the humane UAP (AGX), this motif is involved in binding the 
nucleotide moiety of the nucleotide sugar (Peneff et al., 2001). 
 
This result was very surprising since it was completely unexpected that a UGP can 
complement the CHO Lec8 cell phenotype. A potential explanation is that overexpression 
of this enzyme most likely increases the cellular concentration of UDP-glucose and 
consequently also of UDP-galactose via the Leloir pathway (1.4.1). As mentioned in 
3.1.1, the CHO Lec8 cells exhibit a basal galactosylation capacity though they lack a 
functional UDP-galactose transporter. Besides other mechanisms, it seems possible that 
a second nucleotide sugar transporter exists, which exhibits a low transport activity for 
UDP-galactose as described for some multi-substrate transporters (Martinez-Duncker et 
al., 2003). Thus, an increase in substrate concentration in the cytosol by the UGP might 
stimulate the UDP-galactose transport into the Golgi and restore the wild type situation in 
CHO Lec8 cells.  
Figure 16 Sequence alignment (see next page). The amino acid sequences of L. major, human (EMBL 
BC002954) and S.cerevisiae (EMBL X69584), potato (EMBL D00667) and barley (EMBL X91347) UGPs 
(program MultAlin version 5.4.1, Corpet et al., 1988) are aligned. In addition, the human UAP (AGX1, EMBL 
X 900524) is shown. Conserved amino acids are highlighted with a red background, amino acids that are 
conserved in two out of the six sequences are given in red, stretches of conserved residues are boxed with 
blue lanes. The pyrophosphorylase consensus motif is boxed with a black line. 
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All experiments described so far were carried out in CHOP8 cells, a CHO Lec8 cell line 
stably transformed with the polyoma virus large T antigen (Cummings et al., 1993). In 
order to exclude the possibility that the observed complementation effect is only visible 
on the genetic background of these cells, three additional CHO Lec8 variants were 
analysed for complementation by the L. major UGP.  
 
3.1.6 Complementation of different CHO Lec8 subclones  
Analysing the mutations that cause the Lec8 phenotpye, Oelmann et al. (2001) showed 
that the UDP-galactose transport defects result from different mutational events. While a 
truncation from nucleotide 275 to 374 in the coding region of the UDP-galactose trans-
porte gene leads to the introduction of a premature stop codon (protein ends after amino 
acid 92) in the commercially available Lec8 cells (Lec8), the mutations in Lec3.2.8 and 
Lec4.8.7A interfere with the expression of the gene. In both cell lines no stable mRNA 
encoding for a UDP-galactose transporter was detectable.  
 
To characterise the basal glycosylation capacities in these different mutants, the first 
experiment carried out in this study, was a FACS analysis for polySia surface expression 
using the mAb 735 and a FITC-labelled secondary antibody (2.2.5). For control, CHO WT 
cells (positive control) and CHO cells of the complementation group Lec2 (subclone 6B2; 
negative control) were included in the experiment. Lec2 cells lack a functional CMP-sialic 
acid transporter and are therefore devoid of sialic acid and polySia. The mutant Lec3.2.8 
was not included in the FACS experiment because these cells have a defect in both the 
CMP-sialic acid and UDP-galactose transporters.   
 
Figure 17 FACS analysis of different CHO cell variants. a) CHO Lec8(3D)  and b) CHO Lec 4.8.7A 
were stained with the mAb 735 that recognizes polySia and FITC-labelled secondary antibody. CHO Lec2 
cells and CHO WT cells were taken as negative and positive controls, respectively. In each experiment 10 
000 cells were counted. 
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As can be seen in Figure 17, commercially available CHO Lec8 (subclone 3D, Lec8(3D)) 
and Lec4.8.7A cells clearly express polySia on their surface. In the case of the cell line 
Lec4.8.7A the galactose/polySia level is higher than in the other mutant.  
 
In a second experiment the basal galactosylation capacity of Lec8(3D), CHOP8, 
Lec4.8.7A and Lec3.2.8 was analysed by immunocytochemistry after transfection of cells 
with pEFBos-GlcAT (Figure 18) and staining with the mAb L2-412. Since no signal was 
obtained with the direct detection system, an amplification by biotinylation using biotinty-
ramid was carried out (see 3.1.1.1 and 2.2.3). As shown in Figure 18, all cell lines 
showed intensively stained cells. Again, the cell line Lec4.8.7A demonstrated to be most 
positive, while CHOP8 cells showed the lowest background. Due to a transfection effi-
ciency of about 30% and due to the lower sensitivity of the immunocytochemistry, not all 
cells were stained as would have been expected from the FACS analysis.   
 
 
Figure 18 Analysis of galactose expression in CHO Lec8 variants. Background expression of galactosy-
lated surface structures was determined by immunocytochemistry using mAb L2-412 after transfection with 
pEFBos-GlcAT encoding a rat glucuronyltransferase. After incubation with α−rat secondary antibody coupled 
to HRP and biotinthyramid, positive cells were detected with streptavidin AP using Fast Red as a substrate. 
 
These results clearly showed that the CHO Lec8 cell tested here are still able to galacto-
sylate and polysialylate glycans though they lack a functional UDP-galactose transporter. 
The highest background staining was observed in Lec4.7.8A cells though these cells are 
completely devoid of stable UDP-galactose transporter mRNA.     
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In the next step, the complementary activity of the L. major UGP was analysed. There-
fore, Lec8(3D), Lec3.2.8, and Lec4.7.8A cells were co-transfected with pcDNA3-L. 
majorUGP plus pEFBos-GlcAT and stained with mAb L2-412. A plasmid encoding the 
hamster UDP-galactose transporter (pcDNA3-hamUGT) and the empty vector were 
transfected as positive and negative control, respectively. In excellent agreement with the 
hypothesis that the basal galactose transport visible in Lec8 mutants is responsible for 
the complementation by the L. major UGP, all tested Lec8 variants were complemented 
by this clone. Results are shown in Fig 11. Worthwhile to mention at this point is that the 
cell lines, which exhibit a higher basal galactosylation capacity than CHOP8 cells, 
showed an increased background even without signal amplification as can be seen in 
Figure 19 lane 3.  
 
 
Figure 19 Complementation of different Lec8 variants by L. major UGP. Lec8(3D), Lec 3.2.8 and Lec 
4.7.8A cells were transfected with pcDNA3-L. majorUGP (lane 1) and pcDNA3-ham.UGT encoding the 
hamster UDP-galactose transporter (lane 2) and pcDNA3 (lane 3, control) as positive and negative controls, 
respectively. The co-expression of the rat glucuronyltransferase allowed the detection with the mAb L2-412 
and AP-coupled secondary antibody by immunocytochemistry. Positive cells stained red.  
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3.1.7 Search for UGP negative pools   
Since L. major UGP efficiently complemented CHO Lec8 cells, the identification of the L. 
major UDP-galactose transporter depends on the availability of cDNA pools that do not 
contain UGP. As mentioned before (Table 1), 8 out of 22 cDNA pools tested, comple-
mented Lec8 cells in the initial screen. In order to distinguish Lec8 cell complementation 
by pools containing the L. major UGP or the L. major UDP-galactose transporter, all 
pools of the library were screened for the presence of the UGP cDNA. Based on the 
isolated cDNA, the primers ACM1/ACM2 were designed to amplify a 750 bp fragment by 
PCR. From 86 pools of the library 64 allowed the amplification of a specific PCR product. 
The remaining 22 pools were tested in Lec8 complementation experiments but none was 
positive. This indicated that the potential UDP-galactose transporter was in the same 
pool(s) as the UGP and its complementing activity was masked by this enzyme. There-
fore, it is difficult to isolate the UDP-galactose transporter by Lec8 complementation from 
this cDNA library.  
In addition, all positive subpools from pool #17 generated during the complementation 
cloning were tested since it seemed possible that the UDP-galactose transporter cDNA 
was also present in pool #17.  Unfortunately, all pools complementing Lec8 cells also 
contained the UGP (Figure 20). 
 
 
Figure 20 PCR-screening for the presence of the L. major UGP in positive subpools identified in the 
course of complementation cloning. The cDNA of the positive subpools # 17.16-27, 17.22, 17.22.14, 
17.22.16, 17.22.23, 17.22.27, 17.22.14E, and 17.22.14E1+2 were screened by PCR as described in the text. 
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3.1.8 Complementation experiments using human UGPs 
In order to investigate if other UGPs can complement the Lec8 phenotype, two human 
UGPs from muscle were analysed. The sequences of both UGPs are identical except 
that one enzyme exhibits a longer N-terminus of 11 amino acids due to alternative 
splicing. The cDNA clones were obtained from the RZPD (Deutsches Ressourcenzen-
trum für Genomforschung GmbH, Berlin, see 2.1.3). Both enzymes were cloned into the 
vector pcDNA3. The constructs pcDNA3-L. majorUGP, pcDNA3-hUGP1 (long form) and 
pcDNA3-hUGP2 (short form) along with the plasmid pEFBos-GlcAT were transfected into 
CHOP8 cells. The re-expression of galactose-dependent epitopes was detected with 
mAb L2-412 and AP-coupled secondary antibody. Interestingly, the two human UGPs 
could not complement the CHO Lec8 phenotype whereas the expression of the L. major 
UGP resulted in complementation (Figure 21).  
 
 
Figure 21  Functional comparison of mammalian and L. major UGP. Complementation in CHO Lec8 
cells has been used to functionally compare the L. major and two human UGPs. The constructs pcDNA3-
hUGP1 (lane 1), pcDNA3-hUGP2 (lane 2), and pcDNA3-Lmajor UGP (lane 3) were transfected into CHOP8 
cells. The rat glucuronyltransferase was co-expresed and positive cells were detected with the mAb L-2-412 
and AP-coupled secondary antibody. 
 
Protein expression levels and stability were analysed by Western blotting (2.4.5). Since 
there is no antibody available, which directly recognises UGPs, a Flag-epitop tag was 
fused to the N-terminus. The tagged L. major UGP, the two human muscle UGPs and a 
negative control were expressed in CHO Lec8 cells. After 48 hours, the cells were lysed 
with lysis buffer (2.4.7) and proteins immunoprecipitated with α-Flag M5 agarose beads 
(2.4.8). Aliquots of the lysates and the immunoprecipitates were separated on SDS-
PAGE (2.4.2). In the Western blot analysis, L. major UGP was detected in the lysate as 
well as after immunoprecipitation (Figure 22).  
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Figure 22 Expression of Flag-tagged UGPs. The constructs pcDNAFL-hUGP1, pcDNA3FL-hUGP2, 
pcDNA3FL-L. majorUGP encoding the Flag-tagged humane muscle form 1 and 2 and the L. major UGP, 
respectively, were transiently expressed in CHO Lec8 cells. The empty vector pcDNA3FL was used as a 
negative control. Total cell lysates as well as proteins immunoprecipitated with the α-Flag antibody were 
separated on a 10% SDS PAGE and detected in Western blot using chicken α-Flag primary antibody, AP-
conjugated α−chicken secondary antibody and BCIP/NBT as substrates.   
 
The two human enzymes were also expressed and could be detected after immunopre-
cipitation. Since the expression level was lower compared to the L. major UGP, no 
specific bands were visible in the lysates.  
In addition, the Flag-tagged constructs were tested for complementing activity in CHO 
Lec8 cells, but as describe above, the human UGPs did not complement Lec8 cells (data 
not shown). 
 
Though the sequence homology is very high, the L. major and human UGPs differ in their 
ability to complement Lec8 cells. One explanation might be that the L. major UGP exhib-
its other enzymatic properties or protein stability than the human orthologous. To further 
investigate this assumption, the functional and kinetic characteristics of the L. major UGP 
were analysed as described in the following paragraphs.  
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3.2 Biochemical characterisation of the L. major UDP-glucose 
pyrophosphorylase 
3.2.1 Expression and purification of the L. major UGP 
 
For the functional, structural and kinetic characterisation, the L. major UGP was recom-
binantly expressed in E.coli BL21(DE3) and affinity purified. Since there was no antibody 
available that specifically recognised the UGP, a His-tag was fused to the C-terminus 
and the protein expressed under the control of the T7/lac promoter in the prokaryotic 
expression vector pET22b (pET-UGP-His).  
The construct was transformed into E.coli BL21 (DE3) and the expression induced with 
1mM IPTG for 24 hours at 15°C (2.4.10). The expression at higher temperatures resulted 
in the formation of inclusion bodies. The cells were lysed by sonification and the soluble 
and insoluble fraction analysed in SDS-PAGE (2.4.10.1). After Roti-Blue blue staining 
and Western blotting using α-pentaHis mAb, a protein of about 55 kDa could be detected 
at equal amounts in the soluble and insoluble fraction (Figure 23 and 2.4.3/6). The 
molecular weight corresponded to the calculated MW of L. major UGP. 
Figure 23 Expression of His-tagged UGP in E.coli BL21 (DE3). The construct pET-UGP-His was trans-
formed into E.coli BL21(DE3) and the expression induced at an OD600nm of 0.6 with 1 mM IPTG. After 
incubation at 15°C for 24 hours, soluble and insoluble fractions were prepared by sonification. The lysates 
were separated on a 10% SDS-PAGE. The proteins were detected by Western blotting using mAb 
 α−pentaHis (a) or Roti-Blue staining (b). 
 
After small-scale purification tests, the soluble fraction of a 2 litre culture was passed 
over a 5 ml HisTrapHP Ni2+-column (Amersham Pharmacia) to affinity purify the L. major 
UGP (2.4.11). After washing with loading buffer, the unspecific bound protein was eluted 
with 40 mM imidazole (fractions 1 to 28). The L. major UGP was eluted with 300 mM 
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imidazole using a step gradient (fractions 29 to 50). The fractions 36 to 40 were pooled 
(Figure 24).  
 
 
Figure 24 Elution profile of a HisTrapHP Ni2+-column. The soluble fraction of a 2 L E.coli BL21 (DE3) 
culture overexpressing L. major UGP was loaded onto the column. The blue line represents the amount of 
eluted protein (primary y-axis), the red line indicates the imidazole concentration (secondary y-axis). After 
washing the column with 5 column volumes (CV) of loading buffer, unspecific bound proteins were eluted 
with 40 mM imidazole (fractions 1 to 28). Using a step gradient, the L. major UGP was eluted with 300 mM 
imidazole (fractions 29 to 50) and the fractions 36 to 40 were combined. 
 
The pooled fractions were desalted with a HiPrep 26/10 column and stored at -80°C in a 
buffer containing 50 mM Tris/HCl pH 7.8, 10 mM MgCl2 (2.4.11.3). The protein concen-
tration was determined by a BCA test (2.4.1). About 20 mg protein per 1 litre bacterial 
culture was obtained. Because protein crystallisation was one of the intended goals, the 
stability of the protein in solution was tested at 4°C or at -20°C. Under both conditions 
precipitates were observed after a time period of 2-3 months if the protein concentration 
was over 4 mg/ml.  
An aliquot of the purified protein and aliquots of the soluble E.coli fraction and the flow 
through of the Ni2+-column were separated on SDS-PAGE and analysed by silver stain-
ing (Figure 25a and 2.4.4). The overexpressed protein bound very efficiently to the Ni2+-
column and after elution and desalting a purity of about 95% was achieved. A Western 
blot analysis using mAb α−pentaHis confirmed that the purified protein of 55 kDa was the 
L. major UGP (Figure 25b). A further purification of the L. major UGP was not necessary 
and the protein was used for all following characterisation studies.   
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Figure 25 Purification of recombinant His-tagged UGP. Silver stain (a) and Western blot (b) analysis of 
the purification procedure. Aliquots of the lysate, the flow through of the Ni2+-column and the purified protein 
were separated on a 10% SDS-PAGE. Proteins were analysed by silver staining and by Western blotting. 
The Western blot was developed with an mAb  α−pentaHis and AP-coupled secondary antibody using 
BCIP/NBT as substrate.  
 
In addition, constructs bearing an N-terminal StrepII-tag (IBA) were used in expression 
and purification trials (2.4.11.2). The StrepII-tag is an octapeptide that binds to Strep-
Tactin, a modified streptavidin, which allows a mild elution of the protein. While proteins 
were expressed in the soluble fraction if bacteria were grown at 15°C and turned out to 
be active if tested in vitro (see 3.2.2) and in vivo (see 3.2.3), the purification failed be-
cause the proteins did not bind to the affinity column.  
3.2.2 In vitro testing of L. major UGP 
3.2.2.1 Kinetic analysis of L. major UGP 
The purified enzyme was analysed in an in vitro activity assay (Chang et al., 1993, 
Duggelby et al., 1996, Francois et al., 1999). In the forward reaction, the activity was 
measured by using a coupled enzymatic reaction with the enzyme UDP-glucose dehy-
drogenase (2.4.13.1). The UDP-glucose dehydrogenase catalyses the formation of UDP-
glucuronic acid and NADH+H+ from UDP-glucose and NAD+. In the reverse direction, the 
addition of phosphoglycomutase and glucose-6 phosphate dehydrogenase to the reac-
tion leads to the synthesis of 6-phosphoglucono-δ lacton and NADPH (2.4.13.1). The 
subsequent reduction of NAD+ to NADH+H+ and NADP+ to NADPH+H+ in the forward 
and reverse reaction, respectively, was monitored in a spectrophotometer. The initial 
linear rates of cofactor reduction were used to calculate the enzyme activity by the 
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conversion of the increase in OD340nm to micromoles of NAD(P)H+H+ production based 
on its extinction coefficient. The protein concentration was determined in the BCA test 
(2.4.1).  
In both directions, the enzyme displays a Michaelis Menten kinetic. Using a Lineweaver 
Burk plot the apparent Km values for all substrates were determined (Figure 26).  
The UTP concentration was varied between 0.02 mM to 1 mM. At a saturating glucose-1 
phosphate concentration of 2 mM, the Km value for UTP was 70µM ± 5µM. The determi-
nation of the Km of 192µM ± 4 µM for glucose-1 phosphate was done at a fixed UTP 
concentration of 1 mM and varying the glucose-1 phosphate concentration from 0.02 mM 
to 2 mM. The Vmax of the forward reaction was 3347 ± 54 µmol/min per mg protein. 
In the reverse reaction the non-varied substrate was present at a fixed concentration of 2 
mM. The apparent Km values for UDP-glucose and pyrophosphate (PPi) were 104.8µM ±  
4µM and 200µM ±  40µM, respectively. The analysis was performed by varying the UDP-
glucose concentration from 0.05 mM to 2 mM and the pyrophosphate concentration from 
0.02 mM to 2 mM. Vmax of the reverse reaction was 2316 ± 27µmol/min per mg protein.  
The results are summarised in Table 1. 
 
 
Figure 26 Kinetic characterisation of L. major UGP. The Km values for glucose-1 phosphate (a), UTP (b), 
UDP-glucose (c) and PPi (d) were determined at a constant concentration of 1 mM UTP, 2 mM glucose-1 
phosphate, 2 mM PPi and 2 mM UDP-glucose, respectively. The results are shown as double reciprocal blots 
(Lineweaver Burk).  
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Reaction Constant Value 
   
forward Km (UTP) 70µM ± 5µM 
 Km(Glucose-1-phosphate) 192µM ± 4 µM 
 Vmax 3347 ± 54 µmol/min/mg 
   
reverse Km (UDP-Glucose) 104.8µM ± 4µM 
 Km (PPi) 200µM ± 40µM 
  Vmax 2316 ± 27 µmol/min/mg 
Table 1 Summary of the kinetic constants of L. major UGP.   
 
3.2.2.2 In vitro activity assay using galactose-1 phophate as substrate 
Lai et al. (2000) reported that the S.cerevisiae UGP catalysed the conversion of galac-
tose-1 phosphate and UTP to UDP-galactose and pyrophosphate in vitro. In addition, the 
overexpression of the UGP from S.cerevisiae and from human could rescue a galactose-
1 phosphate uridyltransferase deficient yeast strain (Lai et al., 2000). As mentioned in 
1.4.1, the galactose-1 phosphate uridyltransferase catalyses the reaction galactose-1 
phosphate + UDP-glucose → UDP-galactose + glucose-1 phosphate. A defect in this 
enzymes leads to the metabolisation of galactose-1 phosphate to e.g. galactitol, which is 
a toxic substance, if produced in higher concentration. The accumulation of toxic sub-
stances is the cause for the classical galactosemia in humans. The observed rescue of 
the mutant yeast strain by the two UGPs clearly indicated that galactose-1 phosphate is 
a substrate for UGP. This is in agreement with the report on human, calf and rabbit liver 
UGP by Turnquist et al., (1974). 
Because Lec8 complementation by the L. major UGP was explained by the increase in 
the UDP-galactose concentration, the next test was carried out to identify, if also the L. 
major enzyme can directly use galactose-1 phosphate as substrate. In an in vitro activity 
assay the formation of UDP-galactose from galactose-1 phosphate and UTP was moni-
tored by a coupled reaction with UDP-galactose 4-epimerase and UDP-glucose dehy-
drogenase. As for the coupled assays described above the reduction of NAD was de-
tected in a spectrophotometer. The activity was 0.87 µmol/min per mg protein and about 
a factor of 3000 lower than using glucose-1 phosphate as a substrate. Under physiologi-
cal conditions in the cell this activity can probably be neglected. 
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3.2.3 In vivo activity assay of the L. major UGP 
In E.coli, the deficiency of the UGP renders the bacterium incapable of fermenting 
galactose (Sundararajan et al., 1962). This is most likely due to the lack of UDP-glucose 
in the galactose-1 phosphate uridyltransferase reaction leading to the accumulation of 
toxic substances as mentioned above. As a consequence the mutant is not able to grow 
on agar containing galactose as the only carbohydrate source. Upon transformation with 
a functional UGP, the phenotype is restored. The complementing activity can be deter-
mined by the colour and size of the colonies on MacConkey-galactose agar. Galactose 
fermentation is indicated by the growth of big, red colonies due to the decrease in pH. 
Mutants defective in the UGP show poor growth of white colonies on this kind of agar 
(2.4.13.2).  
To prove in vivo activity of the isolated L. major UGP, the construct pET-UGP-His and, 
for control, the empty vector pET22b were transformed into the E.coli galU mutant strain 
DEV6 (Elseviers et al.,1980, E.coli Stock Center, New Haven, USA). The colonies were 
grown on galactose and IPTG containing MacConkey agar at 37°C for 15 hours. Growth 
of big red colonies could be observed indicating that a functional active UGP was ex-
pressed (Figure 27). 
Figure 27 Complementation of the E.coli galU mutant DEV6 by the L. major UGP. The mutant was 
transformed with pET-UGP-His (a) and as a control with the empty vector pET22b (b) and grown on 2% 
galactose and 1 mM IPTG containing MacConkey agar. 
 
This assay was performed to prove the expression of functional proteins from all con-
structs used in purification trials (see 3.2.1).  
 
3.2.4 Determination of the oligomerisation status of L. major UGP 
The amino acid sequence of eukaryotic UGPs are highly conserved. Despite this fact, the 
oligomerisation status differs between UGPs of various species. The animal UGPs were 
reported to form octamers (Levine et al., 1969), whereas the plant UGPases were found 
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to be mono- or dimers (Nakano et al., 1989, Sowokinos et al., 1993). In a more recent 
study carried out in plants, the monomer has been described to be the active enzyme, 
while oligomers of various sizes seem to exist. Oligomers may be used to sequestrate 
the protein and thus control the concentration of the active enzyme (Martz et al., 2002).  
To investigate the oligomerisation status of L. major UGP, purified protein was used to 
perform gelfiltration experiments (Figure 28 and 2.4.12). A superdex 200 HR10/30 
column was calibrated with the standards yeast alcohol dehydrogenase, bovine serume 
albumin and bovine carbonic anhydrase, which exhibit molecular masses of 150 kDa, 66 
kDa and 29 kDa and retention volumes of 12.3 ml (pink line), 13.5 ml (blue line) and 16.0 
ml (pink line), respectively. The main peak of the L. major UGP was detected at a reten-
tion volume of 14.2 ml (green line) indicating migration as a monomer. Additional analy-
sis of the fractions by SDS-PAGE and Roti-Blue staining confirmed the presence of the 
UGP as a monomer (Figure 29). A smaller peak obtained at a retention volume of 12.6 
ml was also detected and could indicate dimer formation. Since comparable peaks were 
also present in the profiles of the standard proteins, in vitro activity testing was used to 
identify the nature of eluted proteins. In Figure 29, the blue line represents the elution 
profile of the L. major UGP after gelfiltration and the pink line indicates the activity of the 
single fractions. In the forward reaction (see 3.2.2), the main activity could be detected in 
fractions representing the monomer. Because no second activity peak was observed, the 
material eluting at the position of a potential dimer, may count for inactive, aggregated 
protein. In summary, these data clearly demonstrate that the monomer is the active 
protein.    
 
Figure 28 Determination of UGP oligomerisation status. Gelfiltration was used to determine the oligomer-
isation status of L. major UGP. The elution profiles of yeast alcohol dehydrogenase (12.3 ml, pink), bovine 
serume albumin (13.5 ml, blue), and bovine carbonic anhydrase (16.0 ml, pink) were used to calibrate the 
column. L. major UGP (14.2 ml) is shown in green. 
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Figure 29 Determination of functional activity. To determine active fractions in the elution profile of the L. 
major UGP gelfiltration run (Figure 28), an activity test was carried out including all fractions. The primary y-
axis shows the protein concentration and the secondary y-axis the in vitro activity of the forward reaction. 
The elution profile of the L. major UGP gelfiltration is indicated as blue line whereas the activity of the single 
fractions is shown as pink line. The fractions were analysed on a Roti-Blue stained SDS-PAGE. 
 
In addition, a gelfiltration run including the substrates UTP and glucose-1-phosphate in 
the buffers was done. Again, the L. major UGP appeared as a monomer with the same 
elution profile as in Figure 28 (data not shown). No higher order oligomers could be 
detected in this experimental set up, indicating a clear difference to animal UGPs. 
 
3.2.5 Crystallisation of L. major UGP 
3.2.6 Determination of the minimal catalytically active unit 
In crystallisation approaches, the rule is to determine the minimal active protein, to 
optimise protein expression and crystallisation. To reach this goal in the case of L. major 
UGP, N-and C-terminal truncations were carried out. The deletion mutants were tested 
for in vivo activity in the E.coli DEV6 galU mutant. 
In the design of deletion mutants, sequence information from all known UGPs was 
included. Though the overall sequence homology of UGPs from plants, mammals and 
fungi is very high, the N-termini show no strong similarity (see Figure 16, Flores-Diaz et 
al., 1997) and may not be required for activity. Peng et al. (1993) identified a human liver 
clone truncated up to 43 amino acid residues at the N-terminus that was still able to 
complement the E.coli galU defect. This corresponds to amino acid 10 in the L. major 
UGP sequence. In contrast to the N-terminus, the C-terminus contained several con-
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served residues but no functional data was available. However, as reported in 3.1.5, the 
UGP clone initially isolated in this study represented a C-terminally truncated form of the 
gene. The very C-terminal 15 amino acids were missing in the cDNA that was active both 
in Lec8 and E.coli galU complementation assays.  
To predict a potential domain structure of the L. major UGP, a model based on the 
solved crystal structure of the human UAP (AGX1 and 2,  Peneff et al., 2001) using the 
program 3DPSSM (Kelly et al., 2000) was generated.  AGX is composed of three do-
mains: an N-terminal domain, a C-terminal domain and a catalytic core domain including 
the pyrophosphorylase consensus motif and the binding pocket (Figure 30a). Though the 
sequence identity of the L. major UGP and AGX is only 17% (see Figure 16) and many 
gaps exist especially in the N- and C-terminal region, it may be possible that the L. major 
UGP exhibits a similar domain structure. Based on the model shown in Figure 30b, the 
potential N-terminal domain of the L. major UGP encompasses the amino acids 1-40. 
Therefore, one N-terminal truncation missing the first 38 amino acids was cloned. In a 
second construct, the first 69 amino acids were removed. The rational behind this trunca-
tion was to closely approximate the first very well conserved motif in the N-terminus, the 
pyrophosphorylase consensus motif, known to be required for activity.  
The potential C-terminal domain comprises the amino acids 384 to 494 including a linker 
that connects the C-terminus to the core domain. However, the structure prediction 
program was not able to assign a structure to the last 47 amino acids. Therefore, these 
C-terminal residues were not included in Figure 30b. Two C-terminal truncations termi-
nating the protein after amino acid 390 and 440, respectively, were designed (Figure 30). 
The corresponding cDNAs were cloned into the prokaryotic expression vector pET22b 
and were named pET-UGP-∆38, pET-UGP-∆69 and pET-UGP-∆390−494, pET-UGP-
∆440-494, for the N-terminal and C-terminal truncations, respectively.   
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Figure 30 Predicted model of the L. major UGP. Based on the solved structure of the human UAP (AGX1) 
in complex with UDP-GlcNAc (a) a ribbon model has been build for the L. major UGP (program 3D-PSSM) 
(b). AGX consists of three domains an N-terminal, a C-terminal, and a core domain. The N- and C-terminal 
truncations of the L. major UGP are indicated by scissors. The mutant pET-UGP-∆69 is not included in this 
figure, since the position is hidden in this presentation. 
 
The constructs were transformed into E.coli DEV6 and tested for their in vivo activity on 
galactose containing MacConkey agar. The plasmid pET-UGP-His served as positive 
control in E.coli DEV6 complemention studies, visible by the growth of big red colonies 
(Figure 31f). Surprisingly, none of the truncated proteins was able to complement the 
E.coli DEV6 phenotype. These results indicated that deleted parts at either N- and C-
terminus are necessary for functional activity of the UGP (Figure 31a-d). The empty 
vector pET22b was used as negative control (Figure 31e). 
To exclude that the plasmids exhibited a lethal phenotype themselves, all constructs 
were transformed in E.coli DEV6 and cells were grown on glucose containing MacCon-
key agar. In this test system no lethal effects could be observed (data not shown). 
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Figure 31 In vivo activity assay of the N- and C-terminal truncations. The constructs pET-UGP-∆38 (a), 
pET-UGP-∆69 (b),pET-UGP-∆390−494 (c), pET-UGP-∆440-494 (d), pET22b (e) and pET-UGP-His (f) were 
transformed into the E.coli galU mutant DEV6 and grown on 2% galactose and 1 mM IPTG containing 
MacConkey agar. 
 
Since the expression in E.coli DEV6 was usually very low, the synthesis of stable pro-
teins was confirmed in E.coli BL21(DE3). Soluble and insoluble protein fractions were 
prepared as described in 3.2.1. and fractions analysed by SDS-PAGE. The proteins were 
extended by C-terminal His-tags and could thus be identified in Western blot analysis 
using mAb α−pentaHis (Figure 32). Equal loading was confirmed by Roti-Blue staining 
(data not shown). 
 
Figure 32 Expression control of the N- and C-terminal truncated UGPs. E.coli BL21(DE3) were used to 
express the truncated proteins cloned into the vectors pET-UGP-∆38, pET-UGP-∆69,pET-UGP-∆390−494 
and pET-UGP-∆440-494. Expression was induced at an OD600nm of 0.6 with 1mM IPTG for 24 hours at 15°C. 
Cells were sonified and separated into soluble and insoluble fractions by centrifugation. The Western blotting 
was developed with mAb α−pentaHis. 
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The molecular masses of N-terminal truncated constructs were calculated to 53 kDa and 
50 kDa. Protein bands of this size could be detected in the soluble and insoluble fractions 
as shown in Figure 32, lanes 1-4. UGP-∆69 seemed to be less soluble and lower ex-
pressed than UDP-∆38. In the case of the C-terminally truncated constructs UGP-
∆390−494 (50 kDa) was higher expressed and better soluble than UGP-∆440-494 (46 
kDa). Though there were differences in solubility of the different truncations, all cloned 
constructs allowed the expression of stable proteins, indicating that inactivity in vivo was 
not due to the absence of the proteins. In order to obtain more information on the func-
tional domains of the L major UGP the decision was made to crystallise the full length 
protein. 
 
3.2.7 Crystallisation of L. major UGP 
As crystallisation may be hindered by flexible regions (e.g. epitope tags) within the 
protein, a construct bearing a thrombin cleavage site between the C-terminal His-tag and 
the UGP was cloned (pET22-UGP/thrombin-His). The expression, purification and 
activity testing of the His/thrombin-tagged UGP was the same as for His-tagged UGP 
described above. Purified fractions of the His-tagged, of the His/thrombin-tagged, and of 
the non modified UGP (after thrombin release of the His-tag) were used for crystallisation 
trials. These studies were carried out in collaboration with Dipl. Biochem.Thomas Steiner 
in the lab of Prof. Dr. Robert Huber, MPI for Biochemistry, Martinsried. In a first step, the 
crystallisation conditions were tested in a standard large scale approach. 
Crystals were obtained for His- and His/thrombin-tagged UGP but these crystals did not 
diffract to a resolution sufficient for structure determination. Also after release of the His-
tag no well diffracting crystals were obtained.   
However, well-ordered crystals diffracting up to 2Å were obtained by adding the sub-
strate UDP-glucose to the His/thrombin-tagged protein (Figure 33). The data set revealed 
that the crystal belonged to the monocline space group C2 (a= 88.11 Å, b= 80.2 Å, c= 
138.11 Å, α = 90°, β = 90,46°, γ= 90°). To solve the structure the multiwavelength anoma-
lous dispersion phasing method using selenomethionine substituteded protein will be 
used. The selenomethionine labelled protein has already been produced and is currently 
used in crystallisation trials.  
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Figure 33 Crystal of His/thrombin-UGP. The crystal displayed was grown in the presence of UDP-glucose. 
The crystal diffracts up to 2 Å (picture supplied by Thomas Steiner) 
  
3.2.8 Intracellular localisation of L. major UGP 
The intracellular localisation of the L. major UGP was analysed by indirect immunofluo-
rescence microscopy. CHO Lec8 cells were transiently transfected with pcDNAFL-L. 
majorUGP expressing an N-terminally Flag-tagged enzyme. In addition, the plasmid 
peGFP-CI (Clontech) encoding the enhanced green fluorescent protein (eGFP) was 
transfected as a cytosolic and nuclear marker. The endogenous expressed proteins 
calnexin and mannosidase II were used to distinguish ER and Golgi localisation, respec-
tively. 48 hours after transfection the cells were fixed, permeabilised and stained with the 
α−Flag M5 mAb and a α−mannosidase II or α− calnexin polyclonal serum. The secon-
dary antibodies were coupled to Cy3 or Alexa 488 (Figure 34).  
The fluorescence signal of L. major UGP colocalised with the cytosolic localised GFP 
signal. A nuclear localisation could be excluded (see Figure 34, GFP lane 3). This was 
also observed in the overlay with the ER marker calnexin. The fluorescence signal of the 
UGP is distributed within the whole cell and not restricted to the ER locus. 
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Figure 34 Intracellular localisation of L. major UGP. Indirect immunofluorescence labelling was used to 
display the intracellular localisation. The plasmids pcDNA3FL-L. majorUGP and peGFP-CI were transfected 
into CHO Lec8 cells and the fixed cells permeabilised with Saponin. Endogenous calnexin and mannosidase 
II served as ER and Golgi marker, respectively. The intracellular localisation was analysed after 48 hours 
with the α−Flag mAb M5, α−calnexin and α−mannosidase II polyclonal serum, and Cy3- and Alexa488- 
conjugated secondary antibodies.  
 
3.2.9 Production of a polyclonal serum directed against L. major UGP 
So far, all characterisations were carried out with the recombinantly expressed epitope-
tagged enzymes. In order to investigate endogenous L. major UGP, an antibody is 
required and under preparation. Aiming at generating a polyclonal antiserum five female 
New Zeeland rabbits, were immunized with an initial dosis of the purified UDP-glucose 
pyrophosphorylase and two boost injections have been followed after 3 and 7 weeks.   
Titer development was tested in an ELISA (2.4.14) with serum samples taken 60 days 
after the first immunization. Therefore, microtiterplates were coated with the His-tagged 
UGP and incubated with serial dilutions of the sera (1:200 to 1:12800). As a positive 
control a α−pentaHis mAb and as a negative control serial dilutions of the preimmune 
sera were used. Signals were detected with the substrate ABTS after incubation with 
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HRP-coupled α−rabbit mAb or HRP-coupled α−mouse mAb for the positive control. A 
specific signal could be detected in the sera of all five rabbits with dilutions ranging from 
1:3200 (rabbits #1, #2, #4) and 1:6400 (rabbits #3 and #5). Further boost injections are 
required to improve the antibody titre. 
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3.3 Generation and characterisation of a L. major ugp gene 
deletion mutant 
The control of gene expression in Trypanosomatids differs from the mechanisms known 
in other eukaryotes. Leishmania genes contain no introns and are separated by short 
intergenic regions. The transcription is thought to occur in a polycistronic fashion and 
DNA sequences that usually mark promoters in other eukaryotes are absent (Borst et al., 
1986, Kapler et al., 1990). However, the 5’ and 3’ untranslated regions are important for 
the correct transcription and processing into mature mRNA (de Lafaille et al., 1992, Flinn 
et al., 1992). In addition, Leishmania are diploid unicellular organisms that lack a sexual 
cycle. To create a deletion mutant double targeted gene replacement has to be applied. 
Therefore, two independent selectable markers are used to replace both alleles of the 
complete endogenous gene locus by homologous recombination in successive rounds. 
For the proper transcription into polycistronic RNA, the untranslated regions are kept 
unaltered. This ensures not only the expression of the marker but also of surrounding 
genes, which is especially important in assigning a phenotype to a particular gene.  
 
3.3.1 Determination of the ugp gene copy number in L. major 5ASKH 
For a successful generation of a ugp gene deletion mutant, the gene copy number had to 
be determined. Genomic DNA from L. major 5ASKH (supplied by Joachim Clos, BNI 
Hamburg) was analysed by Southern Blotting. Therefore, the DNA was digested with the 
restriction enzymes NcoI, NcoI/BamHI, BlpI, SacI and SapI. These digests allowed to 
determine the existence of different gene loci or multiple gene copies within the same 
locus. After transfer to a nitrocellulose membrane, the blot was hybridised with a Digoxi-
genin (DIG)-labelled ugp probe comprised of the complete open reading frame. The 
sizes of the expected signals assuming a single gene locus are depicted in Figure 35. 
The sequences of the 5’ and 3’ flanking regions were available from the L. major genome 
sequencing project (The Wellcome Trust  Sanger Institute). 
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Figure 35 Schematic display of expected fragments in Southern blot analysis using the 
DIG-labelled ugp probe as shown.  
 
Signals of about 4700 bp, 9200 bp and 2900 bp were obtained from DNA digested with 
BlpI, SacI and SapI, respectively, indicating a single ugp gene locus (Figure 36). The 
NcoI and NcoI/BamHI digests confirmed this result. Since NcoI cuts once in the ugp 
sequence, two signals of about 7800 bp and 1300 bp were detected. The double digest 
using NcoI/BamHI, reduced the 7800 bp fragement of the NcoI digest to a signal of about 
5000 bp. No additional bands were visible. An unlabelled ugp PCR product of the com-
plete coding sequence served as a positive control. 
 
 
Figure 36 Southern Blot analysis of genomic L. major 5ASKH DNA. The DNA was digested with BlpI, 
SacI, NcoI, NcoI/BamHI and SapI. The fragments were separated on a 0.7% agarose gel and transferred to 
a nitrocellulose membrane. The blot was hybridised with a DIG-labelled ugp probe. The control was unla-
belled ugp PCR product.   
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3.3.2 Generation of a L. major gene deletion mutant 
3.3.2.1 Cloning strategy 
For gene replacement by homologous recombination the resistant markers hygromycin 
phosphotransferase (hyg), neomycin phosphotransferase (neo) and the phleomycin 
binding protein (phleo) were cloned between 1.5 kb of the 5’ and 3’ flanking regions of 
the ugp gene. As mentioned before, the sequence information was available from the L. 
major genome project (The Wellcome Trust Sanger Institute). The 5’ and 3’ region were 
amplified by PCR from the genomic L. major 5ASKH DNA using the primers ACM 
54/ACM55 and ACM56/ACM57, respectively. The primers introduced a XbaI and BamHI 
restriction site and a KpnI and BamHI restriction site at the 5’ and 3’ flanking region, 
respectively. These sites were used to subclone both fragments separately into the 
vector pcDNA3 (pcDNA3-5’FRs, pcDNA3-3’FRs). After sequencing, the BamHI restric-
tion site was used to fuse the flanking regions (pcDNA3-3’5’FRs) (Figure 38).  
In addition, the above primers introduced a BspHI and NheI restriction site at the 3’ end 
and 5’ end of the 5’ and 3’ flanking region, respectively, to directly subclone the select-
able markers from the vectors pCR2.1hyg, pCR2.1neo and pCR2.1phleo provided by Dr. 
Martin Wiese, BNI Hamburg. The BspHI site allowed the expression of the selectable 
markers from the same ATG start codon as the UGP, by altering only 2 bp of the 5’ 
flanking region (Figure 37). The stop codon of the resistant markers was cloned in frame 
with the stop codon of the ugp gene separated by the NheI site. No mutations were made 
in the 3’ untranslated region. 
 
 
5’ GGA GGT GAA G TC ATG A GGA TCC GCT AGC TAG GGG TCA CAA GCT 3’   
                                  BspHI           BamHI        NheI 
 
Figure 37 Cloning region of the 5’ and 3’ flanking regions. The start and stop codon of the ugp gene are 
shown bold. The -1 and -2 positions were mutated from C to T and A to C to introduce the BspHI site 
depicted in italic.   
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             Figure 38 Cloning strategy to generate the ugp gene deletion constructs  
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In the next step, the backbone of the vector pYes2/NTA was chosen to create a new 
vector without BspHI and NheI restriction sites. NcoI sites ligate into BspHI sites by the 
loss of both restriction sites. The same is true for NheI and AvrII. 
Therefore, the BspHI restriction site of pYes2/NTA was eliminated by the integration of a 
900 bp NcoI fragment from the vector pcDNA3 resulting in the vector pYes2/NTA∆BspHI. 
The digestion and relegation of pYes2/NTA∆BspHI with NheI and AvrII destroyed the two 
remaining NheI restriction sites (Figure 38). The new vector was named pYes2/NTA 
∆BspHI/∆NheI . Unfortunately, the KpnI site overlapped with the destroyed AvrII site and 
could not be used to directly subclone the fused 5’ and 3’ flanking region. The introduc-
tion of a suitable restriction site was achieved by subcloning the flanking regions into the 
vector puC18 (pUC18-5’3’FRs). After a XbaI/EcoRI restriction digest the flanking regions 
were ligated  into pYes2/NTA ∆NheI/∆BspHI (p3’5’FRs). In the last step, the hygromycin 
and neomycin resistant markers were subcloned between the 5’ and 3’ flanking regions 
using the BspHI and NheI restriction sites (p3’5’FRs-hyg, p3’5’FRs-neo). For the subclon-
ing of the phleomycin resistant marker, the plasmid pCR2.1phleo and p5’3’FRs were 
digested with NcoI/AvrII and BspHI/NheI, respectively (p3’5’FRs-phleo). The ligation of 
the marker into p5’3’FRs resulted in the elimination of both restriction sites. 
 
3.3.2.2 Targeted gene deletion of L. major ugp 
The generation of the L. major knock out mutant was done in the lab of Dr. Martin Wiese, 
BNI Hamburg. Detailed transfection and selection protocols were kindly provided by Prof. 
Jonathan LeBowitz, Purdue University, West Lafayette, USA. 
The hygromycin and phleomycin containing gene replacement cassettes were excised 
from the plasmids p5’3’FRs-hyg, p5’3’FRs-phleo by BsaAI digest resulting in fragments 
of 3.5 kb and 2.9 kb, respectively. The neomycin targeting construct was excised from 
the vector p5’3’FRs-neo by a KpnI/BbvCI digest yielding a fragment of 3.1 kb.  
The fragments were separated on an agarose gel and purified by gel extraction followed 
by ethanol precipitation (2.5.6.2 and 2.5.1). 
Since the efficiency of the homologous recombination of the different markers varies 
depending on the L. major strain used, all three resistant markers were transfected in 
parallel experiments in the first round. Thus, wild-type L. major 5ASKH were transfected 
with 2 µg DNA by electroporation (2.3.2). The selection of the parasites was accom-
plished by growing the transfected parasites on agar plates containing the appropriate 
selective drug. In contrast to selection of transformants in solution, selection on plates 
permits isolation of clonal lines. 
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After 10 days of incubation at 26°C, colonies were visible on the agar plates. In the first 
round, more hygromycin than phleomycin resistant clones were obtained. This phe-
nomenon was reproducible after repetition of the first round of transfection. This result 
suggested that the integration of the phleomycin resistant marker was more difficult than 
the hygromycin resistant marker. No colonies could be obtained using the neomycin 
targeting construct.  
The colonies were transferred into liquid media and cultures were expanded to prepare 
genomic DNA and DMSO stocks (2.3.1 and 2.5.13). The DNA of the different clones 
were screened by PCR for the correct insertion of the resistance marker at the 5’ and 3’ 
end (see 2.5.12.2) and PCR-positive clones were subjected to Southern Blot analysis 
(2.5.14). In the following, figures one representative hygromycin and two representative 
phleomycin resistant clones are shown. These three clones were used in the consecutive 
round to generate homozygous mutants. 
To confirm the integration into the right locus, a probe was designed that hybridized 
outside the region used for homologous recombination (5’UTR). The corresponding DNA 
sequence was subcloned into the vector pcR4-Topo and used for DIG-labelling (see 
2.5.12.3).  
The genomic DNA of the mutants and wild type was digested with BlpI, separated on an 
agarose gel and transferred to nitrocellulose. After hybridisation with the DIG-labelled 
5’UTR probe, the wild type allele was detected at 4.6 kb in all samples (Figure 39). The 
hygromycin and phleomycin resistant mutants showed an additional band at 4.2 kb and 
3.5 kb, respectively. These bands corresponded to the replaced ugp allele by the hygro-
mycin and phleomycin cassettes and indicated successful replacement. In addition, a 
SphI digest using the same probe also confirmed the correct insertions into the ugp gene 
locus (data not shown).  
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Figure 39 Southern Blot analysis of the heterozygous ugp mutants. Genomic DNA of a) phleomycin and 
b) hygromycin resistant clones was digested with BlpI, transferred to nitrocellulose and hybridized with a 
5’UTR probe. The expected fragments are depicted on the left hand side. As a control wild type genomic 
DNA was treated in the same way. 
 
To exclude random integration of the target construct, the genomic DNA was digested 
with SacI and BlpI and hybridised with a DIG-labelled probe consisting of the complete 
coding sequence of the corresponding resistant marker. The signals detected for the 
phleomycin clones, 8.1 kb and 3.5 kb for the SacI and BlpI digest, respectively, indicated 
a single integration into the genome at the ugp locus (Figure 40a). The same result was 
obtained for the hygromycin resistant clone, where fragments of 8.6 kb and 4.2 kb were 
visible (Figure 40b). The probes showed no unspecific hybridisation in wild type para-
sites. 
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 Figure 40 Determination of random integration by the targeting constructs. Genomic DNA of a) 
phleomycin, b) hygromycine resistant clones and of the wild type strain was digested with BlpI and SacI and 
analysed by Southern blotting. The blots were hybridised with a DIG-labelled a) phleomycin and b) hygromy-
cin probe. The expected fragments are shown on the left hand side.  
 
Since the integration of the hygromycin targeting construct seemed to be preferred, two 
phleomycin resistant clones and just one hygromycin resistant were electroporated with 
the hygromycin and phleomycin targeting constructs in the second round, respectively. 
The neomycin targeting construct was not used any more. 
Homozygous lines were obtained from both phleomycin resistant clones, but no clones 
could be obtained in the case of hygromycin resistant clone, confirming the result of the 
first round that integration of phleomycin in L. major 5ASKH is more difficult. The phleo-
mycin/hygromycin resistant lines were expanded and genomic DNA as well as DMSO 
stocks were prepared. 
As for the heterozygous mutants, PCR-positive clones were subjected to Southern blot 
analysis. For each heterozygous clone used in the second round, two representative 
homozygous clones are shown. The wild type and corresponding heterozygous clone 
was included in the analysis. The genomic DNA was digested with BlpI and after transfer 
to a nitrocellulose membrane, the correct insertion was confirmed by hybridisation with a 
DIG-labelled 5’UTR probe. The remaining wild type allele of the heterozygous phleomy-
cin resistant clone was replaced with the hygromycin marker in the homozygous clones 
(Figure 41). The signals obtained for the homozygous clones corresponded to the size of 
the phleomycin (3.5 kb) and hygromycin (4.2 kb) resistant cassettes.  
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Figure 41 Southern Blot analysis of the homozygous ugp mutants. The homozygous ugp mutants, the 
corresponding heterozygous mutant and the wild type strain were transferred to nitrocellulose after BlpI 
digest and analysed with a DIG-labelled 5’UTR probe. On the left hand side the expected fragments are 
outlined.   
 
The successful generation of ugp null mutants was confirmed by a Southern blot using 
the whole open reading frame of ugp as a probe. After SacI digest, the signal intensity of 
the wild type alleles (9.2 kb) in the heterozygous clones was reduced compared to the 
wild type strain whereas no signal was detected for the homozygous clones (Figure 42).  
 
Figure 42 Confirmation of the gene deletion in the ugp locus. The hygromycin ugp mutants, the corre-
sponding heterozygous mutant and the wild type strain were analysed by Southern blotting after SacI digest 
using the complete coding sequence of the ugp gene as a probe. 
 
In addition multiple insertions of the resistant markers in the second round were excluded 
by probing the clones with a DIG-labelled hygromycin probe after BlpI and SacI digest 
and transfer to a nitrocellulose membrane (data not shown).  
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3.3.3 Charactersiation of the ugp knock out mutant 
The deletion of the ugp gene was not lethal and the growth behaviour of homozygous 
and heterozygous clonal lines was normal compared to the parental wild type strain. In 
addition, no obvious differences in shape and size in the mutant lines could be detected 
using a light microscope.  
 
3.3.3.1 Analysis of phosphoglycans 
The major phosphoglycan on the cell surface of L. major is LPG. LPG consists of a GPI 
anchor joined to a glycan core and a large phosphoglycan domain of 15-30 Gal-Man-P 
repeating units (Figure 2). L. major also express proteophosphoglycans (PPGs), contain-
ing a phosphoglycan domain of Gal-Man-P repeating units, which is mainly secreted but 
also present on the cell surface (Foth et al., 2002, see 1.2.1).   
The synthesis of LPG and PPG requires the formation of UDP-glucose and UDP-
galactose by the UDP-glucose pyrophosphorylase and thus should be hindered in the 
ugp mutants. In the following the phosphoglycan content of the ugp mutants was ana-
lysed. 
 
3.3.3.2 Analysis of phosphoglycans by immunofluorescence and immuno-
fluorescence activated cell sorting (FACS) 
Leishmania wild type parasites, a heterozygous (ugp +/-) and two independent homozy-
gous ugp mutant strains (ugp -/-, clone 1 and ugp -/-, clone 2) were analysed by im-
munoflourescence using the mAb WIC79.3 (Greenblatt et al., 1983) and a Cy3-coupled 
secondary antibody (see 2.3.4). The mAb WIC79.3 recognizes the galactose substituted 
repeating unit of phosphoglycans. The nuclei were stained with DAPI and a 40x magnifi-
cation was used to visualize the parasites. 
As expected, the surface coat of wild type cells was strongly labelled. On the heterozy-
gous ugp mutants the signal was less intense compared to the parental wild type strain. 
The homozygous parasites showed a drastically diminished signal (Figure 43). However 
they were not completely devoid of galactose substituted repeating units as can be seen 
using a two times longer exposure time than in Figure 43 (Figure 44). The same result 
was obtained using the mAb LT6 that recognizes unsubstituted Gal-Man-P repeats (data 
not shown).   
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Figure 43 Detection of the phosphogylcans on the cell surface of L. major wild type and ugp het-
erozygous and homozygous mutants. The parasites were fixed on poly-(L)-lysine coated glass slides and 
sequentially incubated with the mAb WIC79.3 and Cy3 coupled secondary antibody. Nuclei were stained with 
DAPI. 
 
Figure 44 Intensified detection of phosphogylcans on the cell surface of L. major wild type and ugp 
heterozygous and homozygous mutants. In order to increase the signal observed in Figure 43 the 
exposure times were doubled in this experiment.   
 
To quantify the phosphoglycan content of the homozygous lines, the parasites were 
analysed by FACS (2.3.3). Therefore, Leishmania wild type cells and homozygous ugp 
mutant cells were incubated with mAb WIC79.3 and FITC-conjugated secondary anti-
body. Prior to the measurement, the parasites were fixed in paraformaldehyd.  L. major 
wild type cells incubated only with secondary antibody were used as negative control 
(Figure 45). The analysis showed that the phosphoglycan content of the homozygous 
ugp mutants was about 100 fold decreased compared to wild type cells.  
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Figure 45 FACS analysis of the homozygous ugp mutants and wild type parasites. Cells were stained 
with the mAb WIC79.3 followed by FITC-coupled secondary antibody. 50 000 fixed parasites were counted 
per experiment. 
 
Though the cells were all grown in the same culture, they can be in slightly different 
stages with a varying number of the phosphoglycan repeating unit (see introduction). 
Since this is the epitope recognized by the mAb WIC79.3 and LT6, the cell populations 
were not homogeneously stained in the immunofluorescence and FACS analysis.  
 
3.3.3.3 Western Blot analysis of LPG 
LPG was solubilised in lysis buffer containing 0.1%TritonX-100 followed by sonification 
(see 2.4.9.1). The protein concentration of the soluble fractions was determined by a 
BCA assay and equal amounts of the lysates from the wild type and ugp mutants strains 
were separated on a gradient SDS-PAGE (2.4.2). The Western Blot was analysed with 
the mAb WIC 79.3 and ECL detection (Figure 46a). Due to microheterogenicity of the 
chain length, LPG appears as a diffuse distending signal between 100 and 30 kDa. In the 
heterozygous line the LPG content is drastically reduced compared to the parental wild 
type strain. However, there was still a LPG signal present in the two independent homo-
zygous lines (lanes 3 and 4) though it is less intense compared to the heterozygous and 
wild type strain. Equal loading was confirmed by Ponceau S staining of the membrane 
(data not shown) and by Roti-Blue staining of a second gel (Figure 46b). This result 
confirmed the data obtained from immunofluorescence and FACS analysis. Though the 
ugp gene was missing, the mutants were still able to produce UDP-galactose. 
 
 
 
 
 
Results                                                                                                                            107 
Figure 46 Detection of LPG by Western blotting. a) Lysates of wild type, ugp heterozygous and two 
independent strains of homozygous parasites were separated on a gradient SDS-PAGE and after Western 
blotting were analysed with the mAB WIC79.3 and ECL detection. b) A second gel was stained with Roti Blue 
to confirm equal loading.  
 
3.3.3.4 Measurement of UDP-glucose pyrophosphorylase activity in the ugp 
mutants 
The UGP activity of the ugp mutants was determined in an in vitro activity assay. The 
activity was measured by a coupled NADH+H+ producing reaction with the UDP-glucose 
dehydrogenase. The NADH+H+ production was monitored at OD340nm in a spectropho-
tometer and used to calculate activity (see 3.2.2). 
Parasites of the wild type strain and the mutant strains were suspended in assay buffer 
(50 mM Tris/HCl, pH 8. 10 mM MgCl2) and sonified. Lysis was confirmed using a light 
microscope and the protein concentration determined by a BCA test (2.4.9.2). In the 
soluble fraction of the wild type strain an activity of 0.41 µmol/min per mg protein was 
measured whereas in the heterozygous ugp sample the activity was reduced by half to 
0.24 µmol/min per mg protein. However, the two homozygous lines (ugp -/-, clone 1, ugp 
-/-, clone 2) tested clearly showed a residual UGP activity of 0.04 and 0.06 µmol/min per 
mg protein, respectively (fig. 40).  
The existence of a second NADH+H+ producing reaction in the lysates itself was ana-
lysed by an activity measurement without the coupling enzyme UDP-glucose dehydro-
genase. No activity could be detected in these controls.    
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Figure 47 In vitro UGP activity of wild type and ugp mutants. The cells were lysed by sonification and the 
activity of the forward reaction analysed by a coupled enzyme assay. NAD+ reduction was measured in a 
spectrophotometer and the linear rates used to calculate activity based on its extinction coefficient.  
      
3.3.3.5 Experimental infection of mice with the ugp mutants 
The influence of the ugp deletion on infectivity was determined in a mouse infection 
model. The virulence of the parasites was assessed following inoculation in footpads of 
female Balb/c mice. The parental wild type line, two clonal heterozygous and 4 clonal 
homozygous lines were grown to late logarithmic phase and 107 parasites per mouse 
were injected. Each group consisted of five mice. The lesion formation was monitored by 
comparing the thickness of the infected and uninfected footpad with a Vernier calliper. 
The footpads were measured every 7 days over a period of 10 weeks. 
Lesion formation of the wild type strain occurred 3 weeks after inoculation and pro-
gressed steadily (Figure 48). In contrast the homozygous lines showed a delayed lesion 
formation and swelling occurred 5 weeks after inoculation. Interestingly infection with the 
heterozygous mutants produced a time course that was exactly between the wild type 
and homozygous lines. This data suggest a gene doses effect. 
The in vivo infection model indicated that the ugp mutants are attenuated for virulence in 
mice.  
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Figure 48 In vivo testing of virulence. The time course of lesion formation after infection of Balb/c mice 
with L. major wild type (blue line), heterozygous (pink line), and homozygous (green line) ugp mutant strains 
was monitored by measuring swelling of footpad. After infection of female Balb/c mice the infected and 
uninfected footpads were measured once a week over 10 weeks. The median size difference (+/- MAD) of 
the infected and uninfected footpad was plotted against the weeks post infection. Two heterozygous and four 
homozygous mutant clones were tested. For each clone 5 animals were infected. 
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4 Discussion 
4.1 Identification of the L. major UDP-glucose pyrophosphory-
lase 
In this study, a functional active UDP-glucose pyrophosphorylase (UGP) from L. major 
was identified and biochemically characterised. The enzyme catalyses the reversible 
reaction of glucose-1 phosphate and UTP to UDP-glucose and pyrophosphate (see 
Figure 5). The enzyme represents a key position in the galactose metabolism allowing 
the entry of galactose-1 phosphate into glycolysis in organisms that utilize the Leloir 
pathway (see 1.4.1). In addition, UDP-glucose is a direct and indirect precursor of a 
number of nucleotide sugars, like UDP-glucuronic acid, UDP-xylose and UDP-rhamnose 
(Kleczkowski et al.,1994).  
Most surprisingly, the L. major enzyme was able to reconstitute the wild type phenotype 
after transfection into Lec8 cell, a CHO cell line defective in the UDP-galactose trans-
porter (Deutscher et al., 1986). This cell line was used before to isolate functionally active 
UDP-galactose transporters from a cDNA library by complementation cloning (Bakker et 
al., 2004). Although, an identical cloning strategy was applied to isolate the UDP-
galactose transporter from an L. major cDNA library, this approach resulted in the identi-
fication of the UGP. In fact, the cloning of this gene cannot be explained by potential 
artefacts caused by the applied staining techniques because different detection systems 
including the use of two antibodies and different colour reactions were used. Moreover, 
the absence of cross-reactions with the secondary antibody was guaranteed. Thus, the 
complementation seen in CHO Lec8 cells by the L. major UGP was real and most likely 
can be explained by the characteristics of the cell line as will be discussed below. 
The UGP-mRNA must be highly expressed in procyclic promastigote parasites because 
the corresponding cDNA was present in 64 out of 86 pools of the cDNA library derived 
from this organism (see 3.1.7). This observation is in line with the fact that procyclic 
promastigote parasites upregulate the expression of galactose containing phosphogly-
cans which requires the expression of enzymes involved in the galactose metabolism 
(reviewed in Naderer et al., 2004). Since the UGP plays a critical role in the galactose 
metabolism, the high expression level provides strong indication for the central function 
of the enzyme in promastigote L. major parasites.   
The initially selected complementing cDNA pool did not contain a complete UGP clone. 
The full length cDNA could be isolated based on homology to a sequence fragment 
identified in the genome data base (The Wellcome Trust Sanger Institute and see 
3.1.5.1). Comparative complementation testings carried out with the truncated and full 
Discussion                                                                                                                      111 
length cDNA did not reveal any significant differences, indicating, that the terminal 15 
amino acids are dispensable for the formation of the active enzyme.  
UGPs have been identified from a number of prokaryotic and eukaryotic organisms, but 
no significant sequence homology can be observed between prokaryotic and eukaryotic 
UGPs. Thus, the motif XLXGGXGTXXGX4K, called the pyrophosphorylase consensus 
motif, highly conserved in all eukaryotic UGPs including L. major and in various eu-
karyotic UDP-GlcNAc/GalNAc pyrophosphorylases (UAP) is absent in the prokaryotic 
UGPs, although, surprisingly, a similar motif (XLXXGXGTX7K) exists in the bacterial UAP 
(Peneff et al., 2001).  
If aligned to the human, yeast and plant homologous, the L. major UGP shows an amino 
acid sequence identity of 37% to 40% (3.1.5.2 ). Conservation is focused to amino acid 
stretches 15-20 residues in length and largely concentrated in the C-terminal part of the 
protein (Figure 16). The function of the conserved motifs is not clear yet. Since, no 
eukarytotic UGP has been crystallised so far, the available data on the human UAP 
(AGX) was used to predict the three dimensional structure of the L. major enzyme 
(Figure 30).   
 
Despite this high identity, the UGP activity was confirmed in vivo and in vitro. The in vivo 
activity was analysed by the complementation of the E.coli galU mutant. Due to a defect 
in the ugp the E.coli galU mutant is not able to metabolise galactose (Sundararajan et al., 
1962). The growth on agar, containing galactose as the only carbohydrate source is 
abolished. The transformation of the L. major UGP restored the wild type situation and 
confirmed activity in vivo (see 3.2.3). In addition, the epitope-tagged L. major UGP was 
recombinantly expressed in E.coli BL21 (DE3) and purified by affinity chromatography 
(see 3.2.1). In a one step purification using a C-terminal His-tag a purity of about 95% 
and a yield of about 20 mg per litre culture was obtained. Interestingly, an N-terminal 
StrepII-tag was not accessible for purification though an N-terminal Flag-tag could be 
used in indirect immunofluorescence (see 3.2.8).  
The activity of the purified enzyme was analysed in the forward (fwd.) and reverse (rev.) 
reaction by coupled enzymatic reactions (see 3.2.2.). The maximum velocities were 
determined to be Vmax,fwd = 3347 µmol/min per mg protein and Vmax,rev. = 2316 µmol/min 
per mg protein indicating a reversible activity in vitro. 
 
4.1.1 Characterisation of the galactose background in CHO Lec8 cells   
As mentioned in chapter 3.1.1, Lec8 cells were found to be not completely devoid of 
galactose on their cell surface though they have been proven to lack a functional UDP-
galactose transporter. In immunocytochemistry, a basal galactose expression on the cell 
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surface of the CHO Lec8 cell line CHOP8 could be detected. The background of positive 
cells could neither be depleted by cultivating the cells in the presence of the sialic acid 
binding lectin WGA (wheat germ agglutinin) nor by incubation with the galactose binding 
lectins European mistletoe or Ricinus communis agglutinin (RIC) (see 3.1.1.1). The 
classification of a glycosylation defective CHO cell line into a certain complementation 
group is based on its resistance or sensitivity to a series of certain plant lectins (Lec-
mutants, Stanley, 1984). However, lectin resistances or sensitivities are relative values 
and are reported as fold resistance/sensitivity compared to the parental cell line. Though 
the CHO Lec8 cell line is a 100 fold more resistant to WGA and 2 fold more resistant to 
RIC than wild type cells, this does not ensure that the cells are completely devoid of 
galactose or sialic acid.  
To gain deeper insight into the galactosylation capacity of Lec8 cells, three additional cell 
lines exhibiting the lec8 defect (Lec3.2.8, Lec4.8.7A and the commercially available 
Lec8(3D))  were investigated. These mutants were chosen, because an earlier study in 
the laboratory (Oelmann et al., 2001) had confirmed the absence of a functional UDP-
galactose transporter. As described in paragraph 3.1.6, these cell lines are still able to 
express galactosylated and sialylated glycans on the cell surface. In addition, the FACS 
analysis demonstrated that all cells in the population show a residual presence of sialyla-
tion and negates the possibility that the background transport of UDP-galactose is due to 
single revertants.   
 
Revertants were known to occur during the cultivation of the CHO Lec32 cell line lacking 
a functional CMP-N-acetylneuraminic acid synthetase (CMP-sialic acid synthetase, see 
PhD thesis, Anja Münster 1999 and Münster et al., 1998). This enzyme catalyses the 
formation of CMP-sialic acid (Neu5Ac) and PPi from Neu5Ac and CTP and is located in 
the nucleus. The reason for this unusual intracellular localisation has been investigated 
for more than 30 years but is still an enigma. The loss of CMP-sialic acid synthetase 
activity results in the absence of sialic acid on the cell surface. The molecular basis for 
the revertation of this cell line is not understood, but may be related to a putative second 
function of this enzyme in the nucleus rather than the requirement of sialic acid on the 
cell surface. Support for this speculation arises from the fact that another asialo mutant 
shows a stable phenotype. This cell line of the complementation group Lec2 lacks a 
functional CMP-sialic acid transporter (Deutscher et al., 1984). The second unknown 
function of the CMP-sialic acid synthetase may result in the activation of the second 
allele that is usually inactivated by methylation in CHO cells (Holliday et al.,1990). The 
existence of revertants in the case of the CHO Lec8 cells was rather unlikely since the 
appearance of positive cells was not increased during the time of cultivation. In addition, 
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a clear complementation could be detected even with the basal level of UDP-galactose 
transport. This could also account for a lower expression of the second allele but most 
likely, Oelmann et al., (2001) would have detected this functional mRNA transcript in the 
detailed characterisation of the CHO Lec8 cells (see PhD thesis Stefan Oelmann and 
Oelmann et al., 2001). Taken together, these findings suggest another reason for the 
basal galactose expression in CHO Lec8 cells. As mentioned in 3.1.5 the possibility 
exists that other nucleotide sugar transporters are able to transport UDP-galactose 
though with a lower efficiency. Until now, four multi-substrate nucleotide sugar transport-
ers have been described. These include a C.elegans transporter transporting UDP-
glucuronic acid (UDP-GlcA), UDP-N-acteylglucosamine (UDP-GlcNAc) and UDP-
galactose (UDP-Gal) (Bernisone et al., 2001), a humane UDP-glucuronic acid/UDP-N-
acteylgalactosamine transporter (Muraoka et al., 2001), and a Drosophila transporter 
called fringe connection that transports UDP-GlcA, UDP-GlcNAc, UDP-GalNAc, UDP-
glucose(UDP-Glc) and UDP-xylose (UDP-Xyl) (Goto et al., 2001,Selva et al., 2001). 
Martinez-Duncker et al. (2002) suggested that all these transporters are able to transport 
UDP-GlcA, UDP-GalNAc, UDP-Xyl, UDP-Gal, UDP-GlcNAc, and UDP-Glc but probably 
with different efficiency. Another example is the human UDP-galactose transporter that 
also transports UDP-GlcNAc (Segawa et al., 2002) and the LPG2 transporter from 
L.donovanii that transports GDP-mannose, GDP-arabinose and GDP-fucose (Hong et 
al., 2000). Thus, broader substrate recognition is not restricted to UDP-sugar transport-
ers.  
Worthwhile to mention at this point is that a basal galactose transport activity has also 
been demonstrated in the Ricinus communis agglutinin resistant MDCKII (Mardi-Darby 
canine kidney strain II, Brandli et al., 1988) cells that also lack a functional UDP-
galactose transporter. All this data point towards the existence of a second transport 
system for UDP-galactose. 
 
 
4.1.2 Characterisation of the complementing activity of UDP-glucose 
pyrophsphorylases 
The efficiency of the UDP-galactose transport by a potential second nucleotide sugar 
transporter in CHO Lec8 cells is lower compared to the transport activity of the UDP-
galactose transporter itself. This is shown by the high expression of galactose on the cell 
surface upon transfection with a plasmid encoding a functional UDP-galactose trans-
porter (see 3.1.3, Figure 12 and 3.1.4, Figure 13). Nevertheless, an increase of the UDP-
galactose concentration in the cytosol might augment the UDP-galactose transport by a 
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multi-substrate transporter. By overexpression of the L. major UGP, elevated levels of 
UDP-galactose could be obtained, since UDP-glucose can be converted to UDP-
galactose by the two enzymes UDP-galactose-4-epimerase and galactose-1 phosphate 
uridyltransferase (see 1.3.1.1).  
 
Similarly, a GDP-fucose transport defect observed in a fibroblast cell line derived from a 
Turkish patient with a leukocyte adhesion deficiency type II (LADII) (Lübke et al., 1999) 
could be complemented by increasing the intracellular level of GDP-fucose. In addition, 
oral administration of fucose restored the fucosylation deficiency in the patient 
(Marquardt et al., 1999), who is mentally retarded and lacks fucosylated glycoproteins. 
This also includes the selectin ligands, which are essential for the intact immune system 
(Etzioni et al., 1992, Becker et al., 1999). Lübke et al. (1999) could show that in the 
patient’s fibroblasts the high affinity transport of UDP-fucose into the Golgi apparatus 
was deficient, but a low level transport for GDP-fucose still occurred. The defect in the 
GDP-fucose transport protein was confirmed by complementation cloning (Lühn et al., 
2001, Lübke et al., 2001) and the analysis of the patient’s GDP-fucose transporter 
identified a homozygous point mutation in the inactive protein. This suggests that like in 
CHO Lec8 cells, the basic GDP-fucose transport can be enhanced by raising the sub-
strate level. Indeed, Lühn et al., (2001) identified a second C. elegans GDP-fucose 
transporter that showed a low complementing activity in the LADII fibroblasts.  
 
Another possible explanation is that the UGP directly or indirectly interacts with a nucleo-
tide sugar transporter and influences substrate specificity or transport efficiency. UGPs 
are usually found in the cytoplasm. However, in some plants, UGP activity was associ-
ated with membrane fractions (Simcox et al., 1977, Nishimura et al., 1979) and in cat 
liver about 10% of the UGPase activity was found to be associated with Golgi mem-
branes (Persat et al., 1983). Indirect immunofluorescence of the L. major UGP showed a 
distribution of the protein within the whole cell indicating a cytosolic and/or ER localisa-
tion. In this kind of experiment, no association with the Golgi apparatus could be detected 
(see 3.2.8). However, a more detailed analysis is necessary to answer the question 
whether low amounts of the L. major UGP are also associated to the Golgi membrane 
and there could interact with nucleotide sugar transporters. In addition, the intracellular 
localisation of the UGP in the parasite itself will be analysed. Since the expression of 
tagged proteins in Leishmania is difficult, antibodies are required to study the endoge-
nous protein. Towards this goal, a polyclonal serum is currently prepared (see 3.2.9) by 
using the purified recombinant protein for immunization. In addition, the detection of the 
endogenous protein is preferable, to develop a detailed picture of the natural situation.    
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In contrast to the L. major UGP, the humane muscle UGPs were not able to complement 
the CHO Lec8 cells. A possible explanation might be differences in the structural and 
kinetic properties of UGPs despite their high sequence homology or in protein stability. 
This will be discussed in more detail in the following chapters.    
 
Unfortunately, the UDP-galactose transporter could not be identified in the remaining 
UGP negative pools and is masked by the signal of this enzyme. A potential way to clone 
the transporter would be to subdivide more pools of the library until a complementing 
subpool without UGP cDNA can be identified. This strategy is however, labour intensive 
and has a high risk to fail. Another option is the generation of a cDNA library from the 
ugp gene deletion L. major mutant (see 3.3). This work is still in progress. 
 
4.2 Structural and functional characterisation of the L. major 
UGP 
4.2.1 Structural analysis of a potential L. major UGP core domain 
A structural homology search in the PDB database and the use of the program 3D-PSSM 
(Kelley et al., 2000) revealed a model of the L. major UGP based on the solved structure 
of the humane UDP-GlcNAc/GalNAc pyrophosphorylase (AGX1 and 2, Peneff et al., 
2001). The structure of AGX1 and the splice variant AGX2 were solved in complex with 
the nucleotide sugars UDP-GlcNAc and UDP-GalNAc. Though the sequence identity is 
rather low (17%, see Figure 16) and this structure could not be used to solve the phase 
problem of the obtained L. major UGP crystal data set (see 3.2.7), some structural 
features seem to be conserved. AGX1 and 2 are composed of three domains: a large 
central domain and clearly discernible N- and C-terminal domains. The central domain 
contains the catalytic site and in its centre binds the nucleotide sugar in a deep pocket. 
The binding of the nucleotide part of the nucleotide sugar involves the first have of the 
core domain including the pyrophosphorylase consensus motif (see Figure 30). The 
second half of the core stabilizes the sugar ring. Though there are many gaps, it may be 
that the fold of the central domain of AGX1 and L. major UGP are conserved. In Figure 
30, the position of a potential binding pocket as well as the position of the pyrophos-
phorylase consensus motif is shown. Still the prediction of residues involved in the 
catalytic mechanisms of the L. major UGP can not be made, since the corresponding 
data of AGX1 and 2 are preliminary and need further confirmation. 
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4.2.2 The N- and C-terminal domain and the oligomerisation state of 
UGP 
The N-terminus of AGX1 contacts a four stranded antiparallele ß-sheet of the core 
domain. In the model of the L. major UGP, the structure prediction of this domain com-
prises many gaps except for one alpha helix that also seems to contact the core domain. 
According to this model, the N-terminal domain of the L. major enzyme is comprised of 
the amino acids 1-40. A truncation of the first 38 amino acid generated an inactive 
protein (see 3.2.6). This indicates that either the contact of the alpha helix to the core 
domain or additional interactions of the N-terminus that are not included in this model, 
are important for activity or stability of the protein. The influence on activity seems more 
likely, since the N-terminus of AGX1 locates on top of the active site pocket and is 
believed to regulate activity (Peneff et al., 2001). The truncated UGP was stably ex-
pressed in E.coli BL21(DE3) suggesting the formation of an intact folded protein. In 
contrast, truncation of the first 69 residues of the N-terminus- including a part of the core 
domain- seems to interfere with protein stability. Though protein of the expected size was 
expressed in E.coli BL21(DE3), a comparatively high amount was detected in the insolu-
ble fraction.  
 
The C-terminus of AGX1 and AGX2 is connected via an alpha helix to the core domain 
and is involved in the subunit interaction. As mentioned above, AGX2 is a splice variant 
of AGX1. Both sequences are identical except for a 17 amino acid insertion in the C-
terminus in the case of AGX2. The site of this insertion contributes to the subunit interac-
tion in the AGX1 dimers and reaches into the active site pocket of the second molecule. 
Furthermore, this part provides additional binding sites for the nucleotide sugar. In AGX2 
the structure of this part of the C-terminus was disordered and could not be traced. 
Interestingly, AGX2 was found to be a monomer in gelfiltration experiments whereas 
AGX1 was dimeric. By diluting AGX1 into the nanomolar range or by increasing the salt 
concentration, dissociation into monomers was observed (Peneff et al., 2001). The 
question whether the dimer or monomer is the physiological relevant form and whether 
the dimeric form is catalytically active remains to be answered.   
The oligomerisation status of the L. major UGP was analysed by gelfiltration experiments 
and revealed the monomer as active species even at high protein concentrations (see 
3.2.4). Unfortunately, the C-terminus of the L. major UGP was very poorly predicted by 
3D-PSSM and the last 44 amino acids are not included in the model. Based on these 
findings, it is possible that the L. major UGP C-terminus comprises a different structure. 
However, the truncation of the last 38 and 69 residues revealed a stably expressed, but 
inactive protein indicating an influence of the C-terminus on the catalytic activity. In 
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addition, some parts of the C-terminus might also be important for the stability of the 
protein, since the expression of UGP-∆380-494 increased the level of non soluble pro-
tein.   
Though the existence of a small fraction of L. major UGP dimers can not be excluded by 
size exclusion chromatography, higher oligomeric structures could not be detected. 
Peaks mimicking higher organized protein fractions were also observed for the standard 
proteins and are believed to represent unspecific protein aggregates. The addition of the 
substrates UTP and glucose-1 phosphate to the buffers confirmed the monomeric nature 
of the L. major UGP. Dissociation from dimers into monomers to achieve an open con-
firmation of the active state could not be observed. This mechanism was suggested for 
the barley UGP that was found to be a mixture of oligomers with the monomer as active 
species (Martz et al., 2002). Mutant analysis of this enzyme revealed that a higher 
polymerisation capacity reduced the maximum velocity in activity assays. Thus, it was 
postulated that deoligomersiation has a critical impact upon catalysis and may be the 
rate-limiting step. Other eukaryotic UGPs, e.g. the human, calf and rabbit liver UGPs are 
suggested to occur as octamer in vivo though also lower oligomeric forms could be 
detected (Turnquist et al., 1974) and the enzyme from potato tuber exists as monomer 
and dimer (Sowokinos et al., 1993). The crystal structure obtained for AGX1 and 2 and 
the data obtained from the barley enzyme suggest a potential role of oligomersiation in 
the regulation of activity and will be discussed further in the next chapter. 
The crystal structure of the L. major UGP shell soon be resolved and will reveal whether 
C- and/or N-terminus participate in the formation of the active enzyme or in mediating 
subunit interaction. 
 
4.2.3 Kinetic comparison of UDP-glucose pyrophosphorylases 
Despite their high homology, eukaryotic UGPs differ in their kinetic characteristics. To 
compare the kinetic data of the L. major UGP with the data available from the human 
(Duggleby et al., 1996), potato (Sowokinos et al., 1993), and barley (Elling et al., 1996) 
UGPs, the purified L. major UGP was used to determine the Km values in an in vitro 
activity assay for both the forward and reverse reaction (see table 2). The enzyme 
displayed a Michaelis Menten kinetic towards all substrates. Compared to the kinetic 
data published by Chang et al., (1995), the L. major UGP showed a higher affinity to the 
substrates UTP (Km = 917 µM) and glucose-1 phosphate (Km = 404 µM) than the human 
muscle form 2, whereas the Km values of the human muscle form 1 (UTP: Km = 301 µM, 
glucose-1 phosphate: Km = 207 µM) were in about the same range. In the reverse reac-
tion, the human forms showed a higher affinity for UDP-glucose (63 µM and 41 µM, for 
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muscle form 2 and 1 respectively) than the Leishmania enzyme. The Km value for pyro-
phosphate was determined only for the human muscle form 2 (384 µM) and was about a 
factor of 1.9 higher than for the L. major UGP (Duggleby et al., 1996). 
 
Substrate muscle form 1 muscle form 2  lacZ/liver potato tuber barley L. major 
       
glucose-1 phosphate                  207                  404           174           80-68      74      192 
UTP                  301                  917           692       180-530      93        70 
       
UDP-glucose                   41                    63             55              140     191      104 
PP           sigmoid                  384           172              130     172      200 
Table 2 Comparison of the UGP Km values for the human muscle form 1 and 2, for the human 
lacZ/liver fusion enzyme, for the barley and L. major enzyme. The enzyme from potato tuber exhibits a 
complex kinetic towards glucose-1 phosphate and UTP, depicted by two Km values for each substrate. 
 
Surprisingly, the muscle form 1 showed sigmoid kinetics with respect to pyrophosphate. 
As mentioned in 3.1.8, the amino acid sequences of the two human muscle enzymes are 
identical except that muscle form 1 contains a N-terminal extension of 11 amino acids 
(Figure 49). The N-terminal elongation is the result of alternative splicing. Duggleby et al. 
(1996) assigned the kinetic difference in regard to the pyrophosphate to the difference in 
the N-terminal region. The influence of the N-terminus on the kinetics was also observed 
using the humane liver UGP (Duggleby et al., 1996). The human liver enzyme differs in 
only 6 amino acid positions from the human muscle form 1 and shows also the elongated 
N-terminus (Figure 49).  
 
 
Figure 49 Primary sequence alignment of the N-terminal regions of UGPs. The N-termini of the en-
zymes isolated from human liver (Peng et al., 1993), human muscle (Duggelby et al., 1996), L. major (this 
study), potato (Sowokinos et al.,1993) and barley (Eimert et al., 1996) are aligned. Conserved amino acids 
are highlighted with a red background, amino acids that are conserved in two out of the three sequences are 
coloured in red, stretches of conserved residues are boxed in blue.      
 
The liver enzyme exhibited a complex kinetic towards pyrophosphate. However, after the 
replacement of the first nine residues by lacZ the protein revealed not longer kinetic 
anomalies and followed a Michaelis Menten kinetic with respect to all substrates. Dug-
gleby et al.,(1996) proposed, that the oligomeric status could account for the complex 
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kinetics of the enzyme, since it was reported that the human liver UGP is an octamer in 
nature (Turnquist et al., 1974). A potential explanation is the existence of different rate 
constants for catalysis when one or all active sites are occupied (Duggleby et al., 1996) 
or for the deoligomerisaton into active monomers as suggested by Martz et al. (2002). In 
either case, the N-terminus could be involved in subunit interaction though a direct proof, 
for example by gelfiltration studies with the lacZ fusion enzyme or the muscle enzyme, 
does not yet exist. The L. major enzyme exhibits a simple Michaelis Menten kinetic 
towards all substrates and has the monomer as active species. This would be in agree-
ment with Duggleby et al. (1996) suggesting that a complex kinetic is coupled to oli-
gomerisation events.  Another explanation on how the N-terminus of the UGP could 
influence the kinetics is based on the solved crystal structure of AGX1. As mentioned 
above, the N-terminal domain is located on top of one site of the active site pocket and 
might regulate activity (Peneff et al., 2001). The N-terminus of the L. major UGP is 24 
amino acids shorter compared to the human muscle form 2 (Figure 49) and does not 
seem to hinder the binding of the substrates to the catalytic pocket as indicated by the 
kinetic data.  
Though these data suggest that the N-terminus influences the kinetic properties, there 
may be other regions of the proteins involved in regulating oligomersiation and/or activity. 
An example is the potato UGP that exhibits a shorter N-terminus than the human muscle 
forms (Figure 42 and 16), has still the ability to form dimers and shows a complex kinetic 
behaviour in regard to UTP and glucose-1 phosphate (Sowokinos et al., 1993). The 
barley enzyme has about the same length as the potato enzyme (Figure 42 and 16) but 
forms a mixture of oligomers with the monomer as active species and exhibits simple 
Michaelis Menten kinetics with regard to all substrates (Elling et al., 1996). As mentioned 
above, a mutant barley UGP showed a higher order of oligomersiation and a reduced 
Vmax suggesting that the transition between oligomer- and monomer state has an impact 
on activity. Interestingly, the mutation was not introduced at the N-terminus of the en-
zyme but in the core domain C-terminal of the pyrophosphorylase consensus motif.  
The data suggest that regulation of the UGP activity is complex. This is also supported 
by the finding that alternative splicing of pyrophosphorylases as in the cases of AGX and 
the human muscle UGPs leads to an alteration in the enzymatic properties even though 
rather small changes within the sequence occur. Unfortunately, the oligomeric difference 
between AGX1 as monomer and AGX2 as dimer could not be measured in the activity 
assays used by Peneff et al. (2001), since nanomolar concentration ranges are used in 
their assay. As mentioned above, both AGX forms are monomers under these conditions 
and show similar kinetics despite the observed structural difference (Peneff et al., 2001). 
However, other studies suggested that AGX1 prefers GalNAc-1 phosphate and AGX2 
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GlcNAc-1 phosphate as substrate indicating an influence of the splicing differences on 
substrate specificity (Wang-Gillam et al., 1998).  
 
Since rather small sequence differences can exhibit changes in the kinetic behaviour 
and/or activity of the UGPs, this may also explain why the human muscle UGPs are not 
able to complement the CHO Lec8 phenotype though the sequence homology to the L. 
major UGP is about 53%. However, more kinetic and functional data has to be collected 
to get a complete data set for all isolated UGPs. This would include the purification of the 
corresponding enzymes, kinetic analysis and studies on the oligomerisation status. In 
addition, the crystal structure of the L. major UGP should provide insight into the regula-
tion of the enzymatic activity.  
 
4.3 Generation and characterisation of a L. major UGP gene 
deletion mutant  
Essential for the parasites survival in the hostile environment of the sand fly vector and 
the mammalian host are various surface glycoconjugates, which collectively form a 
dense cell surface, the glycocalyx (Pimenta et al., 1991). The major surface glucoconju-
gates are the GPI-anchored glycoproteins, the lipophosphoglycan (LPG), free GPI 
glycolipids (GIPLs) and proteophosphoglycans (PPGs) (McConville, 2002, Descoteaux et 
al., 1999). Thus, the enzymes involved in the biosynthesis of the parasite glycocalyx 
provide interesting targets for therapeutic drugs and were intensively investigated (see 
introduction). Essential for the biosynthesis of glycoconjugates is the activation of the 
monosaccharides as nucleotide sugars. The formation of two activated sugars, UDP-
glucose and UDP-galactose, is dependent on the activity of the UGP. To investigate the 
role of the UGP in the parasite, an ugp gene deletion mutant was generated. The cloning 
strategy was influenced by the fact that Leishmania contain no introns and that transcrip-
tion occurs in a polycistronic fashion (Stiles et al., 1999, Stein et al., 1990). In addition, 
consensus elements that are characteristic for eukaryotic promoters are absent. Thus, 
the complete open reading frame of the targeted gene was replaced by the coding 
sequence of the resistant markers leaving the 5’ and 3’ untranslated regions unaltered to 
allow the correct splicing and polyadenylation of the marker. L. major is a diploid asexual 
parasite and requires two consecutive rounds of homologous recombination to create a 
null mutant of a particular gene. 
In the case of the L. major ugp, it was not possible to precisely determine the start and 
end positions of the neighbouring genes by sequence analysis. Therefore, it was impor-
tant to introduce no point mutation in the flanking regions used for homologous recombi-
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nation. Since the L. major ugp is a single copy gene (see 3.3.1), two rounds of targeted 
gene replacement resulted in the exchange of the complete ugp open reading frame by 
hygromycin and phleomycin resistant markers. However, the insertion of hygromycin was 
preferred compared to the insertion of the phleomycin resistant marker. It might be 
possible that the size of the DNA influences the polycistronic gene transcription giving 
advantage to the hygromycin resistant marker, which with 1000 bp closely apporoxi-
mates the size of the ugp gene (1400 bp). The phleomycin resistant gene has a size of 
only 400 bp.  
Using the L. major 5ASKH, it was not possible to obtain neomycin resistant clones. 
Since, other laboratories (Clos et al., BNI Hamburg) also had difficulties introducing a 
neomycin resistant cassette, this phenomenon might be due to some unknown peculiari-
ties of the selected L. major strain.  
In addition, the generation of the gene deletion mutant was extremely influenced by the 
amount and quality of the cDNA as high amounts of the targeting fragments resulted in 
multiple false insertions into the genome. This was also reported by Cruz et al. (1990 and 
1991) who established the technique of the double targeted gene replacement for creat-
ing null mutants in L. major.  
The correct insertion of the resistant markers was confirmed by PCR and Southern Blot 
analysis. Since L. major loose their virulence in culture, it was extremely important to 
work with freshly isolated parasites and to process as fast as possible. In addition, the 
parental wild type strain, was treated and cultivated in the same way as the mutants to 
allow the direct comparison of the results in the following experiments. 
 
4.3.1 Charaterisation of L. major ugp deletion mutants 
The obtained clones showed normal growth in culture compared to the wild type strain 
indicating that the UGP is not required for growth under the applied cultivation conditions. 
Unfortunately, an increased sensitivity to galactose as observed for the E.coli galU 
mutant, could not be tested, because of the complex nutrient requirements of these 
parasites in culture. However, the deletion of this enzyme should not only effect the 
assembly of the major macromolecule LPG in the promastigote surface glycocalyx but 
also the generation of the type-2 free GIPLs, the GPI-anchored and secreted PPGs as 
well as glucoslyated N-glycans (see Figure 3). 
In order to obtain a first insight into the consequences of the ugp gene deletion, the LPG 
and surface bound PPGs were analysed by indirect immunofluorescence. Since galacto-
sylation requires the formation of UDP-galactose and therefore the availability of UDP-
glucose, the mutants should have been devoid of the Gal-Man-P repeating unit charac-
teristic for LPG and PPGs. This epitope was displayed by the antibodies used in im-
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munofluoresence. By comparing the parental wild type strain with the ugp mutants a 
reduction of the signal intensity was observed in the heterozygous clones. However, in 
the case of the homozygous clones a residual signal could be detected especially if 
exposure times were extended (3.3.4). This result was confirmed in FACS analysis and 
also in Western blotting using whole cell lysates to detect LPG. Since two independent 
homozygous mutant lines were tested, this result was not an artefact of a single clone. A 
cross reactivity of the antibody seemed unlikely as two different antibodies showed the 
same result although it might be possible, that the ugp gene deletion induces the expres-
sion of other surface compounds, which mimic the epitope recognized by these antibod-
ies. 
However, using the UGP in vitro activity assay, a residual activity was measurable in the 
lysates of the homozygous mutants confirming the results obtained in immunofluo-
resence, FACS and Western blot analysis. Since, the mutant is a complete deletion of 
the ugp gene locus as could be shown by Southern blot analysis and since no other ugp 
homolog could be found in the database of the L. major genome project, it is likely that 
an alternative pathway exist, or that other pyrophosphorylases synthesize UDP-glucose. 
Since the major activity was deleted in the ugp mutant, this potential enzyme might 
exhibit only a low but sufficient affinity for glucose-1 phosphate. Cross reactivity has been 
demonstrated also for the L. major UGP-glucose pyrophosphorylase, which activates 
galactose-1 phosphate and UTP to UDP-galactose and PPi. Though this activity might 
not be significant under physiological conditions, it was postulated that it is sufficient to 
metabolise galactose in galactosemic patients (Isselbacher et al., 1957). Galactosemia is 
caused by a defect in the enzyme galactose-1 phosphate uridyltransferase. The accumu-
lation of galactose leads to the formation of toxic products like galactitol resulting in 
mentally retarded patients (see 1.4.1).  
It is also possible that an alternative, compensatory galactose-activating pathway exists. 
Compensatory mechanisms were already reported in the context of other gene deletion 
mutants. As mentioned in 1.2.2.4, the alkyldihydroxyacetonephosphate synthase (ADS1) 
gene deletion mutant was still able to express the GPI-anchored protein GP63 at wild 
type level though the GPI-anchor synthesis should have been abolished (Zufferey et al., 
2003). Thus, sufficient GPI synthesis occurred to exhibit protein anchoring whereas no 
detectable levels of LPG and GIPLs were present. This suggested that alternative path-
ways exist that produce protein anchor precursors. Alternatively, modified GPI-anchors 
may be used to substitute for the missing activity. In addition, this mutant contained a 
novel and yet unidentified lipid that is postulated to have a compensatory effect for the 
loss of the glycolipids and renders the parasite virulent though at reduced levels (Zuf-
ferey et al., 2003).  
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Compensatory effects were also observed in the L. major LGP2 mutant lacking the GDP-
mannose transporter gene. Though this mutant had lost virulence, some parasites could 
be reisolated from the site of injection several months after infection. The recovered 
mutants do not synthesize phosphoglycans, but can replicate in macrophages (Späth et 
al., 2003). This property is similar to L .mexicana as these parasites do not require LPG 
or PPGs for infectivity (Ilg et al., 2001, see introduction). In L .mexicana the metacyclic 
promastigotes resemble the amastigote stage that lack LPG and synthesize only low 
level of PPGs. Thus, other metabolic pathways may be upregulated in L. mexicana and 
the L. major LPG2 mutant that facilitate alternative mechanisms to infect the mammalian 
host.     
As no compensatory effects were reported in the bacteria (Chang et l, 1996, Mollerach et 
al., 1998) and yeast (Daran et al., 1995) ugp gene deletion mutants, this feature is 
unique to the L. major ugp mutant and might also indicate the importance of these 
structures for virulence. It will be interesting to investigate the observed galactose activa-
tion in this mutant, since it reflects an alternative pathway to the one described by Leloir. 
To further investigate, whether the residual galactose content on the ugp mutant surface 
is mainly associated with LPG, the proteophosphoglycans and the GIPLs are going to be 
analysed in more detail. In addition, analysis will be carried out to identify whether the 
LPG structure of the mutant is altered. The reduced level of UDP-galactose may change 
the length or composition of the glycoconjugates. 
 
4.3.2 Test of virulence in a mice infection model 
The virulence of the ugp gene deletion mutant was assessed by the lesion formation of 
Balb/c mice after inoculation with the parasites. The lesion formation was measured over 
a time of 10 weeks. This initial experiment showed that the ugp gene deletion mutant 
exhibits attenuated virulence in mice. The inoculum of 107 parasite per mouse was 
relatively high and thus, the reduced infectivity indicates a strong effect of the ugp dele-
tion. Lower doses are known to accentuate the differences between mutant and wild type 
parasites and result in a delayed appearance of lesions (Späth et al., 2000). In the case 
of the L. major LGP1 (galactofuranosyl transferase) mutant, the inoculation of saturating 
doses resulted in the minimization and even elimination of the differences between wild 
type and mutant parasites whereas lower doses of about 106 parasites per inoculum 
showed a significant delayed lesion formation (Späth et al., 2000). In nature, infected 
sand flys transmit only a small number of parasites (less than a 100) into the mammalian 
host (Warburg et al., 1986) and thus, a decreased infectivity could already have a strong 
impact on the resistance to the parasites. However, the inoculation of such a low number 
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of parasites by a syringe into mice would not cause a lesion. One possible explanation is 
the advantage of salvia in establishing the infection in the mammalian host (Solbach and 
Laskay, 2000).  
The loss of virulence in L. major seems more likely by affecting more than one group of 
glycocojungates since compensatory mechanisms occur (Naderer et al., 2004, see 
above). For example, the deletion of LPG alone, achieved by the knock out LPG1, 
resulted in a reduced virulence in mouse and macrophage infection assays whereas 
parasites without LPG and PPGs as in the case of the GDP-mannose transporter (LPG2) 
deletion, were rapidly killed in macrophages and did not form lesions in the mouse 
infection model (Späth et al., 2000, Bogdan et al., 2000). However, as mentioned above, 
a few parasites of the LPG2 mutant survived, may be by infecting other cells of the host 
(Naderer et al., 2004, Rittig et al., 2000).  
The ugp gene deletion should have abolished the galactose metabolism and effected the 
synthesis of various glycoconjugates (see above). However, residual galactose residues 
were detected on the surface of the mutants, most likely explaining the reduced but not 
complete loss of virulence in the mouse model. Whether this phenotype is more severe 
than phenotypes described for other mutants so far, will be investigated by the use of 
lower inoculum doses in the mouse model.   
In addition, to the reduced galactose content of the glycoconjugates on the mutant cell 
surface, the reduced lesion formation of the ugp gene could also be a consequence of 
the hindered energy metabolism. Though the growth of the parasites in culture was 
identical to wild type cells, the altered nutrient availability and endocrine situation in the 
mouse could inhibit the growth of the parasite. Thus, the nature of the delayed lesion 
formation has to be investigated in more detail using macrophage infection models. In 
these kinds of experiments, one can distinguish whether the mutant phenotype is due to 
an inhibited invasion, reduced proliferation within the cells or is facilitated by the survival 
of a few parasites within the initial phase of macrophage infection.  
 
4.4 Outlook 
Leishmaniasis currently affects over 12 million people worldwide. Since there are no 
specific drugs or vaccination strategies available, the goal is to identify and validate 
potential drug targets. Enzymes that are involved in the biosynthesis of the Leishmania 
glycoconjuagtes were intensively investigated within the last years. The UDP-glucose 
pyrophosphorylase (UGP) provides an interesting target since it is a key enzyme for the 
synthesis of UDP-glucose and UDP-galactose that serve as sugar donors in glycoconju-
gates biosynthesis. The deletion of ugp in L. major resulted in a reduced virulence in a 
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mice infection model indicating an important role of UGP in the infection process. Further 
studies will include a more detailed investigation of the infection mechanism in mice and 
macrophage and the analysis of the remaining glycoconjugates in the mutant. 
Though the mutant was not completely avirulent in this model, which may be due to the 
residual galactose-containing glycoconjugates, the reduced virulence might be sufficient 
to hinder Leishmania infection in nature. The investigation of this hypothesis would 
require the identification of a specific L. major UGP inhibitor.  Despite the high sequence 
homology to the mammalian counterparts, the enzymes differ in their enzymatic behav-
iour. The observed differences will be further investigated by the production of the corre-
sponding recombinant protein and biochemical characterisation including kinetic analy-
sis. In addition, the crystal structure of the L. major UGP that is currently solved by 
Thomas Steiner (MPI Martinsried) could be used for in silico predictions of potential 
inhibitors.  
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6 Abbreviations 
α− Anti- 
ABTS  2,2’-Azino-di-(3-ethylenbethiazolin-sulphate) 
AP Alkaline phosphatase 
APS Ammonium peroxidisulphate 
ATP Adenosine triphosphate 
BCA  Bichionic acid 
BCIP  5-Brom-4-chlor-3-indolyl-phosphate 
bp Base pairs 
BSA Bovine serum albumin 
CMP Cytidine 5’-monophosphat 
Da Dalton 
DMEM ‘Dulbecco’s Modified Eagle’s medium’ 
DMF Dimethylformamide 
DMSO Dimethylsulfoxide 
DNA Desoxyribonucleic acid 
DTT Dithiothreito 
EDTA Ethylendiamine-N,N,N’,N’-tetraacetic acid 
ELISA Enzyme linked immono sorbant assay 
IPTG Isopropyl-beta-D-thiogalactopyranoside 
kb kilobase 
kDa Kilodalton 
L.major/mexicana/donovani Leishmania major/mexicana/donovani 
LB Luria-Bertani  
mAb Monoclonal antibody 
NBT Nitrotetrazolium-blue chloride 
NCAM Neural cell adhesion molelcule 
Neu5Ac 5-N-acetyl-neuraminic acid 
OD Optical density 
PAGE Polyacrylamide gelelectrophoresis 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PMSF Phenylmethansulfonylflouride 
polySia  Polysialic acid 
RT Room temperature 
SDS Sodium dodecyl-sulphate 
TEMED  N,N,N’,N’-Tetramethyl-ethylendiamin 
TRIS  Tris(hydroxymethyl)-aminomethan) 
UDP Uridin 5’-diphosphate 
UDP-gal UDP-galactose 
UDP-glc UDP-glucose 
UDP-glcA UDP-glucuronic acid 
UDP-glcNAc/galNAc UDP-N-acetylglucosmanie/galactosamine 
UDP-xyl UDP-xylose 
UGP UDP-glucose pyrophosphorylase 
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